| Entries |
| Document | Title | Date |
|---|
| 20080206817 | Rhamnose Promoter Expression System - Vectors expressible in a host that is the rhaBAD promoter region of the L-rhamnose operon operably linked to a transcriptional unit that is:
| 08-28-2008 |
| 20080206818 | PROCESS FOR THE FERMENTATIVE PRODUCTION OF ANTIBODIES - The present invention relates to a process for producing a correctly folded and assembled full-length antibody using an | 08-28-2008 |
| 20080248529 | MODIFIED ANTI-CD52 ANTIBODY - The present invention provides for modified forms of anti-CD52 antibodies with reduced numbers of potential T-cell epitopes that are expected to display decreased immunogenicity. | 10-09-2008 |
| 20080248530 | Use of Fungal Mutants for Expression of Antibodies - The present invention relates to a filamentous fungal cell in which an endogenous alkaline protease activity, an endogenous neutral metalloprotease activity and an endogenous serine protease activity of the subtilisin type have been completely or partially inactivated. Particularly the endogenous alkaline protease activity, the endogenous neutral metalloprotease activity and the endogenous serine protease activity of the subtilisin type are encoded by the alp, npI and pepC genes respectively. The filamentous fungal cell is particularly suitable for production of heterologous proteins such as antibodies. | 10-09-2008 |
| 20080254512 | Hybrid immunoglobulins with moving parts - Hybrid immunoglobulins containing moving parts are provided as well as related compositions and methods of use and methods of production. In addition, analogous genetic devices are provided as well as related compositions and methods of use and methods of production. | 10-16-2008 |
| 20080261274 | Restoration of Cholesterol Independence and Its Use as a Selectable Marker in Ns0 Cell Culture - Gene complementation is used to restore cholesterol independence in NS lineage murine myeloma cells, such as NSO and NS 1, yielding a selectable system for recombinant production of polynucleotides and polypeptides. | 10-23-2008 |
| 20080274506 | POLYPEPTIDE VARIANTS WITH ALTERED EFFECTOR FUNCTION - The present invention concerns polypeptides comprising a variant Fc region. More particularly, the present invention concerns Fc region-containing polypeptides that have altered effector function as a consequence of one or more amino acid modifications in the Fc region thereof. | 11-06-2008 |
| 20080293105 | Recombinant method for making multimeric proteins - The present invention relates to methods for making multimeric proteins comprising fusion of two or more cells expressing a single subunit of the multimeric protein to generate a single hybrid cell expressing the fully assembled multimeric protein. | 11-27-2008 |
| 20080293106 | Method For the Mass Production of Immunoglobulin Fc Region Deleted Initial Methionine Residues - Disclosed is a method for the mass production of a monomeric or dimeric immunoglobulin Fc region, free of initial methionine residues, using a recombinant expression vector comprising a nucleotide sequence coding for a recombinant immunoglobulin Fc region comprising an immunoglobulin Fc region linked at the N-terminus thereof to an immunoglobulin Fc region via a peptide bond. | 11-27-2008 |
| 20080299617 | METHODS AND HOST CELLS FOR RECOMBINANT PROTEIN EXPRESSION - Methods for expressing recombinant polypeptides in host cells and host cells for polypeptide expression are provided. | 12-04-2008 |
| 20080305526 | Melibiose Operon Expression System - New vectors expressible in a host comprising the promoter region of the melibiose operon operably linked to a transcriptional unit that includes nucleic acid sequence which is heterologous to the host. The expression of the nucleic acid sequence is controlled by the promoter region of the melibiose operon. The new vector can be used for the regulated heterologous expression of a nucleic acid sequence in a prokaryotic host. There is an isolated and purified nucleic acid sequence expressible in a host comprising the promoter region of the melibiose operon operably linked to a transcriptional unit that includes a nucleic acid sequence which is heterologous to the host. The expression of the nucleic acid sequence is controlled by the promoter region of the melibiose operon. A prokaryotic host is transformed with the vector or the isolated and purified nucleic acid sequence. There is a method for producing a polypeptide in a host using the vector. | 12-11-2008 |
| 20080305527 | Single Chain Pan ECTO-NOX Variable Region (ScFv) Antibody, Coding Sequence and Methods - The present Specification describes compositions and methods for production of a recombinant single chain variable region (ScFv) antibody useful for the detection of members of the ECTO-NOX family of cell surface proteins on Western blots. This single chain antibody is especially useful in the detection, diagnosis and monitoring of neoplastic disorders. A linker sequence required to appropriately combine the light and heavy chain variable region fragments to form the functional recombinant single chain antibodies is also provided. The resultant ScFv is a pan ECTO-NOX antibody for detection on Western blots of most if not all tNOX isoforms. | 12-11-2008 |
| 20080311623 | Plasmid system for multigene expression - The present invention provides a plasmid system which facilitates the construction of a single amplifiable plasmid that, having the potential to accommodate many independent expression cassettes, has the ability to express multi-subunit complex proteins such as antibodies and receptors. | 12-18-2008 |
| 20080318275 | Hepatitis C virus asialoglycoproteins - Two Hepatitis C Virus envelope proteins (E1 and E2) are expressed without sialylation. Recombinant expression of these proteins in lower eukaryotes, or in mammalian cells in which terminal glycosylation is blocked, results in recombinant proteins which are more similar to native HCV glycoproteins. When isolated by GNA lectin affinity, the E1 and E2 proteins aggregate into virus-like particles. | 12-25-2008 |
| 20080318276 | Human Coagulation Factor VII Variants - The invention concerns novel coagulation factor VII variants, wherein the Phe residue in position 374 of SEQ ID NO 1 has been replaced by another amino acid residue which can be encoded by nucleic acid constructs and, optionally, wherein at least one other amino acid residue in the remaining positions in the protease domain has been replaced by another amino acid residue which can be encoded by nucleic acid constructs; with the proviso that the variant is not FVII(Ala305). | 12-25-2008 |
| 20090011464 | Humanized immunoglubulin reactive with alph4beta7 integrin - The present invention relates to isolated nucleic acids encoding humanized immunoglobulins having binding specificity for α4β7 integrin, isolated nucleic acids encoding a humanized immunoglobulin heavy chain and isolated nucleic acids encoding a humanized light chain having binding specificity for α4β7 integrin. The invention also relates to expression vectors and host cells comprising a nucleotide sequence which encodes a humanized immunoglobulin or antigen-binding fragment thereof having binding specificity for α4β7. The invention further relates to methods of preparing a humanized immunoglobulin, humanized immunoglobulin heavy chain and humanized immunoglobulin light chain that has binding specificity for α4β7 integrin. | 01-08-2009 |
| 20090029419 | Expression of modified antibodies in avian cells - The present invention relates to construct and methods which allow the expression of immunoglobulins or functional fragments thereof which have been altered to that they are humanised. The expression of the immunoglobulins or fragments thereof takes place in avian cells, and the constructs used have been altered such that the expression levels in avian cells are higher than what would have been expected by simply using a humanised construct. The alterations are based on changing codons so that each amino acid of the codon that is used is the one which is most often found in avians. | 01-29-2009 |
| 20090061485 | Method of Producing an Antibody Using a Cell in Which the Function of Fucose Transporter Is Inhibited - The present invention relates to a method of producing a recombinant protein, particularly an antibody, using a cell in which the function of a fucose transporter is inhibited, and it also provides a cell in which the expression of fucose transporter genes on both homologous chromosomes is artificially suppressed. | 03-05-2009 |
| 20090075338 | DIMERIC FUSION PROTEINS AND MATERIALS AND METHODS FOR PRODUCING THEM - Polypeptide fusions, dimeric fusion proteins, and materials and methods for making them are disclosed. One of the polypeptide fusions consists of a non-immunoglobulin polypeptide, a polypeptide linker, a dimerizing domain, and, optionally, a linking polypeptide. Another of the polypeptide fusions consists of a non-immunoglobulin polypeptide, a polypeptide linker, and a second dimerizing domain. | 03-19-2009 |
| 20090075339 | AUTOPHILIC ANTIBODIES - Autophilic antibodies including an immunoglobulin component and an autophilic peptide fused thereto are provided according to embodiments of the present invention. Particular autophilic antibodies described herein include a chimeric gamma immunoglobulin heavy chain and autophilic peptide expressed as a fusion protein. Preferably the autophilic peptide is expressed at the C-terminus of the immunoglobulin component. Expression vectors according to embodiments of the present invention for use in generating autophilic antibodies are provided which include a first nucleic acid sequence encoding an autophilic peptide, operably linked to a transcription promoter. In particular embodiments, a second nucleic acid sequence encoding a chimeric heavy chain of an immunoglobulin operably linked to the transcription promoter and connected to the first nucleic acid sequence such that expression of the first and second nucleic acid sequences produces a fusion protein of the chimeric heavy chain and the autophilic peptide. | 03-19-2009 |
| 20090075340 | Kir-Binding Agents and Methods of Use Thereof - The present invention relates to agents and methods that are capable of augmenting NK-mediated killing of target cells by reducing inhibitory KIR signalling without reducing the binding of KIR to HLA-C. As described herein, transduction of negative signaling via KIR, upon binding of KIR to its HLA class I ligand, can involve a ligand-binding induced, conformational reorientation of the KIR molecules allowing interactions to form between adjacent KIRs in specific domains, leading to accelerated clustering. Methods and agents such as monoclonal antibodies for reducing KIR-mediated inhibition of NK cell cytotoxicity without reducing or blocking HLA-binding by, e.g., reducing or blocking dimerization of KIR, are provided. | 03-19-2009 |
| 20090093024 | Methods of generating libraries and uses thereof - This invention relates to methods for the generation of polynucleotide seed libraries and the use of these libraries in generating novel mutants of recombinant proteins and, more particularly, for generating focused libraries of recombinant human antibodies and screening for their affinity binding with target antigens. | 04-09-2009 |
| 20090098607 | PRODUCTION OF RECOMBINANT HUMAN HEMOGLOBIN USING PICHIA YEAST - The present invention provides a production method of a functional recombinant human hemoglobin, which comprises transforming a yeast of the genus | 04-16-2009 |
| 20090104660 | Expression vector for secreting antibody fragment using e. coli signal sequence and method for mass-producing antibody fragment - A recombinant expression vector capable of expressing and secreting an antibody fragment fused with | 04-23-2009 |
| 20090104661 | Human Coagulation Factor VII Polypeptides - The present invention relates to novel human coagulation Factor VIIa variants having coagulant activity as well as polynucleotide constructs encoding such variants, vectors and host cells comprising and expressing the polynucleotide, pharmaceutical compositions, uses and methods of treatment. | 04-23-2009 |
| 20090104662 | Use of interleukin-4 antagonists and compositions thereof - Methods for treating medical conditions induced by interleukin-4 involve administering an IL-4 antagonist to a patient afflicted with such a condition. Suitable IL-4 antagonists include, but are not limited to, IL-4 receptors (such as a soluble human IL-4 receptor), antibodies that bind IL-4, antibodies that bind IL-4R, IL-4 muteins that bind to IL-4R but do not induce a biological response, molecules that inhibit IL-4-induced signal transduction, and other compounds that inhibit a biological effect that results from the binding of IL-4 to a cell surface IL-4R. Particular antibodies provided herein include human monoclonal antibodies generated by procedures involving immunization of transgenic mice. Such human antibodies may be raised against human IL-4 receptor. Certain of the antibodies inhibit both IL-4-induced and IL-13-induced biological activities. | 04-23-2009 |
| 20090111144 | Transactivation system for mammalian cells - The present invention is directed generally to compositions and methods for expressing recombinant proteins in a mammalian host cell using a co-expressed transcriptional activator. In particular, the invention provides vectors, host cells, and methods of expressing at least one desired polypeptide by transfecting a mammalian host cell with cistrons encoding a transactivator, a desired polypeptide, and an apoptosis-protective protein. | 04-30-2009 |
| 20090111145 | PRODUCTION OF HETERO-OLIGOMERIC PROTEINS IN PLANTS - Process of producing in a plant, in plant tissue, or in plant cells a hetero-oligomeric protein comprising at least a first and a second protein subunit, said process comprising expressing in plant cells at least said first and said second protein subunit by (i) providing to said plant, said plant tissue or said plant cells a plus-sense single-stranded RNA viral vector encoding at least said first and said second protein subunit or (ii) providing to said plant, said plant tissue or said plant cells a first and a second plus-sense single-stranded RNA viral vector, said first viral vector encoding at least said first protein subunit, said second viral vector encoding at least said second protein subunit, whereby at least said first viral vector and said second viral vector are non-competing viral vectors. | 04-30-2009 |
| 20090130716 | Rationally designed antibodies - Antibodies or fragments thereof having at least two CDR regions replaced or fused with biologically active peptides are described. Compositions containing such antibodies or fragments thereof are useful in therapeutic and diagnostic modalities. | 05-21-2009 |
| 20090137001 | PROCESS FOR PREPARING RECOMBINANT HUMAN THROMBIN WITH CULTURE CELL - The present invention provides for a process for preparing a recombinant human thrombin. A process for preparing a recombinant human thrombin which comprises: (1) obtaining a transfectant cell producing a human prothrombin by introducing an expression vector, wherein a gene fragment coding for a human prothrombin gene is incorporated, into an animal cell; (2) purifying a human prothrombin from the culture of the transfectant cell above by an anion exchanger; (3) converting the purified human prothrombin into a human thrombin by subjecting said human prothrombin to the action of ecarin; and (4) purifying the human thrombin from the solution after treatment with ecarin by an affinity method using benzamidine and a cation exchanger, and human thrombin obtained by said process, and a CHO cell that produces human prothrombin. | 05-28-2009 |
| 20090137002 | ANTI EPHB4 ANTIBODIES AND ANTIBODY FRAGMENTS - The invention concerns antibodies and antibody fragments, specifically recognising the EphB4 receptor comprising heavy chains and light chain, comprising light and heavy CDR's, and their use as medicament for the treatment of pathological angiogenesis, in particular cancer therapy. | 05-28-2009 |
| 20090137003 | Methods for recombinant manufacturing of anti-RSV antibodies - The invention relates to a method for manufacturing recombinant anti-RSV antibodies and antibody compositions. The method comprises obtaining a collection of cells transfected with a collection of variant nucleic acid sequences, wherein each cell in the collection is transfected with and capable of expressing one distinct anti-RSV antibody. The cells are cultured under suitable conditions for expression of the anti-RSV antibody/antibodies. The nucleic acid sequence is introduced into the cells by transfection with expression vectors, which avoid site-specific integration. The present method is suitable for manufacturing recombinant mono- and polyclonal anti-RSV antibodies for therapeutic uses. | 05-28-2009 |
| 20090142805 | High expression cell line that eliminates gene amplification - The present invention relates to methods, cell lines and kits for producing high titers of recombinant proteins without the need for gene amplification. | 06-04-2009 |
| 20090148904 | PRODUCTION OF CYTOTOXIC ANTIBODY-TOXIN FUSION IN EUKARYOTIC ALGAE - Methods and compositions are disclosed to engineer chloroplast comprising heterologous genes encoding target binding domain fused to a eukaryotic toxin and produced within a subcellular organelle, such as a chloroplast. The present disclosure demonstrates that when chloroplasts are used, toxins normally refractive to production in eukaryotic cells may be used to produce recombinant fusion proteins with binding domains that are soluble, properly folded and post-translationally modified, where the multifunctional activity of the fusion protein is intact. The binding domains may include those from antibodies, receptors, hormones, cytokines, chemokines, and interferons. The present disclosure also demonstrates the utility of plants, including green algae, for the production of complex multi-domain proteins as soluble bioactive therapeutic agents. | 06-11-2009 |
| 20090148905 | ANTIGEN-BINDING CONSTRUCTS - The invention relates to antigen-binding constructs comprising a protein scaffold which are linked to one or more epitope-binding domains wherein the antigen-binding construct has at least two antigen binding sites at least one of which is from an epitope binding domain and at least one of which is from a paired VH/VL domain, methods of making such constructs and uses thereof. | 06-11-2009 |
| 20090155849 | GENERATION OF SPECIFIC ADHESION IN GRAM-NEGATIVE BACTERIA BY MEANS OF ANCHORING IMMUNOGLOBULIN SINGLE DOMAINS ON THEIR SURFACE WITH AUTOTRANSPORTERS - The present invention refers to an expression vector for gram-negative bacteria allowing for the production of hybrid proteins between single domain recombinant antibodies and a transporter domain of an autotransporter, as well as to its anchoring and expression on the external surface of a bacterial membrane, and to a method of specific bacterial adhesion to a surface containing a specific antigen. | 06-18-2009 |
| 20090155850 | Horse:Human Chimeric Antibodies - The present invention provides a plurality of chimeric single chain variable region (scFv) antibodies. The chimeric scFv antibodies individually comprise variable regions from both horse and non-horse antibodies. Methods of making and using the plurality are also provided. | 06-18-2009 |
| 20090162900 | EXPRESSION VECTOR, METHODS FOR THE PRODUCTION OF HETEROLOGOUS GENE PRODUCTS AND FOR THE SELECTION OF RECOMBINANT CELLS PRODUCING HIGH LEVELS OF SUCH OF SUCH PRODUCTS - An expression vector for eukaryotic cells comprising a gene which codes for a protein of interest, functionally linked to a hamster-ubiquitin/S27a-promoter and a gene which codes for a fluorescent protein. Preferably the expression vector also contains an amplifiable selectable marker gene. | 06-25-2009 |
| 20090162901 | Inducible Eukaryotic Expression System - Compositions and methods for the inducible expression of genes in eukaryotic cells are provided. Expression of a nucleotide sequence of interest encoding a protein of interest is controlled by a regulatory fusion protein that consists of a transcription blocking domain and a ligand-binding domain. When a cognate ligand for the ligand-binding domain is present, transcription of the nucleotide sequence of interest is blocked. Upon removal of the cognate ligand, the nucleotide sequence of interest is transcribed. The method is useful for large scale bioreactor production of a desired protein of interest in eukaryotic cells. | 06-25-2009 |
| 20090162902 | ANTIBODY WITH PROTEIN A SELECTIVITY - Monoclonal antibodies, and antigen binding fragments thereof, which bind to Protein A of | 06-25-2009 |
| 20090170164 | Recombinant protein production in a human cell - Methods and compositions for the production of recombinant proteins in a human cell line. The methods and compositions are particularly useful for generating stable expression of human recombinant proteins of interest that are modified post-translationally, for example, by glycosylation. Such proteins may have advantageous properties in comparison with their counterparts produced in non-human systems such as Chinese hamster ovary cells. | 07-02-2009 |
| 20090191591 | Taurine Transporter Gene - The present invention provides a method capable of producing a natural or recombinant protein at low cost. | 07-30-2009 |
| 20090191592 | GLYCOENGINEERED, RECOMBINANT ANTIBODY - The present invention relates to a cell for the production of an antibody molecule such as an antibody useful for various diseases having high antibody-dependent cell-mediated cytotoxic activity, a fragment of the antibody and a fusion protein having the Fc region of the antibody or the like, a method for producing an antibody composition using the cell, the antibody composition and use thereof. | 07-30-2009 |
| 20090203077 | METHOD OF PRODUCING FACTOR VIII PROTEINS BY RECOMBINANT METHODS - Provided herein are methods and compositions for producing Factor VIII proteins. Such methods include introducing into a cell a nucleic acid molecule encoding a Factor VIII protein operably linked to a promoter, wherein the promoter is characterized by the ability to produce commercially viable Factor VIII protein; and incubating the cell under conditions for producing commercially viable Factor VIII protein. Also provided are nucleic acid molecules which encode a Factor VIII protein operably linked to a Chinese hamster elongation factor 1-α (CHEF1) promoter, which may be used in the methods provided herein. | 08-13-2009 |
| 20090203078 | PROCESS FOR PRODUCING POLYPEPTIDE - The present invention relates to a process for producing a desired polypeptide using rat cells. Specifically, the present invention relates to a process for producing the polypeptide which comprises culturing rat cells such as YB2/3HL.P2.G11.16Ag.20 (hereinafter referred to as YB2/0), preferably rat cells to which a recombinant DNA comprising DNA encoding a desired polypeptide such as an immunologically functional molecule is introduced, in a medium which does not contain serum (hereinafter referred to as a serum-free medium). Among the desired polypeptides obtained by the process of the present invention, an antibody obtained by using a transformant of YB2/0 has a high antibody-dependent cell-mediated cytotoxic activity (hereinafter sometimes referred to as ADCC activity) and is useful as a pharmaceutical agent. | 08-13-2009 |
| 20090209004 | HUMAN IL-1 BETA ANTAGONISTS - The present invention encompasses isolated antibodies, or antigen-binding portions thereof, that specifically bind mature human IL-1 Beta. These antibodies, or antigen-binding portions thereof, generally exhibit high binding affinities (low k | 08-20-2009 |
| 20090215119 | METHODS FOR PRODUCING SPECIFIC BINDING PAIRS - Provided are improved methods for providing specific binding pairs (SBPs). The methods enable production of libraries of SBP members using both a large population of one member of the SBPs and a smaller, preselected population of the other member of the SBPs having affinity for a preselected target. | 08-27-2009 |
| 20090221036 | RECOMBINANT ANTI-CD4 ANTIBODIES FOR HUMAN THERAPY - Chimeric antibodies specific to human CD4 antigen, DNA encoding, pharmaceutical compositions containing and use thereof as therapeutic agents are taught. These chimeric antibodies contain Old World monkey variable sequences and human constant domain sequences, preferably human gamma 1, gamma 4 or mutated forms thereof. These antibodies possess desirable therapeutic properties including low antigenicity, reduced (or absent) T cell depleting activity, good affinity to human CD4 and enhanced stability (in vivo half-life). | 09-03-2009 |
| 20090239263 | Expression Control Using Antibody Expression Optimisation Sequences - The present invention provides a dicistronic message for producing an antibody molecule, in which the upstream cistron contains DNA coding for the light chain of the antibody and the downstream cistron contains DNA coding for the corresponding heavy chain, characterised in that the dicistronic message comprises a sequence selected from AEOS1 (SEQ ID NO:1), AEOS2 (SEQ ID NO:2), AEOS3 (SEQ ID NO:3), AEOS4 (SEQ ID NO: 4), AEOS5 (SEQ ID NO:5), AEOS6 (SEQ ID NO:6), AEOS7 (SEQ ID NO:7), AEOS8 (SEQ ID NO:8), AEOS9 (SEQ ID NO:9), AEOS1O (SEQ ID NO:10) and AEOS1 1 (SEQ ID NO:11). | 09-24-2009 |
| 20090258392 | SEQUENCE DIVERSITY GENERATION IN IMMUNOGLOBULINS - Compositions and methods are disclosed for generating immunoglobulin structural diversity in vitro, and in particular, for reducing biases in V region and J segment gene utilization, and for generating immunoglobulin V-D-J recombination events in a manner that does not require D-J recombination to precede V-DJ recombination. Selection of advantageous combinations of immunoglobulin gene elements, including introduction of artificial diversity (D) segment genes and optimization of recombination signal sequence (RSS) efficiency, are disclosed. | 10-15-2009 |
| 20090258393 | SINGLE CHAIN CLASS I MAJOR HISTOCOMPATIBILITY COMPLEXES, CONSTRUCTS ENCODING SAME AND METHODS OF GENERATING SAME - Provided are methods of generating a functional mammalian single chain MHC class I complex in prokaryotic expression systems and a host cell transformed with expression construct(s) capable of expressing a functional human single chain MHC class I complex capable of presenting specific antigenic peptides restricted to specific CTL clones. | 10-15-2009 |
| 20090263864 | Recombinant production of mixtures of antibodies - The invention provides methods for producing mixtures of antibodies from a single host cell clone, wherein, a nucleic acid sequence encoding a light chain and nucleic acid sequences encoding different heavy chains are expressed in a recombinant host cell. The recombinantly produced antibodies in the mixtures according to the invention suitably comprise identical light chains paired to different heavy chains capable of pairing to the light chain, thereby forming functional antigen-binding domains. Mixtures of the recombinantly produced antibodies are also provided by the invention. Such mixtures can be used in a variety of fields. | 10-22-2009 |
| 20090263865 | Substance Specific to Human PD-1 - The present invention relates to a substance specific to human PD-1 comprising a part that recognizes human PD-1, a part that recognizes a membrane protein in cell membrane of human PD-1-expressing cells, and linkers. Since the substance specific to human PD-1 selectively can recognize human PD-1 and a membrane protein on cell membrane of human PD-1-expressing cells and can transmit inhibitory signal of human PD-1, it is useful for therapy and/or prevention of diseases caused by immunopathy. | 10-22-2009 |
| 20090269810 | Method for enhancing recombinant antibody production - The present invention is a method for enhancing recombinant antibody production by co-expressing in a host cell a recombinant antibody and ERp23 protein, which facilitates oxidative folding and stability of the recombinant antibody thereby enhancing production. | 10-29-2009 |
| 20090280534 | Recombinant Production of Serum Albumin - The present invention relates to modified nucleotide sequences encoding serum albumin, wherein the mRNA sequence has been codon optimized for expression in a filamentous host cell. Furthermore the present invention relates to serum albumin produced in filamentous fungi or loaded by contacting serum albumin with an extract of a filamentous fungi culture. In an-other aspect the present invention relates to the use of said serum albumin in serum free cell culture media and also to a method of drying and agglomerating serum albumin thereby im-proving wettability and dispersability. | 11-12-2009 |
| 20090286282 | Method for Producing Antibody Fragments - An expression library comprising a repertoire of nucleic acid sequences each encoding at least part of a variable domain of a heavy chain derived from an immunoglobulin naturally devoid of light chains and its use in producing antibodies, particularly fragments thereof, is disclosed. The invention provides a method for preparing antibodies, or fragments thereof, having a specificity for a target antigen which avoids the need for the donor previously to have been immunised with the target antigen. | 11-19-2009 |
| 20090305349 | EXPRESSION OF SOLUBLE FACTOR VIII PROTEINS IN BACTERIA - The present invention provides enhanced methods of producing soluble Factor VIII proteins in microorganisms that have an oxidizing environment. | 12-10-2009 |
| 20090305350 | Gene Differentially Expressed in Breast and Bladder Cancer and Encoded Polypeptides - The present invention relates to a novel human gene that is differentially expressed in human carcinoma. More specifically, the present invention relates to a polynucleotide encoding a novel human polypeptide named C35 that is overexpressed in human breast and bladder carcinoma. This invention also relates to C35 polypeptide, in particular C35 peptide epitopes and C35 peptide epitope analogs, as well as vectors, host cells, antibodies directed to C35 polypeptides, and the recombinant methods for producing the same. The present invention further relates to diagnostic methods for detecting carcinomas, including human breast carcinomas. The present invention further relates to the formulation and use of the C35 gene and polypeptides, in particular C35 peptide epitopes and C35 peptide epitope analogs, in immunogenic compositions or vaccines, to induce antibody or cell-mediated immunity against target cells, such as tumor cells, that express the C35 gene. The invention further relates to screening methods for identifying agonists and antagonists of C35 activity. | 12-10-2009 |
| 20090311750 | METHODS OF CONVERTING FAB SEQUENCES INTO SINGLE CHAIN ANTIBODY SEQUENCES - In various embodiments, the present invention provides methods of converting a Fab molecule to a scFv molecule. The methods include amplifying the polynucleotide sequence of the variable light and variable heavy regions of the Fab molecule from the framework 1 to framework 4 sequences; adding one or more restriction endonuclease sites to the amino or carboxyl terminal of the amplified variable region sequence by PCR or ligation; adding one or more linker sequences to the amino or carboxyl terminal of the amplified variable region sequence by PCR or ligation. Additionally, in various embodiments the variable light chain sequence is either amino terminal or carboxyl terminal to the variable heavy chain sequence. | 12-17-2009 |
| 20090317868 | Rapidly Cleavable Sumo Fusion Protein Expression System for Difficult to Express Proteins - A recombinant expression system for the expression of a poly amino acid, peptide or protein is provided. The poly amino acid of interest is expressed as a fusion protein that includes an amino acid sequence recognized and cleaved by a Ulp1 protease. The amino acid sequence joined to the poly amino acid of interest is preferably from a SUMO (small ubiquitin-like molecule) protein. This sequence imparts favorable solubility and refolding properties to the fusion protein. A purification tag may also be incorporated into the fusion protein for ease of isolation. This recombinant expression system is particularly advantageous for expression and rapid and highly specific cleavage and purification of poly amino acids that have low solubilities or are difficult to express in other systems. | 12-24-2009 |
| 20100009409 | MOLECULAR VARIANT FIBRINOGEN FUSION PROTEINS - Fibrinogen fusion proteins, methods of making, and methods of using fibrinogen fusion proteins are described. In a preferred embodiment the fibrinogen fusion protein contains a truncated Aα chain of fibrinogen. The Aα chain contains truncation site, which is a deletion of amino acids at its C-terminal region. A non-fibrinogen protein or peptide is C-terminally attached to the truncation site. The fibrinogen fusion proteins can be used alone or mixed with native fibrinogen to form fibrin polymer. | 01-14-2010 |
| 20100009410 | Methods and Constructs for Expressing Polypeptide Multimers in Eukaryotic Cells Using Alternative Splicing - The invention provides a method of producing multiple polypeptides, such as antibodies or antibody fragments, in a eukaryotic cell using a single expression vector. The expression vector is engineered to comprise two or more expression cassettes under the control of a single promoter wherein the expression cassettes have splice sites which allow for their alternative splicing and expression as two or more independent gene products at a desired ratio. Use of the vector for the efficient expression of recombinant antibodies in eukaryotic host cells is disclosed as well as the use of such antibodies in diagnostic and therapeutic applications. | 01-14-2010 |
| 20100015665 | ANTIBODIES AND DIAGNOSTICS - Compositions and methods relating to sclerostin binding agents, such as antibodies and polypeptides capable of binding to sclerostin, are provided. | 01-21-2010 |
| 20100028946 | FUSION PARTNER CELLS - Fusion partner cells that enable production of heterohybridomas even from cells of species other than mouse were produced by fusing myeloma cells derived from a first animal species with leukemia cells derived from a second animal species, which have an extra S phase in the cell cycle and have the property of diploidizing. Stable production of substances can be achieved by producing heterohybridomas through cell fusion between the fusion partner cells and substance-producing cells of an animal other than mouse. | 02-04-2010 |
| 20100028947 | USE OF HUMAN CELLS OF MYELOID LEUKAEMIA ORIGIN FOR EXPRESSION OF ANTIBODIES - The invention relates to a method for producing a protein molecule composition having a defined glycosylation pattern, comprising (a) introducing in a host cell which is an immortalized human blood cell at least one nucleic acid encoding at least a part of said protein; and (b) culturing said host cell under conditions which permit the production of said protein molecule composition; and (c) isolating said protein molecule composition. | 02-04-2010 |
| 20100028948 | METHODS OF ADMINISTERING/DOSING ANTI-RSV ANTIBODIES FOR PROPHYLAXIS AND TREATMENT - The present invention encompasses novel antibodies and fragments thereof which immunospecifically bind to one or more RSV antigens and compositions comprising said antibodies and antibody fragments. The present invention encompasses methods preventing respiratory syncytial virus (RSV) infection in a human, comprising administering to said human a prophylactically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject. The present invention also encompasses methods for treating or ameliorating symptoms associated with a RSV infection in a human, comprising administering to said human a therapeutically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject. The present invention further encompasses compositions comprising antibodies or fragments thereof that immunospecifically bind to a RSV antigen, and methods using said compositions for detection or diagnosis a RSV infection. | 02-04-2010 |
| 20100028949 | SHRNA-MEDIATED INHIBITION OF EXPRESSION OF ALPHA 1,6-FUCOSYLTRANSFERASE - The current invention comprises a method for producing a heterologous polypeptide with a reduced degree of fucose modification in a mammalian cell by cultivating the mammalian cell under conditions suitable for the expression of said heterologous polypeptide, and recovering the heterologous polypeptide from the mammalian cell or the culture, wherein in said mammalian cell the enzymatic activity of α1,6-fucosyltransferase is reduced by means of an shRNA directed against α1,6-fucosyltransferase mRNA. | 02-04-2010 |
| 20100041102 | ANTAGONISTS OF PCSK9 - Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure. | 02-18-2010 |
| 20100041103 | COMPOSITION AND METHOD FOR ENHANCING CELL GROWTH AND CELL FUSION - A method of cell-fusion is provided, the method comprising fusing cells in a medium comprising a liquid composition having a liquid and nanostructures, each of the nanostructures comprising a core material of a nanometric size surrounded by an envelope of ordered fluid molecules, the core material and the envelope of ordered fluid molecules being in a steady physical state, thereby fusing cells. Compositions and articles of manufacture are also provided for generating monoclonal antibodies and culturing eukaryotic cells. | 02-18-2010 |
| 20100075379 | METHOD FOR MAKING POLYALKYLENE OXIDE MODIFIED HEMOGLOBIN - The present invention is a method for preparing a hemoglobin based oxygen carrier to deliver oxygen to tissue. The method comprises mixing a deoxygenated hemoglobin with a maleimide-activated polyakylene oxide (PAO) to obtain an oxygen carrying product. This product is characterized as having 2 to about 8 PAO moieties covalently bound to a deoxygenated hemoglobin and a p50 less than native stroma-free hemoglobin from the same animal source when measured under the same conditions. | 03-25-2010 |
| 20100081172 | N-Glycans and Uses Thereof - The present disclosure provides compositions and methods comprising cells producing glycoproteins with variant glycosylation patterns. The methods and compositions may be used in producing antibodies and proteins of therapeutic value. | 04-01-2010 |
| 20100086969 | Antibodies That Bind to EphA2 and Methods of Use Thereof - Provided herein is disclosure about the development and characterization of an antibody that binds to antigen EphA2 which is present on a variety of human cancers from breast, lung, prostate, and colons. Methods of diagnosing and treating various cancers by using such antibodies directed against this antigen are also disclosed. | 04-08-2010 |
| 20100099147 | Anti-IGF-1R Antibodies and Uses Thereof - The invention relates to antibodies which bind to insulin like growth factor receptor-1 (IGF-1R) and uses thereof, in particular in the diagnosis and treatment of cancer. Specific human and murine monoclonal antibodies which inhibit IGF-1R-mediated pro-survival and tumor proliferation pathways, and variants, fragments, and derivatives thereof are provided. Also provided are specific human and murine monoclonal antibodies which block the ability of the ligands, insulin like growth factor 1 (IGF-1) and insulin like growth factor 2 (IGF-2) to bind to IGF-1R, as well as fragments, variants and derivatives of such antibodies. The invention also includes polynucleotides encoding the above antibodies or fragments, variants or derivatives thereof, as well as vectors and host cells comprising such polynucleotides. The invention further includes methods of diagnosing and treating cancer using antibodies of the invention. | 04-22-2010 |
| 20100099148 | Novel Vectors for Production of Antibodies - Novel compositions for the production of the light and heavy chains of an antibody are provided. These novel compositions are also used to produce germline transgenic birds that can successfully pass the transgene encoding the antibody to their offspring. The compositions comprise components of vectors, such as a vector backbone, a promoter, and a gene of interest that encodes the light or heavy chain of an antibody, and the vectors comprising these components. In certain embodiments, these vectors are transposon-based vectors. Also provided are methods of making these compositions and methods of using these compositions for the production of the light and heavy chains of an antibody. In one embodiment, the antibody is a human monoclonal antibody. | 04-22-2010 |
| 20100112640 | POLYNUCLEOTIDE - The present invention relates to a polynucleotide comprising a ubiquitous chromatin opening element (UCOE) which is not derived from 13. The polynucleotide of any one of claims | 05-06-2010 |
| 20100112641 | PROCESS FOR PRODUCING AND PURIFYING FACTOR VIII AND ITS DERIVATIVES - Disclosed is a method for producing proteins having factor VIII procoagulant activity in serum-free medium by in vitro culturing of mammalian cells, wherein the serum-free medium contains an inhibitor against the protease released from cultured cells. In accordance with this invention, the inhibitor can protect the cleavage of a target protein during cultivation and increase homogeneity of a target molecule, wherein the inhibitor can be a dextran sulfate. This invention also relates to a method of purifying target molecules from the culture medium containing both a target molecule and selected inhibitors by affinity chromatography. | 05-06-2010 |
| 20100129869 | Methods and compositions for inactivating glutamine synthetase gene expression - Disclosed herein are methods and compositions for inactivating a glutamine synthetase (GS) gene, using fusion proteins comprising a zinc finger protein and a cleavage domain or cleavage half-domain. Polynucleotides encoding said fusion proteins are also provided, as are cells comprising said polynucleotides and fusion proteins. | 05-27-2010 |
| 20100136624 | Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method - A method of making monoclonal antibodies according to a mixed antigen immunization protocol is described. In addition, antibodies obtainable by the method are disclosed which specifically cross-react with two or more different receptors to which Apo-2 ligand (Apo-2L) can bind. | 06-03-2010 |
| 20100136625 | METHOD FOR THE HIGH LEVEL EXPRESSION OF ACTIVE LYMPHOTOXIN-BETA RECEPTOR IMMUNOGLOBULIN CHIMERIC PROTEINS AND THEIR PURIFICATION - Methods for high level expression of active lymphotoxin-β receptor immunoglobulin chimeric proteins and their purification. | 06-03-2010 |
| 20100136626 | Production and Use of Novel Peptide-Based Agents for Use with Bi-Specific Antibodies - The present invention relates to a bi-specific antibody or antibody fragment having at least one arm that is reactive against a targeted tissue and at least one other arm that is reactive against a targetable conjugate. The targetable conjugate encompasses a hapten to which antibodies have been prepared. In preferred embodiments, the hapten is histamine-succinyl-glycine (HSG). In more preferred embodiments, the at least one arm comprises the CDR sequences of the HSG-binding 679 antibody. The targetable conjugate is attached to one or more therapeutic and/or diagnostic agents. The invention provides constructs and methods for producing the bispecific antibodies or antibody fragments, as well as methods for using them and kits comprising them. | 06-03-2010 |
| 20100136627 | Engineered Rabbit Antibody Variable Domains and Uses Thereof - The present invention relates to methods for screening and producing polypeptides that immunospecifically bind to an antigen, which: polypeptides comprise binding domains that are derived from rabbit immunoglobulin. Using rabbit antibody heavy-chain or light-chain scaffolds, the methods of the invention allow identification of novel CDR loops and framework regions that confer enhanced stability and/or affinity to isolated immunoglobulin variable domains, in particular, relative to those derived from rodent antibodies. The enhanced stability and/or affinity of the variable domains of the invention permit their use in the production research tools or therapeutic immunospecific polypeptides, including single domain immunospecific polypeptides, i.e., comprising one of a V | 06-03-2010 |
| 20100151522 | Process For Producing Recombinant Fibrinogen Highly Producing Cell and Highly Producing Cell - When genes encoding three kinds of proteins constituting fibrinogen, an α chain (or variant of α chain), a β chain and a γ chain (or variant of γ chain) are incorporated into an animal cell, a constitutional ratio of respective genes is such that a γ chain (and/or variant of γ chain) gene is an equal amount to a 1000-fold amount relative to an α chain (and/or variant of α chain) gene and a β chain gene and, further, by using a baculovirus P35 gene, a recombinant fibrinogen highly producing cell is prepared. | 06-17-2010 |
| 20100151523 | REGULATED EXPRESSION OF RECOMBINANT PROTEINS FROM ADENO-ASSOCIATED VIRAL VECTORS - Single AAV vector constructs for regulated expression of an immunoglobulin molecule or fragment thereof and methods of making and using the same are described. The AAV vectors comprise a regulated promoter operably linked to the coding sequence for a first and second immunoglobulin coding sequence, a sequence encoding a self-processing cleavage site between the coding sequence for the first and second immunoglobulin coding sequence and a additional proteolytic cleavage site, which provides a means to remove the self processing peptide sequence from an expressed immunoglobulin molecule or fragment thereof. The vector constructs find utility in enhanced production of biologically active immunoglobulins or fragments thereof in vitro and in vivo. | 06-17-2010 |
| 20100151524 | Compositions and Methods for Increasing Bone Mineralization - A novel class or family of TGF-β binding proteins is disclosed. Also disclosed are assays for selecting molecules for increasing bone mineralization and methods for utilizing such molecules. In particular, compositions and methods relating to antibodies that specifically bind to TGF-beta binding proteins are provided. These methods and compositions relate to altering bone mineral density by interfering with the interaction between a TGF-beta binding protein sclerostin and a TGF-beta superfamily member, particularly a bone morphogenic protein. Increasing bone mineral density has uses in diseases and conditions in which low bone mineral density typifies the condition, such as osteopenia, osteoporosis, and bone fractures. | 06-17-2010 |
| 20100173360 | ZINC OXIDE-BINDING ANTIBODY AND USE THEREOF - The present invention relates to a zinc oxide-binding antibody having high stability and binding activity, and high-throughput sensing technology using the antibody, such as biosensors. Specifically, the present invention relates to a peptide-grafted antibody that contains a zinc oxide-recognizing peptide in the CDR H-1 region of a camel antibody, and a solid support (e.g., a biosensor and a protein chip) containing a zinc oxide layer on which the antibody has been immobilized. | 07-08-2010 |
| 20100173361 | Hepatocyte Growth Factor (HGF) Binding Proteins - The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic activity, the binding proteins can be used to treat certain HGF responsive disorders, for example, certain HGF responsive tumors. | 07-08-2010 |
| 20100173362 | Hepatocyte Growth Factor (HGF) Binding Proteins - The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic activity, the binding proteins can be used to treat certain HGF responsive disorders, for example, certain HGF responsive tumors. | 07-08-2010 |
| 20100178673 | Methods of Gene Amplification and Expression - Disclosed are methods relating to amplification and expression of a nucleic acid sequence encoding a polypeptide of interest in recombinant cells, and cell lines and polypeptides produced from such methods. The methods disclosed herein permit the amplification of cell lines that express a polypeptide of interest in a relatively short period of time through the use of a bioreactor. | 07-15-2010 |
| 20100184143 | Immunoglobulins comprising predominantly a Man3GlcNAc2 glycoform - The present invention relates to immunoglobulin glycoprotein compositions having predominant N-glycan structures on an immunoglobulin glycoprotein which confer a specific effector function. Additionally, the present invention relates to pharmaceutical compositions comprising an antibody having a particular enriched N-glycan structure, wherein said N-glycan structure is Man | 07-22-2010 |
| 20100184144 | IMMUNOGLOBULIN PRODUCTION - The current invention comprises a nucleic acid encoding the amino acid sequence of the C-terminal part of the C | 07-22-2010 |
| 20100184145 | ANTIBODY-BASED THERAPEUTICS WITH ENHANCED ADCC ACTIVITY - Methods for producing antibody-based therapeutics with enhanced ADCC activity are disclosed. The enhanced ADCC activity is attributed to oligomannose-type N-glycans on the antibodies and Fc fusion proteins of the invention. Also disclosed are methods of using such antibody-based therapeutics for targeted killing of cells in a mammal, including therapeutic methods of treating cancers, autoimmune diseases and other diseases. | 07-22-2010 |
| 20100190210 | Protein Purification - The present invention provides methods for purifying proteins. In particular, the methods employ a two-step non-affinity ion exchange chromatography process without the use of an in-process tangential flow filtration step. | 07-29-2010 |
| 20100190211 | IL-18 Receptors - A novel polypeptide that functions as an IL-18 receptor is disclosed. The receptor is multimeric and includes at least one AcPL polypeptide, or fragment thereof, and at least one IL-1Rrp1 polypeptide, or fraction thereof. The receptor binds IL-18 and finds use in inhibiting biological activities mediated by IL-18. | 07-29-2010 |
| 20100196961 | VARIABLE TANGENTIAL FLOW FILTRATION - The current invention reports a method for concentrating an immunoglobulin solution by tangential flow filtration wherein the transmembrane pressure and the cross-flow are variable. | 08-05-2010 |
| 20100203590 | ANTIBODIES THAT BIND INTERLEUKIN-4 RECEPTOR - The present invention relates to antibodies that bind to the IL-4 receptor, fragments, muteins, and derivatives of such antibodies, nucleic acids encoding such antibodies, fragments, muteins and derivatives, and methods of making and using such antibodies, fragments, muteins, derivatives and nucleic acids. Methods for treating medical conditions induced by interleukin-4 involve administering an IL-4 receptor binding antibody, or an IL-4 receptor binding fragment, mutein, or derivative of an IL-4 receptor binding antibody, to a patient afflicted with such a condition. Particular antibodies provided herein include human monoclonal antibodies. Certain of the antibodies inhibit both IL-4-induced and IL-13-induced biological activities. | 08-12-2010 |
| 20100216190 | Novel Selection System - The present invention relates to a method of producing a recombinant protein comprising using a selection method other than antibiotics. In particular, it relates to a stable host/vector system based on the pyrC gene complementation designed to produce high level of heterologous recombinant protein in | 08-26-2010 |
| 20100221781 | CHO-K1 CELL LINE - The current invention reports a CHO-K1 cell, characterized in that said CHO-K 1 cell is derived from CHO-K1 cell deposited as ATCC CCL-61, grows in suspension, requires no glutamine, no insulin, and no growth factors in the cultivation medium for growth, whereby said CHO-K1 cell is not modified compared to the deposited CHO-K1 cell ATCC CCL-61 cell line by the introduction, deletion, or inactivation of a nucleic acid. Also reported are a method for obtaining said CHO-K1 cell and a method for the production of a heterologous polypeptide using such a CHO-K1 cell according to the invention. | 09-02-2010 |
| 20100240099 | rBSA from K. lactis Expression, Secretion and Purification of Recombinant Bovine Serum Albumin (rBSA) from K. lactis and uses thereof - A recombinant BSA (rBSA) that (a) substantially lacks deoxyribonuclease activity as determined by incubating rBSA with linear DNA overnight and gel electrophoresis, (b) lacks animal viruses associated with animal-derived cell growth supplements; and (c) is capable of stabilizing DNA proteins is provided. Methods for making the rBSA and using it to stabilize enzymes are also provided. | 09-23-2010 |
| 20100240100 | HUMAN ANTIBODIES THAT HAVE MN BINDING AND CELL ADHESION-NEUTRALIZING ACTIVITY - The invention is composed of monoclonal human MN antibodies or MN antibody fragments that target the GEEDLP repeat within the proteoglycan domain. The proteoglycan domain of the MN cell surface protein contains four of these identical GEEDLP repeats. Binding to the desired epitope is verified by competition ELISA, where ELISA signal can be attenuated by co-incubation with a peptide containing this repeat (PGEEDLPGEEDLP). This inhibition of binding can also be verified using Biacore assays, where binding of desired antibodies to immobilized MN or proteoglycan peptides can be inhibited by the peptide repeat. In addition to binding to the peptide repeat, human anti-MN antibodies can inhibit the cell adhesion of CGL-1 cells to MN coated plastic plates. Human anti-MN antibodies have been used to diagnose and quantify MN expression in cancer cells and tumors using FACS and immunohistochemical methods. An example is also provided where a human anti-MN IgG1 mediates tumor cell lysis though antibody-dependent cell-mediated cytotoxicity. Therefore, these antibodies will be useful for the treatment of cancers in which MN is upregulated or can be useful for the diagnosis of cancers in which MN is upregulated. | 09-23-2010 |
| 20100248309 | THERMOSTABLE ALPHA1-ANTITRYPSIN MUTEIN WITH A DISULFIDE BOND AND THE METHOD FOR PREPARING IT - The present invention relates to a thermostable alpha-1-antitrypsin mutein with a disulfide bond and a preparation method of the same, more precisely an alpha-1-antitrypsin mutein with improved thermostability, compared with the conventional thermostable alpha-1-antitrypsin mutein (Korean Patent No. 133252), resulted from the process of substituting the 168 | 09-30-2010 |
| 20100255538 | ANTIBODIES TO INSULIN-LIKE GROWTH FACTOR I RECEPTOR - The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to insulin-like growth factor I receptor (IGF-IR), which is preferably human IGF-IR. The invention also relates to human anti-IGF-IR antibodies, including chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulin molecules derived from anti-IGF-IR antibodies and nucleic acid molecules encoding such molecules. The present invention also relates to methods of making anti-IGF-IR antibodies, pharmaceutical compositions comprising these antibodies and methods of using the antibodies and compositions thereof for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-IGF-IR antibodies. The invention also relates to gene therapy methods and transgenic animals comprising nucleic acid molecules of the present invention. | 10-07-2010 |
| 20100255539 | Engineered Antibody-Stress Protein Fusions - Provided are fusion polypeptides comprising an engineered antibody and a stress protein that bind to antigens with high affinity, are highly immunogenic, exhibit MHC class I priming and are able to be produced in non-mammalian cells, such as | 10-07-2010 |
| 20100279351 | Method for Generation of Antibodies - This invention generally relates to methods for the production of antibody producing cells and antibodies in protooncogene expressing animals. The invention also relates to methods for the efficient production of antibodies specific for antigens that are normally subject to immunological constraints such as self tolerance. The invention further relates to the production of antibody producing cells and antibodies without the need for the conventional fusing of antibody producing B cells with a myeloma fusion partner. | 11-04-2010 |
| 20100279352 | Rapid Generation of Antibodies - High efficient methods for producing an antibody molecule that binds an antigen are described. The methods include obtaining a population of PBMC enriched for CD19 | 11-04-2010 |
| 20100285530 | E.Coli Host Cells with Modified Phos/Psts Periplasmic Phosphate-binding Proteins, and Method of Manufacturing Recombinant Fabs - The present invention provides an | 11-11-2010 |
| 20100285531 | Therapeutic and Diagnostic Methods and Compositions Targeting 4Ig-B7-H3 and its Counterpart NK Cell Receptor - The present invention relates to the identification of 4Ig-B7-H3 protein as a tumor associated molecule that imparts protection from NK cell-mediated lysis via a 4Ig-B7-H3 receptor on NK cells. The invention provides compounds that interfere with interactions between the 4Ig-B7-H3 protein and its receptor that can be used to potentiate NK cell cytotoxicity. Also provided are compounds that bind 4Ig-B7-H3-expressing cells so as to inhibit or eliminate them. The compounds are particularly useful in the treatment of tumors, inflammatory conditions, infections and transplantation. Also provided are methods for diagnosing disease by detecting a 4Ig-B7-H3 protein. | 11-11-2010 |
| 20100291627 | METHOD FOR PRODUCTION OF ANTIBODY - The present invention provides a method of producing a recombinant antibody efficiently and at low cost. | 11-18-2010 |
| 20100291628 | Cells in which activity of the protein involved in transportation of GDP-fucose is reduced or lost - A cell in which the activity of a protein relating to transport of an intracellular sugar nucleotide, GDP-fucose, to the Golgi body is more decreased or deleted than its parent cell; a process for producing an antibody composition using the cell; a transgenic non-human animal or plant or the progenies thereof, in which genome is modified so as to have a decreased or deleted activity of a protein relating to transport of an intracellular sugar nucleotide, GDP-fucose, to the Golgi body; a process for producing an antibody composition from the animal or plant; and a medicament comprising the antibody composition. | 11-18-2010 |
| 20100297699 | Nucleic Acids Encoding Humanized Immunoglobulin That Binds Alpha4Beta7 Integrin - The invention relates to an isolated nucleic acid encoding a humanized immunoglobulin that has binding specificity for α4β7 integrin and comprises the complementarity determining regions (CDRs) of mouse Act-1 antibody. The present invention further relates to an isolated nucleic acid encoding a humanized heavy chain and an isolated nucleic acid encoding a humanized light chain. The invention also relates to recombinant vectors and host cells that comprise a nucleic acid which encodes a humanized immunoglobulin, humanized immunoglobulin heavy chain or a humanized immunoglobulin light chain, and to methods of preparing a humanized immunoglobulin. | 11-25-2010 |
| 20100297700 | Antibodies to TNF Alpha - Provided herein are antibodies, antigen binding portions, and derivatives thereof that are capable of binding tumor necrosis factor alpha (TNFα); nucleic acids encoding the antibodies, antigen binding portions, and derivatives thereof, including complementary nucleic acids; vectors; and host cells containing the nucleic acids. | 11-25-2010 |
| 20100304436 | Fucosylation-Deficient Cells - An isolated nucleic acid encoding an FX protein having a serine at position | 12-02-2010 |
| 20100311123 | VECTOR FOR EXPRESSING ANTIBODY FRAGMENTS AND A METHOD FOR PRODUCING RECOMBINANT PHAGE THAT DISPLAYS ANTIBODY FRAGMENTS BY USING THE VECTOR - Disclosed are a plasmid vector (pLA-1 or pLT-2) for producing water-soluble light chain antibody fragments (VL+CL), a phagemid vector (pHf1g3T-1 or pHf1g3A-2) having a heavy chain antibody fragments (VH+CH1)-ΔpIII fusion protein expression and genotype-phenotype linkage function, a host transformed using the vectors, and a method of producing and selecting a water-soluble antibody and recombinant phage displaying an antibody from the host. Also, provided are a method of producing a combinatorial phage display combinatorial Fab fragment libraries DVFAB-IL and DVFAB-13 IL by using a dual vector system (DVS-II) and a method of selecting an antigen-specific human Fab fragment from the combinatorial Fab fragment libraries. | 12-09-2010 |
| 20100311124 | Methods and compositions for inactivating glutamine synthetase gene expression - Disclosed herein are methods and compositions for inactivating a glutamine synthetase (GS) gene, using fusion proteins comprising a zinc finger protein and a cleavage domain or cleavage half-domain. Polynucleotides encoding said fusion proteins are also provided, as are cells comprising said polynucleotides and fusion proteins. | 12-09-2010 |
| 20110003334 | METHOD FOR PRODUCING A CELL CAPABLE OF HIGH-YIELD PRODUCTION OF HETEROPROTEINS - The present invention provides a cell capable of high-yield production of polypeptides and a method for producing the same. | 01-06-2011 |
| 20110003335 | METHODS FOR PROGNOSING THE STATUS OF TUMOR PATIENTS - A method for prognosing the status of a tumor patient is provided, wherein the level of antibodies against | 01-06-2011 |
| 20110003336 | Methods for Increasing the Therapeutic Efficacy of Immunoglobulin G Class 3 (IgG3) Antibodies - The present invention relates to methods for increasing the therapeutic efficacy of immunoglobulin G class 3 (IgG3) antibodies, immunoglobulin G class 3 (IgG3) antibodies with an improved therapeutic efficacy and the use thereof as a medicament, in particularly a medicament for immunotherapy. Specifically, the present invention relates to methods for increasing the therapeutic efficacy of an immunoglobulin G class 3 (IgG3) antibody comprising providing a mutated immunoglobulin G class 3 (IgG3) antibody, wherein the mutation, as compared to the parent immunoglobulin G class 3 (IgG3) antibody, comprises a replacement of the amino acid arginine (R) at position 435 in the C | 01-06-2011 |
| 20110003337 | IMMUNOGLOBULIN COMPOSITIONS AND METHODS OF PRODUCING SAME - 1. A method of producing an immunoglobulin in a bacterial culture, the method comprising: | 01-06-2011 |
| 20110003338 | ANTIBODIES WITH ENHANCED ADCC FUNCTION - The present invention concerns antibodies enhanced antibody-dependent cell mediated cytotoxicity (ADCC) and method for preparation thereof. | 01-06-2011 |
| 20110008840 | ANTI-CD33 ANTIBODIES AND METHODS FOR TREATMENT OF ACUTE MYELOID LEUKEMIA USING THE SAME - The present invention relates to antibodies that bind CD33. More particularly, the invention relates to anti-CD33 antibodies, fragments and homologues of these antibodies, humanized and resurfaced versions of these antibodies, functional equivalents and improved versions of these antibodies, immunoconjugates and compositions comprising these antibodies, and the uses of same in diagnostic, research and therapeutic applications. The invention also relates to a polynucleotide encoding these antibodies, vectors comprising the polynucleotides, host cells transformed with polynucleotides and methods of producing these antibodies. | 01-13-2011 |
| 20110008841 | POLYNUCLEOTIDES ENCODING IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS - The present invention relates to IL-17 receptor A (IL-17RA or IL-17R) antigen binding proteins, such as antibodies, and the polynucleotide sequences encoding them, as well as host cells, expression vectors, and methods of making IL-17 receptor A antigen binding proteins. | 01-13-2011 |
| 20110014653 | PRODUCTION OF ANTIBODIES IN AVIAN CELLS - The present invention relates generally to novel methods of producing immunoglobulin polypeptides. More specifically, the invention relates to methods of inserting immunoglobulin-encoding transgenes into avian cells for immunoglobulin production. In one embodiment, the transgenes include at least two immunoglobulin-encoding nucleic acid sequences and an internal ribosome entry site (IRES). | 01-20-2011 |
| 20110014654 | CELL FOR USE IN PROUDUCTION OF HETEROPROTEINS AND PRODUCTION METHOD USING THE SAME - The present invention provides a method capable of producing a protein efficiently. | 01-20-2011 |
| 20110014655 | Selection of host cells expressing protein at high levels - The invention provides a DNA molecule comprising a multicistronic transcription unit coding for i) a selectable marker polypeptide functional in a eukaryotic host cell, and for ii) a polypeptide of interest, the polypeptide of interest having a translation initiation sequence separate from that of the selectable marker polypeptide, characterized in that the coding sequence for the polypeptide of interest is downstream from the coding sequence for the selectable marker in the multicistronic transcription unit, and the nucleic acid sequence coding for the selectable marker polypeptide comprises a mutation that decreases the translation efficiency of the selectable marker in a eukaryotic host cell. The invention also provides methods for obtaining host cells expressing a polypeptide of interest, the host cells comprising the DNA molecules of the invention. The invention further provides the production of polypeptides of interest, comprising culturing host cells comprising the DNA molecules according to the invention. | 01-20-2011 |
| 20110014656 | SOLUBLE IL-17RA/RC FUSION PROTEINS AND RELATED METHODS - Disclosed are antagonists of IL-17A and IL-17F. The antagonists are based on soluble IL-17RA and IL-17RC fusion proteins, including hybrid soluble receptors comprising portions of both IL-17RC and IL-17RA (“IL-17RC/IL-17RA”). Such antagonists serve to block, inhibit, reduce, antagonize or neutralize the activity of IL-17F, IL-17A, or both IL-17A and IL-17F. Also disclosed are methods of using such antagonists for treating disease, particularly inflammatory diseases mediated at least in part by IL-17A and/or IL-17F. | 01-20-2011 |
| 20110039302 | Method of Producing Factor VIII Proteins by Recombinant Methods - Provided herein are methods and compositions for producing Factor VIII proteins. Such methods include introducing into a cell a nucleic acid molecule encoding a Factor VIII protein operably linked to a promoter, wherein the promoter is characterized by the ability to produce commercially viable Factor VIII protein; and incubating the cell under conditions for producing commercially viable Factor VIII protein. Also provided are nucleic acid molecules which encode a Factor VIII protein operably linked to a Chinese hamster elongation factor 1-α (CHEF1) promoter, which may be used in the methods provided herein. | 02-17-2011 |
| 20110045534 | Nucleic Acid Cassette For Producing Recombinant Antibodies - The invention provides a nucleic acid cassette comprising components in the following structure: A-B-C, wherein “A” is a nucleic acid sequence encoding a light chain of a first antibody (or antigen binding domain thereof), “B” is a nucleic acid sequence encoding a 2A peptide, “C” is a nucleic acid sequence encoding a heavy chain of a second antibody (or antigen binding domain thereof), and “−” is a phosphodiester or phosphorothioate bond. Also provided are methods for making recombinant antibodies using the nucleic acid cassette of the invention, cells and vector comprising the nucleic acid cassette of the invention, and kits for making the nucleic acid cassette of the invention. | 02-24-2011 |
| 20110045535 | Activator for Blood Coagulation Factor VII Promoter and Utilization of the Same - It is intended to provide an activator for blood coagulation factor VII. Ribavirin or its derivative is used as an activator for blood coagulation factor VII promoter. | 02-24-2011 |
| 20110045536 | MAMMALIAN EXPRESSION VECTOR - The invention provides vector nucleic acid for expressing at least one polypeptide of interest in a mammalian cell, comprising (a) at least one expression cassette (POI) for expressing a polypeptide of interest; (b) an expression cassette (MSM) comprising a mammalian selectable marker gene; (c) an expression cassette (MASM) comprising a mammalian amplifiable, selectable marker gene; wherein the expression cassette (POI) is flanked 5′ by the expression cassette (MASM), the expression cassette (MSM) is located 3′ from the expression cassette (POI) and wherein the expression cassettes (MASM), (POI) and (MSM) are arranged in the same 5′ to 3′ orientation. Also provided are host cells, comprising said vector and methods for producing a polypeptide using respective host cells. | 02-24-2011 |
| 20110045537 | Human Anti-IFN-gamma Neutralizing Antibodies as Selective IFN-gamma Pathway Inhibitors - This invention provides antibodies that interact with or bind to human interferon-gamma (IFN-γ) and methods for treating IFN-γ mediated diseases by administering a pharmaceutically effective amount of antibodies to IFN-γ. Methods of detecting the amount of IFN-γ in a sample using antibodies to IFN-γ are also provided. | 02-24-2011 |
| 20110045538 | Peptide, Use Of The Peptide, Method For The Production Of The Peptide, Solid Support Having The Peptide Immobilized Thereon, And Method For Production Of The Solid Support - Provided is a peptide containing a variable region and improved in production efficiency. | 02-24-2011 |
| 20110053222 | PC5 as a Factor IX Propeptide Processing Enzyme - Compositions and methods for preparing Factor IX, Factor IX-containing fusion proteins, and Factor IX-containing conjugates with processing of Factor IX propeptide by PCS, are provided. In one embodiment PCS is used to process a precursor polypeptide for a Factor IX-Fc monomer-dimer hybrid. | 03-03-2011 |
| 20110053223 | CELL CULTURE METHODS TO MAKE ANTIBODIES WITH ENHANCED ADCC FUNCTION - The present invention concerns antibodies with enhanced antibody-dependent cell mediated cytotoxicity (ADCC) and method for preparation thereof. | 03-03-2011 |
| 20110059488 | Anti-MPL Antibodies - Anti-human Mpl antibodies were isolated and purified, and then anti-human Mpl diabodies and anti-human Mpl sc(Fv)2 were purified using genetic engineering techniques. Furthermore, the present inventors succeeded in humanizing anti-human Mpl sc(Fv)2. | 03-10-2011 |
| 20110070613 | Monoclonal Antibody - The present invention is related to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease. The present invention provides novel methods and compositions comprising highly specific and highly effective antibodies having the ability to specifically recognize and bind to specific epitopes from a range of β-amyloid proteins. The antibodies enabled by the teaching of the present invention are particularly useful for the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of diseases and disorders associated with amyloid plaque formation including secondary amyloidosis and age-related amyloidosis including, but not limited to, neurological disorders such as Alzheimer's Disease (AD). | 03-24-2011 |
| 20110070614 | FUCOSE TRANSPORTER - The present invention provides a gene encoding a fucose transporter, a fucose transporter polypeptide, a method for screening for a compound that binds to a fucose transporter or a compound that inhibits fucose transport activity, a cell having inhibited fucose transporter functions, and a cell wherein the expression of the fucose transporter is inhibited. The present invention further relates to a method for producing recombinant protein, and specifically, to a method for producing protein by which fucose existing within the Golgi apparatus of a host cell is decreased, a method for inhibiting the addition of fucose to protein by which fucose existing within the Golgi apparatus of a host cell is decreased upon production of recombinant protein using the host cell, a method for increasing the cytotoxic activity of an antibody by which an antibody is produced using a cell wherein fucose existing within the Golgi apparatus is decreased, and a cell having a Golgi apparatus wherein fucose existing within the Golgi apparatus is decreased. | 03-24-2011 |
| 20110070615 | Compositions and Methods Relating to Anti-IGF-1 Receptor Antibodies - The present invention provides compositions and methods relating to or derived from anti-IGF-1R antibodies. In particular embodiments, the invention provides fully human, humanized, or chimeric anti-IGF-1R antibodies that bind human IGF-1R, IGF-1R-binding fragments and derivatives of such antibodies, and IGF-1R-binding polypeptides comprising such fragments. Other embodiments provide nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having IGF-1R-related disorders or conditions. | 03-24-2011 |
| 20110076722 | STABLE MULTIVALENT ANTIBODY - The present invention relates to a multivalent antibody comprising multiple heavy chain variable regions of antibody linked to each other via a linker comprising an amino acid sequence encoding an immunoglobulin domain or a fragment thereof. | 03-31-2011 |
| 20110076723 | ANTIBODY-PEPTIDE FUSED SYNERGIBODY - Disclosed herein are synergibodies, antibody-peptide fused protein molecules containing antibodies and bioactive peptides, which function in the occurrence or progress of the identical disease. | 03-31-2011 |
| 20110081681 | HUMAN ANTIBODIES TO HUMAN CD20 AND METHOD OF USING THEREOF - A human antibody or antigen-binding fragment of an antibody that specifically binds human CD20 and is capable of inducing complement dependent cytotoxicity (CDC), and is capable of increasing symptom free survival time between about 2-fold to about 9-fold or more, relative to control-treated animals in a mouse model of human lymphoma. The antibody or antigen-binding fragment thereof is useful in a therapeutic method for treating a CD20-mediated disease or condition, such as for example, non-Hodgkin's lymphoma, rheumatoid arthritis, systemic lupus erythematosus, Crohn's disease, chronic lymphocytic leukemia, and inflammatory diseases. | 04-07-2011 |
| 20110104755 | Antibodies immunoreactive with mutant hydroxypenylpyruvatedioxygenase - Antibodies immunoreactive to mutant | 05-05-2011 |
| 20110104756 | HUMAN IgM ANTIBODIES, AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF PARTICULARLY IN THE CENTRAL NERVOUS SYSTEM - Antibodies, and particularly human antibodies, are disclosed that demonstrate activity in the treatment of demyelinating diseases as well as other diseases of the central nervous system that are of viral, bacterial or idiopathic origin, including neural dysfunction caused by spinal cord injury. Neuromodulatory agents are set forth that include and comprise a material selected from the group consisting of an antibody capable of binding structures or cells in the central nervous system, a peptide analog, a hapten, active fragments thereof, agonists thereof, mimics thereof, monomers thereof and combinations thereof. The neuromodulatory agent has one or more of the following characteristics: it is capable of inducing remyelination; binding to neural tissue; promoting Ca | 05-05-2011 |
| 20110104757 | Human anti-B7RP1 Neutralizing Antibodies - This invention provides antibodies that interact with or bind to human B7 related protein-1 (B7RP1) and antibodies that bind to and neutralize the function of B7RP1 thereby. The invention also provides pharmaceutical compositions of said antibodies and methods for neutralizing B7RP1 function, and particularly for treating immune disorders (e.g., inappropriate immune response) by administering a pharmaceutically effective amount of anti-B7RP1 antibodies. Methods of detecting the amount of B7RP1 in a sample using anti-B7RP1 antibodies are also provided. | 05-05-2011 |
| 20110104758 | RECOMBINANT CELL CLONES HAVING INCREASED STABILITY AND METHODS OF MAKING AND USING THE SAME - Disclosed are a stable recombinant cell clones which are stable in serum- and protein-free medium for at least 40 generations, a biomass obtained by multiplying the stable cell clone under serum- and protein-free culturing conditions, and a method of preparing recombinant proteins by means of the biomass. Furthermore, the invention relates to a method of recovering stable recombinant cell clones. | 05-05-2011 |
| 20110111461 | Antigen Binding Molecules that Bind EGFR, Vectors Encoding Same, and Uses Thereof - The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human EGFR. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function. | 05-12-2011 |
| 20110117601 | Glycosylation Profile Analysis - The present invention provides a method for the production of a glycosylated heterologous polypeptide comprising the steps of obtaining a sample from a crude fermentation broth, incubation of the sample with magnetic affinity beads, releasing glycans from the immobilized glycosylated polypeptides, measuring a glycosylation profile, comparing the glycosylation profile with a desired glycosylation profile of the recombinant glycosylated polypeptide, modifying the culture conditions in accordance to the glycosylation profile obtained, and repeating the process in order to obtain a glycosylated heterologous polypeptide with the desired glycosylation profile. With a similar method diagnostic markers can be identified and quantified. | 05-19-2011 |
| 20110117602 | HUMAN ANTIBODY CAPABLE OF INDUCING APOPTOSIS - A human antibody that has a specific reactivity with multiple tumor cell lines including ATL cells and possesses both safety and therapeutic efficacy and a fragment of said antibody are provided. A human antibody and a fragment of said antibody that may recognize HLA-DR β chain expressed on the surface of tumor cells were obtained. In particular, it was found that a dimer of scFv (diabody) of said antibody may induce potent apoptosis in cells expressing the HLA-DR β chain. The antibody and a fragment of said antibody obtained in accordance with the present invention are useful for a detection reagent, a diagnostic and a medicament for protection or treatment of cancers including ATL and/or viral infectious diseases. | 05-19-2011 |
| 20110129875 | IMMUNOSUPPRRESSIVE POLYPEPTIDES AND NUCLEIC ACIDS - The invention provides immunosuppressive polypeptides and nucleic acids encoding such polypeptides. In one aspect, the invention provides mutant CTLA-4 polypeptides and nucleic acids encoding mutant CTLA-4 polypeptides. Compositions and methods for utilizing such polypeptides and nucleic acids are also provided. | 06-02-2011 |
| 20110136173 | Novel Method for the Stabilization of Chimeric Immunoglobulins or Immunoglobulin Fragments, and Stabilized Anti-EGP-2 SCFV Fragment - The present invention relates to a method for stabilizing chimeric immunoglobulins or immunoglobulin fragments. Furthermore, the invention also provides a stabilized anti-EGP-2 scFv fragment. | 06-09-2011 |
| 20110143396 | VECTORS AND YEAST STRAINS FOR PROTEIN PRODUCTION: CA2+ ATPASE OVEREXPRESSION - Lower eukaryote host cells in which an endogenous or heterologous Ca | 06-16-2011 |
| 20110151513 | SHRNA-MEDIATED INHIBITION OF EXPRESSION OF ALPHA-1,6-FUCOSYLTRANSFERASE - The current invention comprises a method for producing a heterologous polypeptide with a reduced degree of fucose modification in a mammalian cell by cultivating the mammalian cell under conditions suitable for the expression of said heterologous polypeptide, and recovering the heterologous polypeptide from the mammalian cell or the culture, wherein in said mammalian cell the enzymatic activity of α1,6-fucosyltransferase is reduced by means of an shRNA directed against α1,6-fucosyltransferase mRNA. | 06-23-2011 |
| 20110159540 | Methods for Chemically Synthesizing Immunoglobulin Chimeric Proteins - The invention provides methods of chemically synthesizing chimeric proteins comprising at least a portion of an immunoglobulin constant region and a biologically active molecule. | 06-30-2011 |
| 20110159541 | Methods and compositions for inactivating alpha 1,6 fucosyltransferase (FUT8) gene expression - Disclosed herein are methods and compositions for inactivating a FUT8 gene, using fusion proteins comprising a zinc finger protein and a cleavage domain or cleavage half-domain. Polynucleotides encoding said fusion proteins are also provided, as are cells comprising said polynucleotides and fusion proteins. | 06-30-2011 |
| 20110165621 | HUMANIZED ANTIBODIES - The invention relates to novel humanized antibodies derived from the conventional antibody repertoire of species in the family Camelidae. | 07-07-2011 |
| 20110165622 | HUMANIZED ANTI-FACTOR D ANTIBODIES AND USES THEREOF - The invention relates to humanized anti-human Factor D monoclonal antibodies, their nucleic acid and amino acid sequences, the cells and vectors that harbor these antibodies and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation. These antibodies are useful for diagnostics, prophylaxis and treatment of disease. | 07-07-2011 |
| 20110171688 | METHOD OF PROVIDING IMMUNOGLOBULIN SECRETING B LYMPHOCYTES AND HUMAN ANTIBODIES - Provided is a method for producing a clone of an immortalized human B memory lymphocyte, comprising the step of inducing or enhancing telomerase activity in the B lymphocyte in the presence of a polyclonal B cell activator. The method is particularly useful in a method for producing a clone of an immortalized human B memory lymphocyte capable of producing a human monoclonal antibody with desired antigen specificity. | 07-14-2011 |
| 20110183376 | NOVEL ANTI-IGF-IR ANTIBODIES AND USES THEREOF - The present invention relates to novel antibodies capable of binding specifically to the human insulin-like growth factor I receptor IGF-IR and/or capable of specifically inhibiting the tyrosine kinase activity of said IGF-IR receptor, especially monoclonal antibodies of murine, chimeric and humanized origin, as well as the amino acid and nucleic acid sequences coding for these antibodies. The invention likewise comprises the use of these antibodies as a medicament for the prophylactic and/or therapeutic treatment of cancers overexpressing IGF-IR or any pathology connected with the overexpression of said receptor as well as in processes or kits for diagnosis of illnesses connected with the overexpression of the IGF-IR receptor. The invention finally comprises products and/or compositions comprising such antibodies in combination with anti-EGFR antibodies and/or compounds and/or anti-cancer agents or agents conjugated with toxins and their use for the prevention and/or the treatment of certain cancers. | 07-28-2011 |
| 20110189734 | NOVEL METHODS AND CELL LINES - This invention relates to fermentation processes for producing antibodies and other antigen binding compounds. Specifically, the present invention provides methods for increasing the specific productivity of an antibody produced in cell culture, increasing cell growth and increasing viability of cells in cell culture. Also provided are, expression stable, viable cell lines comprising DNA encoding adenovirus GAM1 and capable of producing a monoclonal antibody or fragment and/or variant thereof. | 08-04-2011 |
| 20110189735 | Superagonistic Anti-CD28 Antibodies - The present invention relates to one or more nucleic acid(s) encoding a binding molecule specifically binding to a human CD28 molecule, comprising
| 08-04-2011 |
| 20110195452 | SET OF SEQUENCES FOR TARGETING EXPRESSION AND CONTROL OF THE POST-TRANSLATIONAL MODIFICATION OF A RECOMBINANT POLYPEPTIDE - The present invention provides new tools useful for controlling the post-translational modifications of recombinant polypeptides. These tools are particular signal peptides allowing the targeting of recombinant polypeptides during their synthesis in a host cell to specific sub-cellular compartments and a specific designing of said recombinant polypeptides within said sub-cellular compartments. These signal peptides are SEQ ID no 1 to SEQ ID no 31 disclosed herein. The present invention relates therefore also to a process for producing a recombinant polypeptide, in particular to a post-translationally modified polypeptide comprising the steps of transfecting or transforming a cell with at least one numleic acid vector encoding a recombinant protein which is the polypeptide before being post-translationally modified or a recombinant protein different to said polypeptide, said recombinant protein comprising a peptide signal according to the present invention; growing the transfected cell; and harvesting the post-translationally modified polypeptide; wherein, when said recombinant protein is different to said polypeptide, the method also comprises a step of transfecting said cell with at least one vector encoding said polypeptide. The present invention allows advantageously, for example, to increase the yield of production of recombinant polypeptides, to prevent immunogenicity if recombinant polypeptides and to obtain therapeutically active recombinant polypeptides that are the exact copy of their natural counterpart. This invention relates particularly to the field of reorientation of plants made pharmaceuticals (PMP). | 08-11-2011 |
| 20110195453 | Antibodies Specific for Sclerostin and Methods for Increasing Bone Mineralization - Compositions and methods relating to antibodies that specifically bind to TGF-beta binding proteins are provided. These methods and compositions relate to altering bone mineral density by interfering with the interaction between a TGF-beta binding protein sclerostin and a TGF-beta superfamily member, particularly a bone morphogenic protein. Increasing bone mineral density has uses in diseases and conditions in which low bone mineral density typifies the condition, such as osteopenia, osteoporosis, and bone fractures. | 08-11-2011 |
| 20110195454 | Common Light Chain Mouse - A genetically modified mouse is provided, wherein the mouse is incapable of rearranging and expressing an endogenous mouse immunoglobulin light chain variable sequence, wherein the mouse expresses only one or two human light chain variable domains encoded by human immunoglobulin sequences operably linked to the mouse kappa (κ) constant gene at the endogenous mouse κ locus, wherein the mouse expresses a reverse chimeric antibody having a light chain variable domain derived from one of only two human light chain variable region gene segments and a mouse κ constant domain, and a human heavy chain variable domain and a mouse heavy chain constant domain, from an endogenous mouse heavy chain locus. Bispecific epitope-binding proteins that are fully human are provided, comprising two different heavy chains that associate with an identical light chain that comprises a variable domain derived from one of two different human light chain variable region gene segments. | 08-11-2011 |
| 20110195455 | Nucleic Acids Encoding Human Anti-IL-23 Antibodies - A human anti-IL-23p19 antibody, including isolated nucleic acids that encode at least one anti-IL-23p19 antibody, vectors, host cells, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices. | 08-11-2011 |
| 20110207174 | Peptide-containing culture medium for culturing animal cell - Disclosed is a culture medium for culturing an animal cell, which is characterized by containing a peptide comprising, as a constituent unit, an amino acid residue selected from the amino acid group consisting of serine, tyrosine and cysteine. The culture medium is suitable for the high level production of a protein by an animal cell. | 08-25-2011 |
| 20110229933 | HIGH TITER ANTIBODY PRODUCTION - The present invention provides, in part, methods for recombinantly expressing proteins at a high level along with cell culture media for doing the same. | 09-22-2011 |
| 20110244516 | Rage Fusion Proteins And Methods Of Use - Disclosed are RAGE fusion proteins comprising RAGE polypeptide sequences linked to a second, non-RAGE polypeptide. The RAGE fusion protein may utilize a RAGE polypeptide domain comprising a RAGE ligand binding site and an interdomain linker directly linked to an immunoglobulin C | 10-06-2011 |
| 20110244517 | SYSTEM FOR ANTIBODY EXPRESSION AND ASSEMBLY - The present invention provides methods and compositions for expression and production of recombinant antibodies in a host cell system, such as prokaryotic and eukaryotic expression systems. Particularly contemplated are recombinant systems for temporally separated expression of light chain and heavy chain of antibodies. The antibody products including antibody fragments can be used in various aspects of biological research, diagnosis and medical treatment. | 10-06-2011 |
| 20110250642 | Method for Displaying Antibodies - There is disclosed vector designs, constructs and approaches to construct antibody libraries that display antibodies, such as full-length immunoglobulins, single chain antibody (SCA) scFv, or Fab on the host cell surface. There is also disclosed screening approaches to isolate desired antibody binders from above mentioned antibody libraries for selective antibody targets. | 10-13-2011 |
| 20110250643 | ANTIBODY COMPOSITION-PRODUCING CELL - The present invention relates to a cell for the production of an antibody molecule such as an antibody useful for various diseases having high antibody-dependent cell-mediated cytotoxic activity, a fragment of the antibody and a fusion protein having the Fc region of the antibody or the like, a method for producing an antibody composition using the cell, the antibody composition and use thereof. | 10-13-2011 |
| 20110256587 | HIGH AFFINITY HUMAN ANTIBODIES TO HUMAN NERVE GROWTH FACTOR - A human antibody or antigen-binding fragment of an antibody which specifically binds human nerve growth factor (NGF) with K | 10-20-2011 |
| 20110262967 | USE OF HSA-PRODUCING CELLS - The present invention refers to the area of cell culture technology and relates to methods for multiplying/cloning cells, preferably cell lines, which are important to the production of biopharmaceuticals. The invention further relates to methods for manufacturing proteins and to the use of cells extracted and multiplied through single cell sorting and to media compositions that enable a multiplication of single cells. Through the use of albumin-producing, preferably HSA-producing, cells as feeder cells for the conditioning of medium or as host cells, the recloning efficiency and thereby the quantity of clones obtained can be significantly increased. A combination of these approaches is also possible. Through the use of albumin-producing, preferably HSA-producing, cells, an increase in the recloning efficiency can be achieved in serum-free and/or insulin-free medium as well, and in different cell types. | 10-27-2011 |
| 20110262968 | ANTIBODIES THAT BIND TO PSCA PROTEINS FOR DIAGNOSIS OF CANCER - Antibodies and molecules derived therefrom that bind to novel PSCA protein, and variants thereof, are described wherein PSCA exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, PSCA provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The PSCA gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with PSCA can be used in active or passive immunization. | 10-27-2011 |
| 20110269186 | ANTIBODIES AGAINST VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1 - Monoclonal antibodies that are specific for vascular endothelial growth factor receptor 1 (VEGFR-I). This invention also provides nucleotide sequences encoding and amino acid sequences comprising variable heavy and light chain immunoglobulin molecules, including sequences corresponding to the complementarity determining regions of CDR1, CDR2, and CDR3. The invention also provides methods for generation and expression of anti-VEGFR-I antibodies and methods of treating angiogenic-related disorders and reducing tumor growth by administering anti-VEGFR-I antibodies. | 11-03-2011 |
| 20110269187 | High Affinity Human Antibodies to Human IL-18 Receptor - An isolated antibody or antibody fragment that binds human interleukin-18 receptor alpha (hIL-18Rα), comprising a light chain variable region (LCVR) selected from the group consisting of SEQ ID NO: 5, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, 53, 61, 65, 69, 73, 77, and 81 and/or a heavy chain variable region (HCVR) selected from the group consisting of SEQ ID NO: 3, 7, 11, 15, 19, 23, 27, 31, 35, 39, 43, 47, 51, 55, 59, 63, 67, 71, 75, and 79, or a fragment or sequence modified by an amino acid substitution, deletion or addition thereof. | 11-03-2011 |
| 20110281301 | THE SECRETORY CAPACITY IN HOST CELLS - The invention concerns the field of protein production and cell culture technology. It describes a method of producing a heterologous protein of interest in a cell comprising a. Increasing the expression or activity of a secretion enhancing gene, and b. Increasing the expression or activity of an anti-apoptotic gene, and c. Effecting the expression of said protein of interest, whereby the secretion enhancing gene is a gene encoding a protein whose expression or activity is induced during one of the following cellular processes: plasma-cell differentiation, unfolded protein response (UPR), endoplasmic reticulum overload response (EOR). | 11-17-2011 |
| 20110287484 | EXPRESSION VECTOR CONTAINING THE MAJOR ENVELOPE PROTEIN P9 OF CYSTOVIRUS PHI6 AS A FUSION PARTNER, AND PROCESS FOR PRODUCING A MEMBRANE PROTEIN USING THE SAME - The present invention relates to a membrane protein expression vector containing the major envelope protein P9 of Cystovirus phi6 as a fusion partner, to cells transformed by the expression vector, and to a process for producing membrane proteins using the cells. Target proteins can be effectively expressed by the expression vector of the present invention. | 11-24-2011 |
| 20110287485 | METHODS OF GENERATING LIBRARIES AND USES THEREOF - This invention relates to methods for the generation of humanized antibodies, particularly a humanized antibody heavy chain protein and a humanized antibody light chain protein. The method comprises using cells that express or can be induced to express Activation Induced Cytidine Deaminase (AID). | 11-24-2011 |
| 20110287486 | Method for In Vitro Molecular Evolution of Protein Function - The present invention relates to a method for in vitro creation of molecular libraries evolution of protein function. Particularly, it relates to variability and modification of protein function by shuffling polynucleotide sequence segments. A protein of desired characteristics can be obtained by incorporating variant peptide regions (variant motifs) into defined peptide regions (scaffold sequence). The variant motifs can be obtained from parent DNA which has been subjected to mutagenesis to create a plurality of differently mutated derivatives thereof or they can be obtained from in vivo sequences. These variant motifs can then be incorporated into a scaffold sequence and the resulting coded protein screened for desired characteristics. This method is ideally used for obtaining antibodies with desired characteristics by isolating individual CDR DNA sequences and incorporating them into a scaffold which may, for example, be from a totally different antibody. | 11-24-2011 |
| 20110294162 | B-7 RELATED NUCLEIC ACIDS AND POLYPEPTIDES USEFUL FOR IMMUNOMODULATION - The present invention provides nucleic acids encoding B7-related factors that modulate the activation of immune or inflammatory response cells, such as T-cells. Also provided are expression vectors and fusion constructs comprising nucleic acids encoding B7-related polypeptides, including BSL1, BSL2, and BSL3. The present invention further provides isolated B7-related polypeptides, isolated fusion proteins comprising B7-related polypeptides, and antibodies that are specifically reactive with B7-related polypeptides, or portions thereof. In addition, the present invention provides assays utilizing B7-related nucleic acids, polypeptides, or peptides. The present invention further provides compositions of B7-related nucleic acids, polypeptides, fusion proteins, or antibodies that are useful for the immunomodulation of a human or animal subject. | 12-01-2011 |
| 20110300577 | NOVEL INHIBITORS OF VASCULAR ENDOTHELIAL GROWTH FACTOR ACTIVITY, THEIR USES AND PROCESSES FOR THEIR PRODUCTION - The present invention is directed to novel chimeric VEGF receptor proteins comprising amino acid sequences derived from the vascular endothelial growth factor (VEGF) receptors flt-1 and KDR, including the murine homologue to the human KDR receptor FLK-1, wherein said chimeric VEGF receptor proteins bind to VEGF and antagonize the endothelial cell proliferative and angiogenic activity thereof. The present invention is also directed to nucleic acids and expression vectors encoding these chimeric VEGF receptor proteins, host cells harboring such expression vectors, pharmaceutically acceptable compositions comprising such proteins, methods of preparing such proteins and to methods utilizing such proteins for the treatment of conditions associated with undesired vascularization. | 12-08-2011 |
| 20110300578 | NOVEL INHIBITORS OF VASCULAR ENDOTHELIAL GROWTH FACTOR ACTIVITY, THEIR USES AND PROCESSES FOR THEIR PRODUCTION - The present invention is directed to novel chimeric VEGF receptor proteins comprising amino acid sequences derived from the vascular endothelial growth factor (VEGF) receptors flt-1 and KDR, including the murine homologue to the human KDR receptor FLK-1, wherein said chimeric VEGF receptor proteins bind to VEGF and antagonize the endothelial cell proliferative and angiogenic activity thereof. The present invention is also directed to nucleic acids and expression vectors encoding these chimeric VEGF receptor proteins, host cells harboring such expression vectors, pharmaceutically acceptable compositions comprising such proteins, methods of preparing such proteins and to methods utilizing such proteins for the treatment of conditions associated with undesired vascularization. | 12-08-2011 |
| 20110306094 | METHOD FOR OBTAINING IMMUNOGLOBULIN ENCODING NUCLEIC ACID - The current invention is directed to a method for obtaining a nucleic acid encoding an immunoglobulin variable domain from a single cell comprising the following steps:—performing a first polymerase chain reaction with three to six 5′-primer and one 3′-primer, performing with the product of the first polymerase chain reaction a second polymerase chain reaction with thirteen to sixteen 5′-primer and one 3′-primer, whereby the distance of the binding locations of the primer employed in the second polymerase chain reaction is reduced compared to the first polymerase chain reaction. | 12-15-2011 |
| 20110306095 | METHODS FOR SELECTING EUKARYOTIC CELLS EXPRESSING A HETEROLOGOUS PROTEIN - The invention pertains to a method for selecting at least one eukaryotic host cell expressing a product of interest, comprising
| 12-15-2011 |
| 20120003696 | DIAGNOSTIC METHODS FOR DISEASES BY SCREENING FOR HEPCIDIN IN HUMAN OR ANIMAL TISSUES, BLOOD OR BODY FLUIDS, MONOCLONAL ANTIBODIES SPECIFIC TO HUMAN HEPCIDIN AND ASSOCIATED USES THEREFOR - The present invention concerns antibodies specific for the C-terminus of human hepcidin, and related methods and kits for diagnosing and/or treating a disease condition characterized by non-physiological levels of hepcidin protein, including prohepcidin and fragments thereof, comprising obtaining a tissue or fluid sample from a subject; contacting the sample with an antibody or fragment thereof that specifically binds to a polypeptide corresponding to the amino acid sequence between and including amino acids 60 and 84, or, in another embodiment, amino acids 74 and 81, as aligned with the human pre-pro-hepcidin precursor protein, and quantifying the pro-hepcidin and/or mature hepcidin level using an assay based on binding of the antibody and the polypeptide; wherein the non-physiological level of prohepcidin/mature hepcidin is indicative of the disease condition. The present invention also concerns diagnostic methods and kits for applications in genetic technological approaches, such as for overexpressing or downregulating hepcidin. | 01-05-2012 |
| 20120003697 | HIGH AFFINITY ANTIBODIES TO HUMAN IL-6 RECEPTOR - A human antibody or an antigen-binding fragment which binds human IL-6 receptor (hIL-6R) with a K | 01-05-2012 |
| 20120009621 | NOVEL ANTIBODY AND ANTIBODY FRAGMENT INTRODUCED NEW MODIFICATION SITES - The present invention relates to an antibody or antibody fragment comprising novel Cys residue, to which a hydrophilic macromolecular group or amphipathic macromolecular group can be bound at a high efficiency. In addition, the present invention relates to a monoclonal antibody modified product or an antibody fragment modified product in which cysteine residue is chemically modified. | 01-12-2012 |
| 20120009622 | ALPHA5-BETA1 ANTIBODIES AND THEIR USES - The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies, or antigen binding portions thereof, that specifically bind to integrin α5β1 with high affinity. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies or antigen binding portions thereof are also provided. The disclosure also provides methods for treating various cancers using the anti-α5β1 antibodies or antigen binding portions thereof described herein. | 01-12-2012 |
| 20120009623 | Methods for Recombinant Manufacturing of Anti-RSV Antibodies - The invention relates to a method for manufacturing recombinant anti-RSV antibodies and antibody compositions. The method comprises obtaining a collection of cells transfected with a collection of variant nucleic acid sequences, wherein each cell in the collection is transfected with and capable of expressing one distinct anti-RSV antibody. The cells are cultured under suitable conditions for expression of the anti-RSV antibody/antibodies. The nucleic acid sequence is introduced into the cells by transfection with expression vectors, which avoid site-specific integration. The present method is suitable for manufacturing recombinant mono- and polyclonal anti-RSV antibodies for therapeutic uses. | 01-12-2012 |
| 20120015402 | Method of Proliferating Plasma Cells - An objective of the present invention is to facilitate the acquisition of antibody-producing cells that are infiltrating virus-infected cells, cancer cells, abnormal cells forming a benign hyperplasia, and the like, and to improve the efficiency of the production of antibodies as well as nucleic acids encoding them from the antibody-producing cells. | 01-19-2012 |
| 20120028302 | Production of oligoclonal mixtures of immunoglobulins in single cells - The present invention provides methods to produce mixtures of exogenous proteins in single cells. Preferably said exogenous proteins are heteromeric and multimeric proteins, such as immunoglobulins. The method enables the controlled expression of proteins, thereby allowing the correct formation and assembly of multimeric proteins, such as immunoglobulins. | 02-02-2012 |
| 20120028303 | SYNTHETIC IMMUNOGLOBULIN DOMAINS WITH BINDING PROPERTIES ENGINEERED IN REGIONS OF THE MOLECULE DIFFERENT FROM THE COMPLEMENTARITY DETERMINING REGIONS - A method of engineering immunoglobulins which each have one or more amino acid modifications in at least one structural loop region of such immunoglobulins, where the modified loop region specifically binds to an epitope of an antigen to which an un-modified immunoglobulin does not significantly bind. | 02-02-2012 |
| 20120028304 | ANTIBODIES WITH MODIFIED ISOELECTRIC POINTS - The invention relates generally to compositions and methods for altering the isoelectric point of an antibody, and in some cases, resulting in improved plasma pharmacokinetics, e.g. increased serum half-life in vivo. | 02-02-2012 |
| 20120034656 | Neutralising Antibody Molecules Having Specificity for Human IL-17 - The invention relates to an antibody molecule having specificity for antigenic determinants of IL-17, therapeutic uses of the antibody molecule and methods for producing said antibody molecule. | 02-09-2012 |
| 20120034657 | THROMBOPOIETIC COMPOUNDS - The invention relates to the field of compounds, especially peptides or polypeptides, that have thrombopoietic activity. The peptides and polypeptides of the invention may be used to increase platelets or platelet precursors (e.g., megakaryocytes) in a mammal. | 02-09-2012 |
| 20120040401 | Method For Producing Proteins - The invention relates to a transcriptionally active recombinant linear polynucleotide encoding a multimeric protein comprising in the following order, a first promoter sequence, a first encoding polynucleotide sequence, a bidirectional regulatory sequence, a second encoding polynucleotide sequence and a second promoter sequence, wherein the first and second encoding polynucleotide sequences are in convergent transcriptional orientation, each encoding polynucleotide sequence encodes a component of the multimeric protein and the bidirectional regulatory sequence is operably linked to the first and second encoding polynucleotide sequences and the multimeric protein is an antibody or fragment thereof and each encoding polynucleotide sequence encodes one or more antibody domains or fragments thereof. | 02-16-2012 |
| 20120040402 | PLASMID SYSTEM FOR MULTIGENE EXPRESSION - The present invention provides a plasmid system which facilitates the construction of a single amplifiable plasmid that, having the potential to accommodate many independent expression cassettes, has the ability to express multi-subunit complex proteins such as antibodies and receptors. | 02-16-2012 |
| 20120045795 | METHOD FOR PRODUCING A CELL CAPABLE OF HIGH-YIELD PRODUCTION OF HETEROPROTEINS - The present invention provides a cell capable of high-yield production of polypeptides and a method for producing the same. | 02-23-2012 |
| 20120070860 | COMBINATION STIRRER - The present patent application describes a stirrer comprising a combination of at least one axially-conveying element and at least one radially-conveying element relative to the rotary shaft of the stirrer wherein the largest diameter of the at least one axially-conveying element is equal to or less than the inner diameter d | 03-22-2012 |
| 20120077229 | Compositions and methods relating to proteins requiring Gamma-Carboxylation - The present invention relates a host cell comprising an expression vector comprising a nucleic acid molecule encoding a protein requiring gamma-carboxylation and associated expression control sequences and a nucleic acid molecule encoding a vitamin K epoxido reductase and associated expression control sequences and a nucleic acid molecule encoding a γ-glutamyl carboxylase and associated control sequences. The invention further relates to a method of producing a protein requiring gamma-carboxylation in high yields. | 03-29-2012 |
| 20120094329 | INCREASING PROTEIN PRODUCTION BY INCREASING ABC50 EXPRESSION OR ACTIVITY - The disclosure provides methods and materials for increasing the expression of a protein of interest such as an antibody by a cell. ABC50 expression or activity is increased which increases expression of the protein or antibody of interest. The disclosure also provides methods and materials for increasing the sensitivity of a cell to an endoplasmic reticulum stress agent such as Econozole by decreasing the level of ABC50. | 04-19-2012 |
| 20120100575 | ANTIBODIES HAVING ALTERED EFFECTOR FUNCTION AND METHODS FOR MAKING THE SAME - The invention provides a method of producing aglycosylated Fc-containing polypeptides, such as antibodies, having desired effector function. The invention also provides aglycosylated antibodies produced according to the method as well as methods of using such antibodies as therapeutics. | 04-26-2012 |
| 20120107874 | Modified Host Cells and Uses Thereof - The present disclosure provides compositions and methods comprising cells producing glycoproteins with variant glycosylation patterns. The methods and compositions may be used in producing antibodies and proteins of therapeutic value. | 05-03-2012 |
| 20120129219 | Antibody Molecules Which Bind Human IL-17 - The invention relates to antibody molecules having specificity for antigenic determinants of IL-17, therapeutic uses of the antibody molecules and methods of producing the antibody molecules. | 05-24-2012 |
| 20120142056 | MAMMALIAN EXPRESSION VECTOR pUHAB - The present invention relates to the construction and utilization of a new mammalian expression vector that contains a unique multiple cloning site (MCS), designated pUHAB. The pUHAB vector comprises a high copy replication origin (ColE1), a drug resistance gene (TK-Hygromycin), and a human cytomegalovirus promoter operably associated with a unique intron (hCMV/intron). Further, pUHAB comprises a selectable marker conferring resistance to kanamycin in bacterial cells, and a phage f1(+) region. pUHAB can be used to transiently or stably express cloned genes when transfected into mammalian cells. The invention also encompasses kits and host cells and cell lines comprising pUHAB, and methods of producing a recombinant protein using pUHAB. | 06-07-2012 |
| 20120142057 | METHOD FOR PRODUCTION OF POLYPEPTIDE - The present invention provides a method capable of producing a natural or recombinant protein in high yield. The present invention relates to a method of producing a polypeptide, comprising culturing a cell which strongly expresses cysteine sulfinic acid decarboxylase and has a transferred DNA encoding a desired polypeptide and thereby allowing the cell to produce the polypeptide. Hamster cysteine sulfinic acid decarboxylase, a DNA encoding the same, a recombinant vector and a transformed cell are also provided. | 06-07-2012 |
| 20120149061 | Modified Antibody Compositions, Methods of Making and Using Thereof - The present disclosure provides modified antibodies which contain an antibody or antibody fragment (AB) modified with a masking moiety (MM). Such modified antibodies can be further coupled to a cleavable moiety (CM), resulting in activatable antibodies (AAs), wherein the CM is capable of being cleaved, reduced, photolysed, or otherwise modified. AAs can exhibit an activatable conformation such that the AB is more accessible to a target after, for example, removal of the MM by cleavage, reduction, or photolysis of the CM in the presence of an agent capable of cleaving, reducing, or photolysing the CM. The disclosure further provides methods of making and using such modified antibodies and activatable antibodies. | 06-14-2012 |
| 20120156724 | HUMANIZED ANTI-CD47 ANTIBODY - The present invention relates to humanized antibodies binding to CD47; diabodies binding to human CD47, characterized in that a disulfide bond exists between diabody-forming fragments; genes encoding any one of said antibodies; vectors containing said genes; host cells containing said vectors; processes for preparing antibodies comprising the step of culturing said host cells; and therapeutic agents for hematological disorders comprising said antibodies. | 06-21-2012 |
| 20120156725 | Human Anti-OPGL Neutralizing Antibodies As Selective OPGL Pathway Inhibitors - Monoclonal antibodies and hybridomas producing them that interact with osteoprotegerin ligand (OPGL) are provided. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are also provided. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are further provided. | 06-21-2012 |
| 20120164688 | HIGH AFFINITY HUMAN ANTIBODIES TO HUMAN NERVE GROWTH FACTOR - A human antibody or antigen-binding fragment of an antibody which specifically binds human nerve growth factor (NGF) with K | 06-28-2012 |
| 20120178126 | METHODS AND MATERIALS FOR INCREASING EXPRESSION OF RECOMBINANT POLYPEPTIDES - The present invention provides novel methods and materials for increasing the expression of recombinant polypeptides. Methods and materials of the invention allow increased expression of transcription units that include recombinant DNA sequences which encode polypeptides of interest. The present invention provides expression vectors which contain multiple copies of a transcription unit encoding a polypeptide of interest separated by at least one selective marker gene and methods for sequentially transforming or transfecting host cells with expression vectors to increase transcription unit dosage and expression. | 07-12-2012 |
| 20120178127 | Nucleic acid encoding apoptotic anti-ige antibodies - The present application relates to apoptotic anti-IgE antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use in the treatment of IgE-mediated disorders. | 07-12-2012 |
| 20120183996 | ANTIBODY MOLECULES HAVING SPECIFICITY FOR HUMAN IL-6 - The invention relates to antibody molecules having specificity for antigenic determinants of IL-6, therapeutic uses of the antibody molecules and methods for producing said antibody molecules. | 07-19-2012 |
| 20120183997 | METHODS AND COMPOSITIONS FOR MAKING ANTIBODIES AND ANTIBODY DERIVATIVES WITH REDUCED CORE FUCOSYLATION - The invention provides methods and compositions for preparing antibodies and antibody derivatives with reduced core fucosylation. | 07-19-2012 |
| 20120190070 | Sp35 Antibodies and Uses Thereof - Endogenous Sp35 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination. Molecules that block endogenous Sp35 function, such anti-Sp35 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. The present invention provides antibodies specific for Sp35, and methods of using such antibodies as antagonists of endogenous Sp35 function. The invention further provides specific hybridoma and phage library-derived monoclonal antibodies, nucleic acids encoding these antibodies, and vectors and host cells comprising these antibodies. The invention further provides methods of promoting oligodendrocyte survival and myelination in a vertebrate, comprising administering to a vertebrate in need of such treatment an effective amount of an anti-Sp35 antibody. | 07-26-2012 |
| 20120196327 | PROCESS FOR PRODUCTION OF PROTEIN - The present invention relates to a method for integrating a gene fragment inserted between a pair of transposon sequences into a chromosome of a mammalian cell, comprising introducing at least one expression vector which comprises a gene fragment comprising a DNA encoding a protein of interest and also comprises a pair of transposon sequences at both terminals of the gene fragment, into a suspension mammalian cell; and a method for producing the protein of interest comprising suspension-culturing a suspension mammalian cell which produces the protein of interest; and an a suspension mammalian cell which expresses the protein of interest. | 08-02-2012 |
| 20120208237 | HUMAN ANTI-KIR ANTIBODIES - Compositions and methods for regulating an immune response in a subject are described. More particularly, described are human antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects, and antibodies having antigen-binding properties similar to those of human monoclonal antibody 1-7F9 or 1-4F1. Described also are also fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly for use in therapy, to increase NK cell activity or cytotoxicity in subjects. | 08-16-2012 |
| 20120208238 | ENGINEERED IMMUNOGLOBULIN FC POLYPEPTIDES - Methods and compositions involving polypeptides having an aglycosylated antibody Fc domain. In certain embodiments, polypeptides have an aglycosylated Fc domain that contains one or more substitutions compared to a native Fc domain. Additionally, some embodiments involve an Fc domain that is binds some Fc receptors but not others. For example, polypeptides are provided with an aglycosylated Fc domain that selectively binds FcγRIIa, but that is significantly reduced for binding to the highly homologous FcγRIIb receptors. Furthermore, methods and compositions are provided for promoting antibody-dependent cell-mediated toxicity (ADCC) using a polypeptide having a modified aglycosylated Fc domain and a second non-Fc binding domain, which can be an antigen binding region of an antibody or a non-antigen binding region. Some embodiments concern antibodies with such polypeptides, which may have the same or different non-Fc binding domain. | 08-16-2012 |
| 20120219990 | PRE-FILTRATION ADJUSTMENT OF BUFFER SOLUTES - Herein is reported a tangential flow filtration method with a pre-filtration solute concentration adjustment in order to ensure a defined concentration of the components of the solution after tangential flow filtration. | 08-30-2012 |
| 20120219991 | CLONAL EXPANSION OF B CELLS - The present invention provides recombinant proteins comprising the amino acid sequence of an intracellular segment of CD40 and an amino acid sequence mediating the association of the recombinant protein with the constant region of an immunoglobulin heavy chain. The recombinant proteins according to the present invention are useful for inducing clonal expansion of a B cell having a predetermined antigen-specificity without the need for T cell or CD40L mediated co-stimulation. Thus, the present invention provides tools for clonal expansion of B cells specific for an antigen of interest and the production of B cells secreting antibodies specific for an antigen of interest. The recombinant proteins of the present invention may also be used for generating fully human monoclonal antibodies with a predetermined antigen-specificity from the B cell repertoire of a human subject. | 08-30-2012 |
| 20120231506 | MULTISTEP FINAL FILTRATION - Herein is reported a method for the final filtration of concentrated polypeptide solutions comprising the combination of two immediately consecutive filtration steps with a first filter of 3.0 μm and 0.8 μm pore size and a second filter of 0.45 μm and 0.22 μm pore size. | 09-13-2012 |
| 20120237975 | ENGINEERED NUCLEIC ACIDS AND METHODS OF USE THEREOF - Provided are compositions and methods for delivering biological moieties such as modified nucleic acids into cells to modulate protein expression. Such compositions and methods include the use of modified messenger RNAs, and are useful for production of proteins. | 09-20-2012 |
| 20120237976 | MAMMALIAN EXPRESSION VECTORS AND USES THEREOF - The present invention features nucleic acids for recombinant protein expression in mammalian cell culture. The episomal vectors of the invention promote high protein production in mammalian cells expressing the SV40 T Ag or Epstein-Barr virus nuclear antigen (e.g., COS7 or HEK293-6E cells). The methods and systems are useful, for example, in pharmaceutical drug development and cloning, especially for the production of antibodies. | 09-20-2012 |
| 20120237977 | Activatable Binding Polypeptides and Methods of Identification and Use Thereof - Activatable binding polypeptides (ABPs), which contain a target binding moiety (TBM), a masking moiety (MM), and a cleavable moiety (CM) are provided. Activatable antibody compositions, which contain a TBM containing an antigen binding domain (ABD), a MM and a CM are provided. Furthermore, ABPs which contain a first TBM, a second TBM and a CM are provided. The ABPs exhibit an “activatable” conformation such that at least one of the TBMs is less accessible to target when uncleaved than after cleavage of the CM in the presence of a cleaving agent capable of cleaving the CM. Further provided are libraries of candidate ABPs, methods of screening to identify such ABPs, and methods of use. Further provided are ABPs having TBMs that bind VEGF, CTLA-4, or VCAM, ABPs having a first TBM that binds VEGF and a second TBM that binds FGF, as well as compositions and methods of use. | 09-20-2012 |
| 20120244577 | MULTIVALENT HETEROMULTIMER SCAFFOLD DESIGN AND CONSTRUCTS - Provided herein are multifunctional heteromer proteins. In specific embodiments is a heteromultimer that comprises: at least two monomeric proteins, wherein each monomeric protein comprises at least one cargo polypeptide, attached to a transporter polypeptide, such that said monomeric proteins associate to form the heteromultimer. These therapeutically novel molecules comprise monomers that function as scaffolds for the conjugation or fusion of therapeutic molecular entities resulting in the creation of bispecific or multivalent molecular species. | 09-27-2012 |
| 20120244578 | MONOMERIC ANTIBODY FC - The invention relates to monomeric Fc polypeptides and methods of making and using such polypeptides. The polypeptides comprise substitution of one or more hydrophobic interface residues in the CH3 region with a polar amino acid. | 09-27-2012 |
| 20120258495 | SEQUENCE DIVERSITY GENERATION IN IMMUNOGLOBULINS - Compositions and methods are disclosed for generating immunoglobulin structural diversity in vitro, and in particular, for reducing biases in V region and J segment gene utilization, and for generating immunoglobulin V-D-J recombination events in a manner that does not require D-J recombination to precede V-DJ recombination. Selection of advantageous combinations of immunoglobulin gene elements, including introduction of artificial diversity (D) segment genes and optimization of recombination signal sequence (RSS) efficiency, are disclosed. | 10-11-2012 |
| 20120258496 | PRODUCTION OF LOW FUCOSE ANTIBODIES IN H4-II-E RAT CELLS - The invention concerns the field of cell culture technology. It specifically concerns a rat hepatoma cell, preferably a H4-II-E rat hepatoma cell, carrying a DNA encoding an antibody or Fc-fusion protein and having low fucosylation activity for adding fucose to glycosidic structures such as biantennary glycans, e.g. N-acetylglucosamine. The invention furthermore concerns a method for producing low fucose glycoproteins especially antibodies or Fc-fusion proteins in rat hepatoma cells, preferably in H4-II-E rat hepatoma cells. It further concerns the identification and generation of new host cell lines which are capable of synthetizing glycoproteins with beneficial properties, improving the therapeutic efficacy and/or serum half-life of the product compared to products from commonly used host cell lines. | 10-11-2012 |
| 20120258497 | Alpha-Amylases - The present invention relates to alpha-amylase variants, polynucleotides encoding the variants and nucleic acid constructs, vectors, and host cells comprising the polynucleotides, and methods of using the variant enzymes. | 10-11-2012 |
| 20120264170 | CELL LINE 3M - The present invention provides, inter alia, an isolated cell line, 3M as well as methods for making such a cell line and methods of using such a cell line, e.g., to produce a protein such as an immunoglobulin. | 10-18-2012 |
| 20120264171 | Stabilization of Alpha-Amylases Towards Calcium Depletion and Acidic PH - The present invention relates to variants of a parent alpha-amylase, the variant having improved stability or activity at low calcium conditions or at low pH. | 10-18-2012 |
| 20120270265 | METHODS OF OBTAINING A SPECIFIC BINDING MEMBER THAT BINDS EOTAXIN - Specific binding members directed to eotaxin-1, in particular human antibodies and antibody fragments against human eotaxin-1 and especially those which neutralise eotaxin-1 activity. The antibodies VH and/or VL domain of the scFv fragment herein termed CAT-212 and of the IgG4 antibody herein termed CAT 213. One or more complementary determining regions (CDRs) of the CAT-212-213 VH and/or VL domains, especially VH CRD3 in other antibody framework regions. Compositions containing specific binding members, and their use in methods of inhibiting or neutralising eotaxin, including methods of treatment of the human or animal body by therapy. | 10-25-2012 |
| 20120270266 | NUCLEIC AC1D AND AMINO AC1D SEQUENCES ENCODING HIGH-LEVEL EXPRESSOR FACTOR VIII POLYPEPTIDES AND METHODS OF USE - Methods and compositions are provided that allow for high-level expression of a factor VIII polypeptide. More specifically, methods and compositions are provided comprising nucleic acid and amino acid sequences comprising a modified factor VIII that result in high-level expression of the polypeptide. The methods and compositions of the invention find use in the treatment of factor VIII deficiency including, for example, hemophilia A. | 10-25-2012 |
| 20120270267 | Alpha-Amylases - The present invention relates to alpha-amylase variants, polynucleotides encoding the variants and nucleic acid constructs, vectors, and host cells comprising the polynucleotides, and methods of using the variant enzymes. | 10-25-2012 |
| 20120270268 | Anti-CD100 Neutralizing Antibodies and Methods of Using the Same - Compositions and methods are provided for treating diseases associated with CD100, including certain autoimmune diseases, inflammatory diseases, and cancers. In particular, anti-CD100 monoclonal antibodies have been developed to neutralize CD100. | 10-25-2012 |
| 20120276591 | Compositions and Methods for Use for Antibodies Against Sclerostin - The present invention relates to antibodies against sclerostin and compositions and methods of use for said antibodies to treat a pathological disorder that is mediated by sclerostin or disease related to bone abnormalities such as osteoporosis. | 11-01-2012 |
| 20120282654 | ANTIBODY PURIFICATION - The present invention provides, in part, a multi-step process for purifying antibodies including chromatographic purification and filter purification. | 11-08-2012 |
| 20120288894 | BACTERIAL HOST STRAIN EXPRESSING RECOMBINANT DSBC AND HAVING REDUCED TSP ACTIVITY - The present invention provides a recombinant gram-negative bacterial cell, characterized in that the cell comprises a recombinant polynucleotide encoding DsbC and has reduced Tsp protein activity compared to a wild-type cell. | 11-15-2012 |
| 20120288895 | Compositions and Methods for Modulating Hemostasis Using Variant Forms of Activated Factor V - Methods for the treatment of coagulation disorders using Factor V/Va variants are provided. | 11-15-2012 |
| 20120288896 | NUCLEIC ACID MOLECULES ENCODING ANTI-AMYLOID-BETA ANTIBODIES - The present invention is related to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease. The present invention provides novel methods and compositions comprising highly specific and highly effective antibodies having the ability to specifically recognize and bind to specific epitopes from a range of β-amyloid proteins. The antibodies enabled by the teaching of the present invention are particularly useful for the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of diseases and disorders associated with amyloid plaque formation including secondary amyloidosis and age-related amyloidosis including, but not limited to, neurological disorders such as Alzheimer's Disease (AD). | 11-15-2012 |
| 20120295309 | BACTERIAL HOST STRAIN COMPRISING A MUTANT SPR GENE AND HAVING REDUCED TSP ACTIVITY - The present invention provides a recombinant gram-negative bacterial cell comprising a mutant spr gene encoding a spr protein having a mutation at one or more amino acids selected from D133, H145, H157, N31, R62, I70, Q73, C94, S95, V98, Q99, R100, L108, Y115, V135, L136, G140, R144 and G147 and wherein the cell has reduced Tsp protein activity compared to a wild-type cell. | 11-22-2012 |
| 20120295310 | NUCLEIC ACIDS ENCODING ANTI-IL-23 ANTIBODIES - The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17, IL-23 via it's p19 subunit or both IL-17 and IL-23 (via p19). IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease. | 11-22-2012 |
| 20120301919 | IRES MEDIATED MULTICISTRONIC VECTORS - This invention relates to nucleic acid molecules comprising at least one nucleic acid sequence encoding for a peptide or protein of interest, at least one nucleic acid sequence encoding for a selectable marker, and at least one IRES sequence, wherein the at least one IRES sequence is located between the at least one nucleic acid sequence encoding for the peptide or protein of interest and the at least one nucleic acid sequence encoding for the selectable marker. Furthermore, this invention relates to host cells comprising such nucleic acid molecule and to methods of recombinant protein expression using such host cells. | 11-29-2012 |
| 20120301920 | BACTERIAL HOST STRAIN COMPRISING A MUTANT SPR GENE AND A WILD-TYPE TSP GENE - The present invention provides a recombinant gram-negative bacterial cell comprising a mutant spr gene encoding a mutant spr protein and wherein the cell comprises a non-recombinant wild-type chromosomal Tsp gene. | 11-29-2012 |
| 20120309054 | Products Comprising Inactivated Yeasts or Moulds and Active VHH-Type Antibodies - The use of VHHs in the preparation of products to provide stability of antibody specificity under destabilising conditions whereby normally lower eukaryotes or traditional antibodies are killed or inactivated. | 12-06-2012 |
| 20120309055 | Secretion of antibodies without signal peptides from bacteria - The present invention is directed generally to compositions and methods for obtaining secretion of antibodies or antigen-binding antibody fragments from prokaryotes without the need for a signal peptide through making use of mutant host strains with altered secretory properties. In particular, the invention provides host cells and methods for obtaining secretion of antibodies or antigen-binding antibody fragments from bacteria without the need for a signal peptide and provides diverse libraries of antibody sequence resulting from such methods. The invention additionally provides diverse libraries. | 12-06-2012 |
| 20120309056 | FED-BATCH PROCESS USING CONCENTRATED CELL CULTURE MEDIUM FOR THE EFFICIENT PRODUCTION OF BIOLOGICS IN EB66 CELLS - The present invention relates to a glucose fed-batch process using concentrated cell culture for the efficient production of biologics, such as viral vaccines and recombinant proteins. In particular, the invention relates to culturing duck embryonic derived stem cells EB66 to obtain high yield of biological products from such cells. | 12-06-2012 |
| 20120322108 | Adam6 Mice - Mice are provided that comprise a reduction or deletion of ADAM6 activity from an endogenous ADAM6 locus, or that lack an endogenous locus encoding a mouse ADAM6 protein, wherein the mice comprise a sequence encoding an ADAM6 or ortholog or homolog or fragment thereof that is functional in a male mouse. In one embodiment, the sequence is an ectopic ADAM6 sequence or a sequence that confers upon a male mouse the ability to generate offspring by mating. Mice and cells with genetically modified immunoglobulin heavy chain loci that comprise an ectopic nucleotide sequence encoding a mouse ADAM6 or functional fragment or homolog or ortholog thereof are also provided. | 12-20-2012 |
| 20120329093 | POLYNUCLEOTIDES ENCODING ANTIBODIES THAT BIND BOTH IL-17A AND IL-17F - The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. The present invention includes antibodies that bind both IL-17A and IL-17F, hybridomas that produce the antibodies, and methods of using the same in inflammation. | 12-27-2012 |
| 20120329094 | Anti-CD22 Antibodies And Immunoconjugates and Methods of Use - Anti-CD22 antibodies and immunoconjugates thereof are provided. Methods of using anti-CD22 antibodies and immunoconjugates thereof are provided. | 12-27-2012 |
| 20130011877 | KEX2 CLEAVAGE REGIONS OF RECOMBINANT FUSION PROTEINS - The invention relates to a fusion DNA construct comprising a KEX2 region comprising a KEX2 site and a KEX2 site pre-sequence immediately 5′ to the KEX2 site, a fusion polypeptide, vectors and cells comprising the fusion DNA construct, methods for producing desired proteins from filamentous fungal cells and methods for enhancing the secretion and/or cleavage of a desired protein from a cell. | 01-10-2013 |
| 20130011878 | ANTIGEN BINDING PROTEINS THAT BIND PAR-2 - The present invention provides compositions and methods relating to or derived from anti-PAR-2 antibodies. In particular embodiments, the invention provides human antibodies that bind PAR-2, PAR-2-binding fragments and derivatives of such antibodies, and PAR-2-binding polypeptides comprising such fragments. Other embodiments provide nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having PAR-2-related disorders or conditions. | 01-10-2013 |
| 20130017575 | Nucleic acids encoding anti-IL-6 antibodies of defined epitopic specificity - The invention relates to nucleic acids encoding antibody or antibody fragments that specifically binds to an epitope on an intact human IL-6 polypeptide, which epitope when ascertained by epitopic mapping includes one or more residues comprised in each of the following IL-6 fragments (i) a fragment consisting of amino acid residues 37-51 of human Il-6, (ii) a fragment consisting of amino acid residues 70-84 of human Il-6, (iii) a fragment consisting of amino acid residues 169-183 of human Il-6, (iv) a fragment consisting of amino acid residues 31-45 of human Il-6 and (v) a fragment consisting of amino acid residues 58-72 of human IL-6. | 01-17-2013 |
| 20130017576 | METHOD FOR THE PRODUCTION OF PROTEINS AND PEPTIDESAANM Merk; HelmutAACI BerlinAACO DEAAGP Merk; Helmut Berlin DEAANM Stiege; WolfgangAACI BerlinAACO DEAAGP Stiege; Wolfgang Berlin DEAANM Gless; ChristineAACI BerlinAACO DEAAGP Gless; Christine Berlin DEAANM GERRITS; MichaelAACI BerlinAACO DEAAGP GERRITS; Michael Berlin DE - The invention relates to a method for producing monomeric or dimeric proteins or peptides containing internal or external disulfide bonds, comprising the following steps: a) a cell-free lysate, obtainable from eukaryotic cells, is provided, which contains functional microsomal vesicles, b) a nucleic acid coding the protein or peptide and additionally containing a signal sequence is added to the lysate, c) the lysate with the nucleic acid is held for a given time at a temperature in the range from 20 to 35° C., proteins or peptides formed with the nucleic acid being translocated into the microsomal vesicles, d) the microsomal vesicles are then dissolved, and the proteins or peptides obtained thereby are optionally separated from the lysate. | 01-17-2013 |
| 20130023009 | METHOD FOR SPECIFICALLY PRODUCING A JOINED DNA FRAGMENT COMPRISING A SEQUENCE DERIVED FROM A TARGET GENE - Provided is a method for selectively obtaining, for a given target gene, a “joined DNA fragment” wherein just a target gene fragment is joined with desired other DNA fragments, regardless of whether a DNA fragment containing a target gene sequence has been purified. In the provided method, a double-stranded joining DNA fragment containing a sequence A and/or a sequence B is selectively joined to the ends of a target gene fragment. A mixture of a double-stranded gene fragment, the 3′ end of which is protruding, and the double-stranded joining DNA fragment, which are related in a prescribed manner, undergoes at least two cycles of thermal denaturation, reassociation, and DNA synthesis, resulting in a “joined DNA fragment,” which is a double-stranded DNA fragment including at least one instance of a sequence resulting from joining sequence A, the target gene sequence, and sequence B. A “single-side joined DNA fragment” can also be obtained, by a similar method. | 01-24-2013 |
| 20130059337 | Therapeutic Uses of Humanized Antibodies Against ALPHA-4 Integrin - The invention provides method of treatment using humanized immunoglobulins that specially bind to alpha-4 integrin. The methods are useful for treatment of asthma, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, transplant rejection, graft versus host disease, tumor metastasis, nephritis, atopic dermatitis, psoriasis, myocardial ischemia, and acute leukocyte mediated lung injury. | 03-07-2013 |
| 20130065276 | COMPOSITIONS AND METHODS OF TREATING DISEASE WITH FGFR FUSION PROTEINS - The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein. | 03-14-2013 |
| 20130065277 | SEQUENCE DEPENDENT AGGREGATION - Herein is reported a method for reducing the aggregation of an immunoglobulin in solution comprising the steps of i) comparing the amino acid sequence of the fourth framework region of the heavy chain of an antibody with a reference or germline sequence and determining whether one or more threonine residues and/or serine residues have been replaced by a different amino acid residue, and ii) modifying the amino acid sequence of the immunoglobulin by reverting the exchanged threonine residues and/or serine residues back to threonine or serine of the reference or germline sequence and thereby reducing the aggregation of an immunoglobulin in solution. | 03-14-2013 |
| 20130078675 | HIGH AFFINITY HUMAN ANTIBODIES TO HUMAN IL-4 RECEPTOR - The present invention provides nucleic acid molecules that encode antibodies or antigen-binding fragments thereof, which specifically bind human interleukin-4 receptor (IL-4R). Also provided are expression vectors comprising nucleic acid molecule that encode anti-IL-4R antibodies, host cells comprising the expression vectors, and methods of producing anti-IL-4R antibodies or antigen-binding fragments thereof comprising growing the host cells under conditions permitting production of the antibody or fragment, and recovering the antibody or fragment so produced | 03-28-2013 |
| 20130084605 | DECREASING LACTATE LEVEL AND INCREASING POLYPEPTIDE PRODUCTION BY DOWNREGULATING THE EXPRESSION OF LACTATE DEHYDROGENASE AND PYRUVATE DEHYDROGENASE KINASE - The present invention provides methods and compositions for reducing lactate production and increasing polypeptide production in cultured cells. In one aspect, the invention provides a method comprising culturing cells expressing a) a small interfering RNA (siRNA) specific for a lactate dehydrogenase (LDH) and b) an siRNA specific for a pyruvate dehydrogenase kinase (PDHK). In another aspect, the invention provides cultured cells or vectors comprising an siRNA specific for a LDH and an siRNA specific for a PDHK. | 04-04-2013 |
| 20130095526 | ANTI-A(BETA) OLIGOMER HUMANIZED ANTIBODY - An anti-Aβ oligomer humanized antibody which does not bind to Aβ monomers and specifically binds only to Aβ oligomers; an anti-cognitive dysfunction agent, an agent for treating Alzheimer's disease, an agent for suppressing formation of neuritic plaque and an inhibitor of formation of Aβ amyloid fiber comprising the antibody as an active ingredient; a method for at least one of preventing and treating cognitive dysfunction or Alzheimer's disease, comprising the step of administering the antibody; and a method for suppressing progression of Alzheimer's disease, comprising the step of administering the antibody. | 04-18-2013 |
| 20130095527 | PROCESS FOR THE CULTURING OF CELLS - The invention relates to a process for the coloring of cells, preferably E1-immortalized HER cells, more preferably PER.C6 cells in a reactor in suspension in a cell culture medium, wherein the cells produce a biological substance, preferably an antibody, wherein at least one cell culture medium component is fed to the cell culture and wherein the cell culture comprising the cells, the biological substance and cell culture medium is circulated over a separation system and wherein the separation system separates the biological substance from substances having a lower molecular weight than the biological substance and wherein the biological substance is retained in or fed back into the reactor. Preferably part of the substances of lower molecular weight is continuously removed from the cell culture. | 04-18-2013 |
| 20130102030 | Antibody Molecules Which Bind IL-17A and IL-17F - The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules. | 04-25-2013 |
| 20130102031 | USE OF SOMATIC HYPERMUTATION TO CREATE INSERTION AND DELETION MUTATIONS IN VITRO - The invention is directed to an in vitro method for introducing one or more insertion mutations and/or one or more deletion mutations in a nucleic acid sequence encoding a polypeptide. The method comprises contacting a cell in vitro with a nucleic acid sequence, and expressing Activation Induced Cytidine Deaminase (AID) in the cell. The invention also is directed to a method of producing an immunoglobulin. | 04-25-2013 |
| 20130102032 | CELL CULTURE MEDIUM - A cell culture medium with high content of choline chloride is provided. The cell culture media further comprise only moderate amounts of amino acids, in particular the amount of glutamine in the cell culture media is limited. The cell culture media can be used for large scale production of polypeptides using cell cultures. The cell culture media with high content of choline chloride are particularly suitable for fed-batch cell culture whereby cell viabilities stay at a higher level for a longer time and high polypeptide titers although limited amounts of amino acids are used. | 04-25-2013 |
| 20130109056 | Immunoglobulin aggregate removal | 05-02-2013 |
| 20130109057 | METHOD FOR IMMUNIZING ANIMAL, COMPOSITION FOR IMMUNIZATION, METHOD FOR PRODUCING ANTIBODY, METHOD FOR PRODUCING HYBRIDOMA, AND METHOD FOR PRODUCING MONOCLONAL ANTIBODY | 05-02-2013 |
| 20130109058 | POLYPEPTIDE PRODUCING CELLS | 05-02-2013 |
| 20130115657 | HUMANIZED ANTI-CD19 ANTIBODIES AND THEIR USE IN TREATMENT OF ONCOLOGY, TRANSPLANTATION AND AUTOIMMUNE DISEASE - The present invention provides chimeric and humanized versions of anti-CD19 mouse monoclonal antibodies. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using therapeutic antibodies that bind to the human CD19 antigen and that may mediate ADCC, CDC, and/or apoptosis for the treatment of B cell diseases and disorders, such as, but not limited to, B cell malignancies, for the treatment and prevention of autoimmune disease, and for the treatment and prevention of graft-versus-host disease (GVHD), humoral rejection, and post-transplantation lymphoproliferative disorder in human transplant recipients. | 05-09-2013 |
| 20130130315 | FUSION PROTEIN - An isolated nucleic acid molecule selected from the group consisting of: vi. a nucleic acid molecule comprising a nucleotide sequence which is at least 85% identical to the nucleotide sequence of SEQ ID NO:1 or a complement thereof; vii. a nucleic acid molecule comprising a fragment of at least 1500 consecutive nucleotides of the nucleotide sequence of SEQ ID NO:1, or a complement thereof; viii. a nucleic acid molecule which encodes a polypeptide comprising an amino acid sequence at least 85% identical to SEQ ID NO:2; ix. a nucleic acid molecule which encodes a fragment of a polypeptide comprising the amino acid sequence of SEQ ID NO:2, wherein the fragment comprises at least 500 contiguous amino acids of SEQ ID NO: 2; and x. a nucleic acid molecule encoding a polypeptide containing a humanized immunoglobulin or parts of an immunoglobulin having binding specificity for CD133 a nucleic acid molecule which encodes a variant of a polypeptide comprising the amino acid sequence of SEQ ID NO: 2, wherein the nucleic acid molecule hybridizes to a nucleic acid molecule comprising the entire SEQ ID NO: 1, or complement thereof under conditions of incubation at 45° C. in 6.0×SSC followed by washing in 0.2×SSC/0.1% SDS at 65° C. | 05-23-2013 |
| 20130130316 | CELL CULTIVATION PROCESS - This invention relates to a cell culture process for the production of polypeptides in mammalian CHO cells characterized by one or more temperature and pH shifts which are adjusted in respect to their timing and step size to reduce cell death, increase product yield and improve product quality. | 05-23-2013 |
| 20130130317 | METHOD FOR PRODUCING SUBSTANCE - The present invention provides a medium suitable for animal cell culture, a culture method using the same, and the like. The present invention relates to a method for culturing animal cells having an ability to produce a substance, which comprises culturing the animal cells in a medium supplemented with an oligopeptide having one or more L-cysteines and excluding glutathione, a method for producing a substance by culturing animal cells having the ability to produce the substance, which comprises culturing the animal cells in a medium supplemented with an oligopeptide having one or more L-cysteines and excluding glutathione to produce and accumulate the substance in the culture, and collecting the substance from the culture, and a culture medium comprising an oligopeptide having one or more L-cysteines and excluding glutathione. | 05-23-2013 |
| 20130137141 | PRODUCTION CELL LINE - The invention refers to a method of producing a recombinant polypeptide of interest (POI) in a cell culture, comprising genetically engineering a eukaryotic cell line—to specifically cause prolongation of the G2+M cell cycle phase in a pre-culture phase, and—to produce the POI in a producing phase following the pre-culture phase, a high producer cell line and cell culture as well as a method of increasing the yield of a recombinant POI production in a cell culture. | 05-30-2013 |
| 20130143266 | ANTI-EPHRINB2 ANTIBODIES AND METHODS USING SAME - The invention provides anti-EphrinB2 antibodies, and compositions comprising and methods of using these antibodies. | 06-06-2013 |
| 20130143267 | VECTORS AND METHODS FOR TRANSDUCING B CELLS - The present disclosure provides compositions and methods for transducing B cells. In particular, the present disclosure provides for vectors and methods for transducing resting B cells and methods for differentiating same to express a transgene of interest. | 06-06-2013 |
| 20130143268 | METHOD OF PRODUCING THE POLYPEPTIDE FOR TREATING VIRUS-INDUCED CANCER - The present invention relates to methods of producing the polypeptides that are capable of killing cells. The polypeptides comprise a targeting agent covalently attached to a channel-forming moiety. In a preferred embodiment, the channel-forming moiety comprises a colicin and the targeting agent is a reconstructed antibody mimetic derived from monoclonal antibody variants against Epstein-Barr virus gp350/220. | 06-06-2013 |
| 20130143269 | KIR-Binding Agents and Methods of Use Thereof - The present invention relates to agents and methods that are capable of augmenting NK-mediated killing of target cells by reducing inhibitory KIR signalling without reducing the binding of KIR to HLA-C. As described herein, transduction of negative signaling via KIR, upon binding of KIR to its HLA class I ligand, can involve a ligand-binding induced, conformational reorientation of the KIR molecules allowing interactions to form between adjacent KIRs in specific domains, leading to accelerated clustering. Methods and agents such as monoclonal antibodies for reducing KIR-mediated inhibition of NK cell cytotoxicity without reducing or blocking HLA-binding by, e.g., reducing or blocking dimerization of KIR, are provided. | 06-06-2013 |
| 20130157313 | HIGH AFFINITY ANTIBODIES TO HUMAN IL-6 RECEPTOR - A human antibody or an antigen-binding fragment which binds human IL-6 receptor (hIL-6R) with a K | 06-20-2013 |
| 20130164784 | Compositions and methods including B lymphocyte cell line expressing membrane immunoglobulin different from secreted immunoglobulin - Compositions and methods are disclosed herein for producing one or more immunoglobulins in an isolated B lymphocyte cell line. An isolated cell line includes an isolated B lymphocyte cell line capable of expressing at least one exogenously incorporated membrane immunoglobulin reactive to a first antigen and at least one endogenous secreted immunoglobulin reactive to a second antigen. | 06-27-2013 |
| 20130164785 | METHODS AND COMPOSITIONS FOR INACTIVATING GLUTAMINE SYNTHETASE GENE EXPRESSION - Disclosed herein are methods and compositions for inactivating a glutamine synthetase (GS) gene, using fusion proteins comprising a zinc finger protein and a cleavage domain or cleavage half-domain. Polynucleotides encoding said fusion proteins are also provided, as are cells comprising said polynucleotides and fusion proteins. | 06-27-2013 |
| 20130164786 | FUCOSYLATION-DEFICIENT CELLS - An isolated nucleic acid encoding an FX protein having a serine at position | 06-27-2013 |
| 20130171694 | DNA ELEMENT HAVING THE ACTIVITY OF ENHANCING FOREIGN GENE EXPRESSION - Disclosed is a method for stably achieving high expression of a foreign gene in mammalian cells using a novel DNA element. More specifically disclosed is a DNA element which enhances the activation of transcription by changing the chromatin structure around a gene locus into which a foreign gene expression unit has been introduced. | 07-04-2013 |
| 20130171695 | Human Anti-B7RP1 Neutralizing Antibodies - This invention provides antibodies that interact with or bind to human B7 related protein-1 (B7RP1) and antibodies that bind to and neutralize the function of B7RP1 thereby. The invention also provides pharmaceutical compositions of said antibodies and methods for neutralizing B7RP1 function, and particularly for treating immune disorders (e.g., inappropriate immune response) by administering a pharmaceutically effective amount of anti-B7RP1 antibodies. Methods of detecting the amount of B7RP1 in a sample using anti-B7RP1 antibodies are also provided. | 07-04-2013 |
| 20130177944 | ANTI-CD4 ANTIBODY - An anti-CD4 antibody which binds to CD4, has a high affinity and has a high effector activity, such as an antibody-dependent cellular cytotoxicity (ADCC activity) or complement-dependent cellular cytotoxicity (CDC activity), is required for a disease relating to a CD4-expressing cell. | 07-11-2013 |
| 20130189735 | Process for engineering polyvalent, polyspecific fusion proteins using uteroglobin as skeleton and so obtained products. - It is described a processes for generating stable and soluble polyvalent and polyspecific fusion proteins based on the use of uteroglobin (UG) as a reaction skeleton; proteins as above defined produced with said process are also described. | 07-25-2013 |
| 20130189736 | ANTIBODY COMPOSITION-PRODUCING CELL - The present invention relates to a cell for the production of an antibody molecule such as an antibody useful for various diseases having high antibody-dependent cell-mediated cytotoxic activity, a fragment of the antibody and a fusion protein having the Fc region of the antibody or the like, a method for producing an antibody composition using the cell, the antibody composition and use thereof. | 07-25-2013 |
| 20130189737 | DIPEPTIDES TO ENHANCE YIELD AND VIABILITY FROM CELL CULTURES - The present invention relates to the culture of animal cells in serum-free culture medium. The present invention provides particular dipeptides that can improve recombinant protein production and cell viability in such cultures, especially in the absence of peptones. | 07-25-2013 |
| 20130196376 | Method for the High Level Expression of Active Lymphotoxin-Beta Receptor Immunoglobulin Chimeric Proteins and Their Purification - Methods for high level expression of active lymphotoxin-β receptor immunoglobulin chimeric proteins and their purification. | 08-01-2013 |
| 20130196377 | PROTEIN COMPLEX AND METHOD OF PREPARING SAME - A protein complex including at least two monoclonal antibodies is provided. By using the protein complex, a system for simultaneously targeting at least two antigens is effectively constructed. | 08-01-2013 |
| 20130196378 | HUMAN MONOCLONAL ANTIBODY - The present invention provides an anti-CD81 antibody usable as a pharmaceutical product for human. Specifically, the present invention provides an anti-human CD81 antibody capable of binding to a peptide region consisting of the amino acid sequence of the amino acid numbers 80 to 175 in the amino acid sequence shown in SEQ ID NO:22. | 08-01-2013 |
| 20130196379 | Antibodies - The present invention provides antibodies which bind to an epitope in the extracellular domain of human CC chemokine receptor 4 (CCR4) and which are capable of inhibiting the binding of macrophage-derived chemokine (MDC) and/or thymus and activation regulated chemokine (TARC) to CCR4. Also provided are inter alia immunoconjugates and compositions comprising such antibodies and methods and uses involving such antibodies, particularly in the medical and diagnostic fields. | 08-01-2013 |
| 20130210075 | ENHANCED PROTEIN EXPRESSION - The application describes methods to enhance protein production using mammalian cells. Increased production of heterologous protein can be obtained by increasing osmolality and lowering temperature. The method maintains the cell growth rate and provides high product yield. | 08-15-2013 |
| 20130230886 | Antibodies to TNF Alpha - Provided herein are antibodies, antigen binding portions, and derivatives thereof that are capable of binding tumor necrosis factor alpha (TNFα); nucleic acids encoding the antibodies, antigen binding portions, and derivatives thereof, including complementary nucleic acids; vectors; and host cells containing the nucleic acids. | 09-05-2013 |
| 20130236931 | SEQUENCE DIVERSITY GENERATION IN IMMUNOGLOBULINS AND OTHER PROTEINS - An in vitro system for generating sequence, and thus structural, diversity in proteins is described. The system can be constructed using appropriately selected nucleic acid molecules that encode regions of a selected protein or proteins and recombination signal sequences (RSS). The selected protein(s) can be, for example, immunoglobulin (Ig) V, D, J and/or C regions, regions of a non-immunoglobulin (non-Ig) protein, or a combination of Ig regions and non-Ig regions. Assembly of such appropriately selected components and their introduction into suitable recombination-competent host cells allows for recombination between the RSS sequences and introduction of sequence and structural diversity into the protein(s). | 09-12-2013 |
| 20130244281 | Toll-Like Receptor 3 Antagonists - Toll Like Receptor 3 (TLR3) antibody antagonists, polynucleotides encoding TLR3 antibody antagonists or fragments thereof, and methods of making and using the foregoing are disclosed. | 09-19-2013 |
| 20130244282 | METHOD OF PRODUCING ANTIBODIES - Provided are compositions and methods for delivering biological moieties such as modified nucleic acids into cells to modulate protein expression. Such compositions and methods include the use of modified messenger RNAs, and are useful for production of proteins. | 09-19-2013 |
| 20130260419 | CONTINUOUS PROCESSING METHODS FOR BIOLOGICAL PRODUCTS - The present invention is directed to the development of continuous processing technology for the purification of biopharmaceuticals and biological products, such as monoclonal antibodies, protein therapeutics, and vaccines. Methods for continuous processing of a biological product in a feed stream toward formulation of a purified bulk product are described. | 10-03-2013 |
| 20130273607 | METHODS FOR PROCESSING INCLUSION BODIES - The present application relates to methods for purifying recombinant proteins, including antibodies and antibody fragments. Suitably, the methods utilize depth filtration to clarify the desired proteins from a solubilized mixture, and provide refolding methods and refolding buffers to allow for refolding of the recombinant proteins into functional and active proteins. Exemplary antibody fragments include anti-CD22 antibody fragments that comprise V | 10-17-2013 |
| 20130280758 | FUSION POLYPEPTIDES CAPABLE OF ACTIVATING RECEPTORS - A fusion polypeptide comprising (A) | 10-24-2013 |
| 20130280759 | NOVEL ANTIGEN ASSOCIATED WITH THE NEOVASCULATURE OF TUMOUR METASTASES - The invention relates to a binding member that binds the Extra Domain-A (ED-A) isoform of fibronectin for the treatment of tumour metastases. | 10-24-2013 |
| 20130288302 | HUMANIZED ANTI-BETA7 ANTAGONISTS AND USES THEREFOR - The invention provides therapeutic anti-beta7 antibodies, compositions comprising, and methods of using these antibodies. | 10-31-2013 |
| 20130288303 | Humanized c-Kit Antibody - This invention relates to compositions and methods for treating c-Kit associated disorders such as fibrosis, and more particularly, to compositions containing humanized c-Kit antibodie | 10-31-2013 |
| 20130288304 | POLYNUCLEOTIDES ENCODING ANTIBODIES THAT BIND BOTH IL-17A AND IL-17F - The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. The present invention includes antibodies that bind both IL-17A and IL-17F, hybridomas that produce the antibodies, and methods of using the same in inflammation. | 10-31-2013 |
| 20130288305 | ANTI-FGFR2 ANTIBODIES - Monoclonal antibodies that bind and inhibit biological activities of human FGFR2 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation or overexpression of FGFR2. | 10-31-2013 |
| 20130295611 | HUMANIZED ANTIBODY MOLECULES SPECIFIC FOR IL-31 - The invention provides humanized mouse anti-human IL-31 antibodies and antibody fragments that are capable of binding IL-31 and thereby neutralizing, inhibiting, limiting, or reducing the proinflammatory or pro-pruritic effects of IL-31. | 11-07-2013 |
| 20130295612 | ANTI-GLYPICAN-3 ANTIBODY HAVING IMPROVED KINETICS IN PLASMA - A method of modulating the plasma half-life of anti-glypican 3 antibody, a pharmaceutical composition comprising as an active ingredient the anti-glypican 3 antibody that has a plasma half-life that has been modulated, a method of preparing the anti-glypican 3 antibody and a pharmaceutical composition comprising the anti-glypican 3 antibody as an active ingredient are provided. Disclosed is a method of modulating the plasma half-life of anti-glypican 3 antibody by modifying an amino acid residue that is exposed on the surface of the anti-glypican 3 antibody; and anti-glypican 3 antibody that has a plasma half-life that has been modulated by amino acid residue modification, a pharmaceutical composition comprising as an active ingredient the anti-glypican 3 antibody, and a method of preparing the anti-glypican 3 antibody and producing a pharmaceutical composition comprising the anti-glypican 3 antibody as an active ingredient. | 11-07-2013 |
| 20130295613 | ANIMAL CELL CULTURING METHOD - While a desired protein is prepared by culturing an animal cell that produces the protein to cause the protein to be produced, level of heterogeneity components of the protein is modulated by performing the culture at a normal culture temperature for a certain period and then continuing the culture at a culture temperature lowered to 25-35° C. | 11-07-2013 |
| 20130316402 | ANTIBODIES AND IMMUNOCONJUGATES AND USES THEREFOR - Anti-STEAP-1 antibodies and immunoconjugates thereof are provided. Methods of using anti-STEAP-1 antibodies and immunoconjugates thereof are provided. | 11-28-2013 |
| 20130316403 | VECTORS AND YEAST STRAINS FOR PROTEIN PRODUCTION: CA2+ ATPASE OVEREXPRESSION - Lower eukaryote host cells in which an endogenous or heterologous Ca | 11-28-2013 |
| 20130323786 | Composition Comprising Antibodies to LINGO or Fragments Thereof - Endogenous LINGO-1 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination. Molecules that block endogenous LINGO-1 function, such anti-LINGO-1 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. The present invention provides antibodies specific for LINGO-1, and methods of using such antibodies as antagonists of endogenous LINGO-1 function. The invention further provides specific hybridoma and phage library-derived monoclonal antibodies, nucleic acids encoding these antibodies, and vectors and host cells comprising these antibodies. The invention further provides methods of promoting oligodendrocyte survival and myelination in a vertebrate, comprising administering to a vertebrate in need of such treatment an effective amount of an anti-LINGO-1 antibody | 12-05-2013 |
| 20130323787 | PHAGE DISPLAYING SYSTEM EXPRESSING SINGLE CHAIN ANTIBODY - Disclosed are nucleic acid libraries for identifying a signal peptide that facilitates production of disulfide-stabilized single chain antibody, and for facilitating production of a disulfide-stabilized single chain antibody. Also disclosed are host cell libraries and phage libraries including the nucleic acid libraries. Further disclosed are methods for identifying a signal peptide that facilitates production of disulfide-stabilized single chain antibody, and methods for producing a disulfide-stabilized single chain antibody and non-fusion form thereof. | 12-05-2013 |
| 20130323788 | PRODUCTION CELL LINE ENHANCERS - The present invention relates to discovery of the ectopic expression of EDEM2 in a production cell to improve the yield of a useful multi-subunit protein. Thus, the present invention provides for production cell lines, such as the canonical mammalian biopharmaceutical production cell—the CHO cell, containing recombinant polynucleotides encoding EDEM2. Also disclosed is a production cell containing both an EDEM2-encoding polynucleotide as well an XBP1-encoding polynucleotide. Improved titers of antibodies produced by these cell lines are disclosed, as well as the improved cell densities attained by these cells in culture. | 12-05-2013 |
| 20130323789 | ANTI SYSTEM ASC AMINO ACID TRANSPORTER 2 (ASCT2) ANTIBODY - An object of the present invention is to provide a monoclonal antibody which is useful for treating or diagnosing a disease relating to system ASC amino acid transporter 2 (ASCT2) or a method using the antibody. The present invention provides a monoclonal antibody which specifically recognizes a native three-dimensional structure of an extracellular region of system ASC amino acid transporter 2 (ASCT2) and binds to the extracellular region, or an antibody fragment thereof; a hybridoma which produces the antibody; a DNA which encodes the antibody; a vector which contains the DNA; a transformant obtainable by introducing the vector; a process for producing an antibody or an antibody fragment thereof using the hybridoma or the transformant; and a therapeutic agent using the antibody or the antibody fragment thereof, and a diagnostic agent using the antibody or the antibody fragment thereof. | 12-05-2013 |
| 20130330770 | METHODS FOR MODULATING MANNOSE CONTENT OF RECOMBINANT PROTEINS - The present invention relates to methods of modulating (e.g., reducing) the mannose content, particularly high-mannose content of recombinant glycoproteins. | 12-12-2013 |
| 20130330771 | ANTIBODY PRODUCTION - A transgenic non-human mammal containing a heterologous lambda light chain gene locus, and/or a heterologous kappa light chain gene locus, and/or a heterologous heavy chain gene locus, each of which can re-arrange so that immunoglobulin heavy and light chain genes are formed and expressed in B-cells following antigen challenge. | 12-12-2013 |
| 20130330772 | ANTI-ERBB3 ANTIBODIES - Monoclonal antibodies that bind and inhibit activation of epidermal growth factor receptor related member ErbB3/HER3 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation of ErbB3/HER3. | 12-12-2013 |
| 20130337505 | MONOCLONAL ANTIBODY CAPABLE OF BINDING TO HEPARIN-BINDING EPIDERMAL GROWTH FACTOR-LIKE GROWTH FACTOR - Medicaments for treating diseases related to HB-EGF escalation are in demand. The present invention provides a method for producing a monoclonal antibody or an antibody fragment thereof which binds to a cell membrane-bound HB-EGF, a membrane type HB-EGF and a secretory HB-EGF. | 12-19-2013 |
| 20130337506 | CELL CULTURE MEDIUM AND PROCESS FOR PROTEIN EXPRESSION, SAID MEDIUM AND PROCESS COMPRISING A PAM INHIBITOR - The present invention is related to a cell culture medium for the expression of a protein, which medium comprises a PAM inhibitor, or a physiological equivalent thereof, and to a cell culture process for the expression of a protein, in which process a PAM inhibitor, or a physiological equivalent thereof, is used (FIG. | 12-19-2013 |
| 20130344537 | MAMMALIAN EXPRESSION VECTORS AND USES THEREOF - The present invention features nucleic acids for recombinant protein expression in mammalian cell culture. The episomal vectors of the invention promote high protein production in mammalian cells expressing the SV40 T Ag or Epstein-Barr virus nuclear antigen (e.g., COS7 or HEK293-6E cells). The methods and systems are useful, for example, in pharmaceutical drug development and cloning, especially for the production of antibodies. | 12-26-2013 |
| 20130344538 | HUMAN ANTIBODIES TO THE GLUCAGON RECEPTOR - The present invention provides antibodies that bind to the human glucagon receptor, designated GCGR and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human GCGR. The antibodies of the invention are useful for lowering blood glucose levels and blood ketone levels and are also useful for the treatment of diseases and disorders associated with one or more GCGR biological activities, including the treatment of diabetes, diabetic ketoacidosis and long-term complications associated with diabetes, or other metabolic disorders characterized in part by elevated blood glucose levels. | 12-26-2013 |
| 20140024077 | ANTIBODY MOLECULES HAVING SPECIFICITY FOR HUMAN IL-6 - The invention relates to antibody molecules having specificity for antigenic determinants of IL-6, therapeutic uses of the antibody molecules and methods for producing said antibody molecules. | 01-23-2014 |
| 20140024078 | PRODUCTION OF PROTEINS IN GLUTAMINE-FREE CELL CULTURE MEDIA - The present invention relates generally to glutamine-free cell culture media supplemented with asparagine. The invention further concerns the production of recombinant proteins, such as antibodies, in asparagine-supplemented glutamine-free mammalian cell culture. | 01-23-2014 |
| 20140024079 | METHODS FOR PRODUCING BIOLOGICAL MATERIALS - Methods of producing biological materials from cells and organisms are provided. Aspects of the methods include modulating the stress conditions of the cells and/or organism to produce biological materials having one or more desired properties. In certain aspects, the cell or organism is evaluated to detect the presence or absence of a stressed phenotype, wherein an unstressed phenotype may be produced before the cell or organism produces the biological material of interest. The biological materials produced from such cells and organisms may be used for a variety of applications, including therapeutic, research, and other applications. | 01-23-2014 |
| 20140030761 | METHOD OF CLONING NUCLEIC ACID - The present disclosure provides methods for producing expression constructs comprising linking a plurality of unlinked nucleic acids, including nucleic acid encoding a marker protein. | 01-30-2014 |
| 20140045215 | NEUTRALIZING ANTI-CCL20 ANTIBODIES - The present invention relates to novel humanized, chimeric and murine antibodies that have binding specificity for the human CC chemokine ligand 20 (CCL20). The present invention further relates to heavy chains and light chains of said antibodies. The invention also relates to isolated nucleic acids, recombinant vectors and host cells that comprise a sequence which encodes a heavy chain and/or a light chain of said antibodies, and to a method of preparing said antibodies. The anti-CCL20 antibodies of the invention can be used in therapeutic applications to treat, for example, inflammatory and autoimmune disorders and cancer. | 02-13-2014 |
| 20140051120 | HUMANIZED ANTI-EGFL7 ANTIBODIES AND METHODS USING SAME - The present invention concerns antibodies to EGFL7 and the uses of same. | 02-20-2014 |
| 20140051121 | FEED MIXING DEVICE AND ITS USE - Herein is reported a feed mixing device for adding feed solutions with a non-physiologically pH value to a cell cultivation vessel comprising a chamber for mixing the feed solutions prior to their addition to the cell cultivation vessel as well as its use. With the feed mixing device as reported herein feed components can be provided in solution at a pH value at which they have good solubility and/or good stability whereby the pH value can be clearly different from the pH value of the cultivation medium, i.e. different from the physiological pH value. This allows performing the cultivation with more flexibility compared to a cultivation in which the pH value of the feed solution is limited to a small range around the pH value of the cultivation. | 02-20-2014 |
| 20140051122 | LARGE SCALE AND STABLE PRODUCTION OF HUMAN FVIII IN THE HUMAN CELL LINE SK-HEP-1 - The present invention refers to: 1) the method for the production of recombinant FVIII in human Sk-Hep-1 cells, comprising von Willebrand Factor (vWF) and 2) the population of human cells transduced with a vector encoding the clotting protein (FVIII). The technical object of the present patent application is intended for the cultivation of human cells in suspension and in adhesion and isolation of the culture medium containing the desired protein. | 02-20-2014 |
| 20140051123 | METHOD OF INCREASING THE PRODUCTIVITY OF EUCARYOTIC CELLS IN THE PRODUCTION OF RECOMBINANT FVIII - A method of increasing productivity, in particularly cell-specific productivity, of recombinant factor VIII (rFVIII) produced in a eukaryotic cell suspension during culturing of the eucaryotic cell suspension in a culturing medium containing not more than 500 μM CaCl | 02-20-2014 |
| 20140065673 | MEMBRANE PROTEIN EXPRESSION VECTOR COMPRISING MAJOR ENVELOPE PROTEIN P9 OF SYSTOVIRUS PHI12 AS A FUSION PARTNER AND METHOD FOR PRODUCING MEMBRANE PROTEIN USING THE SAME - The present invention relates to an expression vector containing the major envelope protein P9 of Cystovirus phi12 as a fusion partner, and a process for producing a membrane protein using the same. Particularly, the present invention is directed to an expression vector comprising a major envelope protein P9 gene of Cystovirus phi12, a multicloning site (MCS) for inserting a target membrane protein, and a protease recognition site located between a P9 gene and the MCS. | 03-06-2014 |
| 20140065674 | ANTIBODY MOLECULES WHICH BIND IL-17A AND IL-17F - The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules. | 03-06-2014 |
| 20140073010 | Methods of Modifying Eukaryotic Cells - A method for engineering and utilizing large DNA vectors to target, via homologous recombination, and modify, in any desirable fashion, endogenous genes and chromosomal loci in eukaryotic cells. These large DNA targeting vectors for eukaryotic cells, termed LTVECs, are derived from fragments of cloned genomic DNA larger than those typically used by other approaches intended to perform homologous targeting in eukaryotic cells. Also provided is a rapid and convenient method of detecting eukaryotic cells in which the LTVEC has correctly targeted and modified the desired endogenous gene(s) or chromosomal locus (loci) as well as the use of these cells to generate organisms bearing the genetic modification. | 03-13-2014 |
| 20140080180 | HARVEST OPERATIONS FOR RECOMBINANT PROTEINS - The present invention contemplates methods of producing a recombinant protein comprising fermenting a prokaryotic host cell wherein said prokaryotic host cell has been transformed with a nucleic acid encoding said recombinant protein, harvesting said recombinant protein under conditions where dO | 03-20-2014 |
| 20140080181 | POLYNUCLEOTIDES ENCODING IL-31 MONOCLONAL ANTIBODIES - The present invention relates to methods of treating pruritic diseases, including but not limited to Contact dermatitis, Atopic Dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphigoid, Alopecia wereata, Vitiligo, Acne Rosacea, Prurigo nodularis, Scleroderma, Herpes simplex virus, or combination thereof by administering IL-31 monoclonal antibodies. The invention further provides the hybridomas that generate the monoclonal antibodies. | 03-20-2014 |
| 20140087422 | Nucleic acids related to fusion proteins - The present invention concerns a family of nucleic acids, polypeptides and cloning vectors which direct expression of fusion proteins that can mimic aggregated IgG (AIG) and immune complex function with respect to their interactions with FcγR and which allow for the inclusion and targeting of a second protein domain to cells expressing FcγR. This was accomplished by expressing multiple linear copies of the hinge and CH2 domains (HCH2) of human IgG | 03-27-2014 |
| 20140093915 | IL-18 RECEPTOR ANTIGEN BINDING PROTEINS - Provided herein are IL-18 receptor antigen binding proteins and polynucleotides encoding the same. Expression vectors and host cells comprising the same for production of the antigen binding proteins are also provided. In addition, provided are compositions and methods for diagnosing and treating diseases mediated by IL-18 receptor. | 04-03-2014 |
| 20140099670 | RANKL ANTIBODY-PTH/PTHrP CHIMERIC MOLECULES - Chimeric molecules comprising receptor activator of NF-κB ligand (RANKL) antibodies and parathyroid hormone/parathyroid hormone-related protein (PTH/PTHrP) peptides are described. Compositions and methods for the treatment of bone diseases are also described. | 04-10-2014 |
| 20140099671 | IL-1 BINDING PROTEINS - Proteins that bind IL-1α and IL-1β are described along with their use in compositions and methods for treating, preventing, and diagnosing IL-1-related disorders and for detecting IL-1α and IL-1β in cells, tissues, samples, and compositions. | 04-10-2014 |
| 20140106404 | METHOD FOR PRODUCING HETEROLOGOUS PROTEIN USING YEAST WITH DISRUPTION OF VPS GENE - An object of the present invention it to improve the secretion productivity of a heterologous protein in a methanol-assimilating yeast. The present invention provides a method for producing a heterologous protein, characterized by comprising using a methanol-assimilating yeast with disruption of the VPS gene as a host for secretory production of the heterologous protein. | 04-17-2014 |
| 20140113330 | MODIFIED VITAMIN K-DEPENDENT POLYPEPTIDES - The invention provides vitamin K-dependent polypeptides with enhanced membrane binding affinity. These polypeptides can be used to modulate clot formation in mammals. Methods of modulating clot formation in mammals are also described. | 04-24-2014 |
| 20140120580 | SYSTEM FOR ANTIBODY EXPRESSION AND ASSEMBLY - The present invention provides methods and compositions for expression and production of recombinant antibodies in a host cell system, such as prokaryotic and eukaryotic expression systems. Particularly contemplated are recombinant systems for temporally separated expression of light chain and heavy chain of antibodies. The antibody products including antibody fragments can be used in various aspects of biological research, diagnosis and medical treatment. | 05-01-2014 |
| 20140120581 | HETERODIMER PROTEIN COMPOSITION - According to the present invention, a heterodimer protein composition that is composed of a first polypeptide comprising an immunoglobulin heavy chain constant region and a second polypeptide comprising CL-Fc prepared by fusion of an immunoglobulin light chain constant region (CL) and Fc region, and also has a deletion or substitution of Cys residues involved in disulfide bonds between CL and CH1, a purification method of the protein composition thereof, a preparation method of the protein composition thereof, a DNA and a vector encoding the protein composition thereof are provided | 05-01-2014 |
| 20140120582 | ANIMAL MODELS AND THERAPEUTIC MOLECULES - The invention discloses methods for the generation of chimaeric human-non-human antibodies and chimaeric antibody chains, antibodies and antibody chains so produced, and derivatives thereof including fully humanised antibodies; compositions comprising said antibodies, antibody chains and derivatives, as well as cells, non-human mammals and vectors, suitable for use in said methods. | 05-01-2014 |
| 20140120583 | CELL CULTURE PROCESS - Polypeptides having target levels of C-terminal variants are described. | 05-01-2014 |
| 20140134674 | CELL CULTURE IMPROVEMENTS - The invention describes improved methods and compositions for producing a recombinant protein, e.g., an antibody, in mammalian cell culture. In addition, the invention provides improved cell culture media, including improved production media, feed solutions, and combination feeds, which may be used to improve protein productivity in mammalian cell culture. | 05-15-2014 |
| 20140134675 | CELL CULTURE IMPROVEMENTS - The invention describes improved methods and compositions for producing a recombinant protein, e.g., an antibody, in mammalian cell culture. In addition, the invention provides improved cell culture media, including improved production media, feed solutions, and combination feeds, which may be used to improve protein productivity in mammalian cell culture. | 05-15-2014 |
| 20140141468 | BACTERIAL HOST STRAIN EXPRESSING RECOMBINANT DSBC - The present invention provides a recombinant gram-negative bacterial cell comprising an expression vector, comprising a recombinant polynucleotide encoding DsbC and one or more polynucleotides encoding an antibody or an antigen binding fragment thereof specifically binding to CD154. | 05-22-2014 |
| 20140141469 | METHODS OF PRODUCING HUMAN HEMOGLOBIN IN A BIOREACTOR - Methods for producing hemoglobin in a bioreactor comprising providing a bioreactor containing a strain of | 05-22-2014 |
| 20140154743 | METHODS AND MATERIALS FOR ENHANCING FUNCTIONAL PROTEIN EXPRESSION IN BACTERIA - Novel materials and methods useful for expressing heterologous proteins in prokaryotic cells are provided, including prokaryotic cells expressing FkpA and/or Skp. | 06-05-2014 |
| 20140154744 | Compositions and Methods for Making Selenocysteine Containing Polypeptides - Non-naturally occurring tRNA | 06-05-2014 |
| 20140154745 | PROCESS FOR THE CULTURING OF CELLS - The invention relates to a process for the culturing of cells, preferably E | 06-05-2014 |
| 20140162316 | Anti-GLP-1R Antibodies and Their Uses - The present invention relates to antibodies reactive with GLP-1R, and methods of making and using them. | 06-12-2014 |
| 20140162317 | ISOFORM ENTRICHED ANTIBODY PREPARATION AND METHOD FOR OBTAINING IT - Herein is reported a method for producing an antibody preparation comprising the steps of a) applying a buffered solution comprising different isoforms of an antibody to a cation exchange chromatography material, b) applying a first solution with a first conductivity to the cation exchange chromatography material, whereby the antibody isoforms remain bound to the cation exchange chromatography material, and c) applying a second solution with a second conductivity to the cation exchange chromatography material and thereby obtaining the antibody preparation, whereby the conductivity of the second solution exceeds the conductivity of the first solution by not more than 10%. | 06-12-2014 |
| 20140170704 | Production of Carrier-Peptide Conjugates Using Chemically Reactive Unnatural Amino Acids - Provided are methods of making carrier polypeptide that include incorporating a first unnatural amino acid into a carrier polypeptide variant, incorporating a second unnatural amino acid into a target polypeptide variant, and reacting the first and second unnatural amino acids to produce the conjugate. Conjugates produced using the provided methods are also provided. In addition, orthogonal translation systems in methylotrophic yeast and methods of using these systems to produce carrier and target polypeptide variants comprising unnatural amino acids are provided. | 06-19-2014 |
| 20140170705 | METHODS OF GENERATING LIBRARIES AND USES THEREOF - This invention relates to methods for the generation of humanized antibodies, particularly a humanized antibody heavy chain protein and a humanized antibody light chain protein. The method comprises using cells that express or can be induced to express Activation Induced Cytidine Deaminase (AID). | 06-19-2014 |
| 20140178934 | HEPATOCYTE GROWTH FACTOR (HGF) BINDING PROTEINS - The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic activity, the binding proteins can be used to treat certain HGF responsive disorders, for example, certain HGF responsive tumors. | 06-26-2014 |
| 20140178935 | HEPATOCYTE GROWTH FACTOR (HGF) BINDING PROTEINS - The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic activity, the binding proteins can be used to treat certain HGF responsive disorders, for example, certain HGF responsive tumors. | 06-26-2014 |
| 20140178936 | Humanized Anti-CD70 Binding Agents and Uses Thereof - Disclosed are CD70 binding agents, such as humanized anti-CD70 antibodies and fragments and derivatives, that exert a cytotoxic, cytostatic or immunomodulatory on CD70 expressing cells, as well as pharmaceutical compositions and kits comprising the antibody, fragment or derivative. Also disclosed are methods for the treatment of CD70-expressing cancers and immunological disorders, comprising administering to a subject the CD70 binding agents or pharmaceutical compositions. | 06-26-2014 |
| 20140186889 | ANTIBODY GENERATION FROM PLASMACYTOMA-PRONE TRANSGENIC ANIMALS - Certain transgenic animals which are prone to the rapid cell division of their antibody-secreting cells have superior properties for the generation of monoclonal antibodies. Not only can their antibody producing cells can be made into hybridomas with superior growth to hybridomas from non-prone animals, but the antibody producing cells themselves can be cultured directly without cell fusion or further manipulation. Disclosed herein are methods of making monoclonal antibodies comprising exposing the transgenic animals disclosed herein to an antigen and extracting antigen-specific antibody secreting cells from the transgenic animal. | 07-03-2014 |
| 20140186890 | SELECTION OF HOST CELLS EXPRESSING PROTEIN AT HIGH LEVELS - Provided is a DNA molecule comprising a multicistronic transcription unit coding for i) a selectable marker polypeptide functional in a eukaryotic host cell, and for ii) a polypeptide of interest, the polypeptide of interest having a translation initiation sequence separate from that of the selectable marker polypeptide, wherein the coding sequence for the polypeptide of interest is downstream from the coding sequence for the selectable marker in the multicistronic transcription unit, and the nucleic acid sequence coding for the selectable marker polypeptide comprises a mutation that decreases the translation efficiency of the selectable marker in a eukaryotic host cell. Also provided are methods for obtaining host cells expressing a polypeptide of interest, the host cells comprising the described DNA molecules. Further provided is the production of polypeptides of interest, comprising culturing host cells comprising the DNA molecules hereof. | 07-03-2014 |
| 20140186891 | POLYNUCLEOTIDES ENCODING IL-31 MONOCLONAL ANTIBODIES - The invention provides humanized mouse anti-human IL-31 antibodies and antibody fragments that are capable of binding IL-31 and thereby neutralizing, inhibiting, limiting, or reducing the proinflammatory or pro-pruritic effects of IL-31. | 07-03-2014 |
| 20140186892 | MONOCLONAL ANTIBODIES AGAINST GLYPICAN-3 - The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to Glypican-3 with high affinity. Nucleic acid molecules encoding Glypican-3 antibodies, expression vectors, host cells and methods for expressing the Glypican-3 antibodies are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the Glypican-3 antibodies are also provided. Methods for detecting Glypican-3, as well as methods for treating various Glypican-3-related conditions, including hepatocellular cancer, are disclosed. | 07-03-2014 |
| 20140199728 | METHODS OF USING CELL-CYCLE INHIBITORS TO MODULATE ONE OR MORE PROPERTIES OF A CELL CULTURE - Methods of modulating the properties of a cell culture expressing a protein of interest are provided. In various embodiments the methods relate to the addition of cell cycle inhibitors to growing cell cultures. | 07-17-2014 |
| 20140199729 | Method for Reducing Heterogeneity of Antibodies and a Process of Producing the Antibodies Thereof - The present disclosure relates to a method of reducing heterogeneity in antibodies during culturing, wherein the heterogeneity is due to proportion of charge variant of the antibody. The disclosure also comprises a process of growing cells in a cell culture system that results in antibodies with the reduced heterogeneity. In one embodiment antibody heterogeneity is reduced by the addition of divalent transitional metal ions such as zinc (Zn | 07-17-2014 |
| 20140206038 | CELL CULTURE IMPROVEMENTS - The invention describes improved methods and compositions for producing a recombinant protein, e.g., an antibody, in mammalian cell culture. In addition, the invention provides improved cell culture media, including improved production media, feed solutions, and combination feeds, which may be used to improve protein productivity in mammalian cell culture. | 07-24-2014 |
| 20140212925 | IL-1 BINDING PROTEINS - Proteins that bind IL-1α and IL-1β are described along with their use in compositions and methods for treating, preventing, and diagnosing IL-1-related disorders and for detecting IL-1α and IL-1β in cells, tissues, samples, and compositions. | 07-31-2014 |
| 20140220634 | Antibodies binding human collagen II - The present invention relates to antibodies against human collagen II, polypeptides and polynucleotides encoding human collagen II antibodies or fragments thereof, and methods of making and using the foregoing. | 08-07-2014 |
| 20140220635 | Alpha-Amylase Variants and Polynucleotides Encoding Same - The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants. | 08-07-2014 |
| 20140234905 | CELL CULTURE IMPROVEMENTS - The invention describes improved methods and compositions for producing a recombinant protein, e.g., an antibody, in mammalian cell culture. In addition, the invention provides improved cell culture media, including improved production media, feed solutions, and combination feeds, which may be used to improve protein productivity in mammalian cell culture. | 08-21-2014 |
| 20140234906 | Alpha-Amylase Variants and Polynucleotides Encoding Same - The present invention relates to alpha-amylase variants. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants. | 08-21-2014 |
| 20140242637 | ARTIFICIAL INTRONS - The invention concerns the field of recombinant gene engineering. It concerns novel artificial introns and compositions comprising such introns as well as a method to improve expression of polypeptides from nucleic acids such as cloned genes, especially genes encoding antibodies and antibody derived fragments, and the production of various polypeptides in eukaryotic host cells using said novel artificial intron sequences. | 08-28-2014 |
| 20140242638 | TRANSCRIPTION UNIT AND USE THEREOF IN (YB2/0) EXPRESSION VECTORS - A transcription unit constituted by a polynucleotide including the hCMVie virus enhancer, the enhancer having the nucleotide sequence SEQ ID NO: 1, or a nucleotide acid having at least 70% sequence identity with the sequence SEQ ID NO: 1 and essentially having transcription activation properties, and the promoter region of Cyclin-Dependent Kinase 9 (CDK9), the promoter region having the nucleotide sequence SEQ ID NO: 2, or a nucleotide acid having at least 70% sequence identity with the sequence SEQ ID NO: 2 and essentially having a promoter activity. | 08-28-2014 |
| 20140248664 | READILY ISOLATED BISPECIFIC ANTIBODIES WITH NATIVE IMMUNOGLOBULIN FORMAT - A bispecific antibody format providing ease of isolation is provided, comprising immunoglobulin heavy chain variable domains that are differentially modified in the CH3 domain, wherein the differential modifications are non-immunogenic or substantially non-immunogenic with respect to the CH3 modifications, and at least one of the modifications results in a differential affinity for the bispecific antibody for an affinity reagent such as Protein A, and the bispecific antibody is isolable from a disrupted cell, from medium, or from a mixture of antibodies based on its affinity for Protein A. | 09-04-2014 |
| 20140248665 | NOVEL INTRON SEQUENCES - The invention concerns the field of recombinant gene engineering. It concerns novel introns and compositions comprising such introns as well as a method to improve expression of polypeptides from nucleic acids such as cloned genes with heterologous introns, especially genes encoding antibodies and antibody derived fragments, and the production of various polypeptides in eukaryotic host cells using said novel intron sequences as heterologous introns. | 09-04-2014 |
| 20140248666 | EPITOPES - Compositions and methods relating to epitopes of sclerostin protein, and sclerostin binding agents, such as antibodies capable of binding to sclerostin, are provided. | 09-04-2014 |
| 20140255993 | MAMMALIAN CELL CULTURE - The invention provides a method for culturing mammalian cells. The method provides greater control over cell growth to achieve high product titer cell cultures by changing the temperature of the cell culture and/or by starving the cells in their asparagine supply. | 09-11-2014 |
| 20140255994 | Integrated Continuous Manufacturing of Therapeutic Protein Drug Substances - Provided herein are integrated continuous biomanufacturing processes for producing a therapeutic protein drug substance. Also provided are systems that are capable of continuously producing a therapeutic protein drug substance. | 09-11-2014 |
| 20140255995 | HIGH AFFINITY ANTIBODIES TO HUMAN IL-6 RECEPTOR - A human antibody or an antigen-binding fragment which binds human IL-6 receptor (hIL-6R) with a K | 09-11-2014 |
| 20140255996 | Method for Secretory Production of Protein - A method for secretory production of a heterologous protein is provided by developing a novel technique for improving ability of a coryneform bacterium to produce a heterologous protein by secretory production. By utilizing a coryneform bacterium having an ability to produce a heterologous protein by secretory production which has been modified so that the activity of a penicillin-binding protein is reduced and in which the activity of a cell surface layer protein has been reduced as an expression host, a heterologous protein is produced by secretory production. | 09-11-2014 |
| 20140273092 | MANUFACTURING METHODS TO CONTROL C-TERMINAL LYSINE, GALACTOSE AND SIALIC ACID CONTENT IN RECOMBINANT PROTEINS - Provided herein is a method for producing an antibody, such as an anti-TNFα antibody (e.g., infliximab) having a C-terminal lysine content of about 20% to about 70%, and a sialic acid content of about 1% to about 20%, comprising culturing a zinc-responsive host cell transfected with DNA encoding the antibody in a culture medium comprising at least 0.5 μM zinc; and controlling the concentration of zinc in the culture medium, thereby producing the antibody. | 09-18-2014 |
| 20140273093 | METHODS OF PRODUCING ANTIBODIES IN YEAST - The present invention describes a method for producing an antibody in | 09-18-2014 |
| 20140273094 | METHODS OF ENHANCING PROTEIN QUALITY AND QUANTITY BY YEAST FED-BATCH FERMENTATION - The present invention describes a method for producing an antibody in | 09-18-2014 |
| 20140273095 | Serum-Free Cell Culture Medium - The specification describes an improved serum-free animal cell culture medium, which can used for the production of a protein of interest. Ornithine, or a combination of ornithine and putrescine can be added to serum-free media or chemically defined media to improve viable cell density, to reduce cell doubling time, and to increase the production of a protein of interest. | 09-18-2014 |
| 20140273096 | MODIFIED COAGULATION FACTORS WITH PROLONGED IN VIVO HALF-LIFE - The present invention relates to nucleic acid sequences coding for modified coagulation factors, preferably coagulation factor VIII, and their derivatives; recombinant expression vectors containing such nucleic acid sequences; host cells transformed with such recombinant expression vectors; and recombinant polypeptides and derivatives coded for by said nucleic acid sequences, whereby said recombinant polypeptides and derivatives have biological activities and prolonged in vivo half-lives compared to the unmodified wild-type proteins. The invention also relates to corresponding sequences that result in improved in vitro stability. The present invention further relates to processes for the manufacture of such recombinant proteins and their derivatives. The invention also relates to a transfer vector for use in human gene therapy, which comprises such nucleic acid sequences. | 09-18-2014 |
| 20140273097 | METHODS AND COMPOSITIONS FOR INACTIVATING ALPHA 1,6 FUCOSYLTRANSFERASE (FUT8) GENE EXPRESSION - Disclosed herein are methods and compositions for inactivating a FUT8 gene, using fusion proteins comprising a zinc finger protein and a cleavage domain or cleavage half-domain. Polynucleotides encoding said fusion proteins are also provided, as are cells comprising said polynucleotides and fusion proteins. | 09-18-2014 |
| 20140287464 | In Vivo Unnatural Amino Acid Expression in the Methylotrophic Yeast Pichia Pastoris - The invention provides orthogonal translation systems for the production of polypeptides comprising unnatural amino acids in methylotrophic yeast such as | 09-25-2014 |
| 20140295494 | HIGH AFFINITY, ANTI-HUMAN IgE ANTIBODIES - The invention relates to high affinity human monoclonal antibodies, particularly those directed against isotypic determinants of immunoglobulin E (IgE), as well as direct equivalents and derivatives of these antibodies. These antibodies bind to their respective target with an affinity at least 100 fold greater than the original parent antibody. These antibodies are useful for diagnostics, prophylaxis and treatment of disease. | 10-02-2014 |
| 20140295495 | Methods of Preventing and Removing Trisulfide Bonds - The present invention pertains to methods of preventing and eliminating trisulfide bonds in proteins such as antibodies. In one embodiment, trisulfide bonds in proteins are converted to disulfide bonds as part of chromatographic purification procedures. In another embodiment, the formation of trisulfide bonds in proteins is inhibited by implementation of methods described herein during the cell culture production of such proteins. In another embodiment, monoclonal antibodies are produced by the methods described herein. | 10-02-2014 |
| 20140295496 | RECOMBINANT BACULOVIRUS AND USE THEREOF - The present invention provides a recombinant baculovirus. The baculovirus has a genome into which a gene encoding γ-glutamyl carboxylase (GGCX) and a gene encoding DT-diaphorase (NQO1) are incorporated. | 10-02-2014 |
| 20140295497 | VECTORS AND HOST CELLS COMPRISING A MODIFIED SV40 PROMOTER FOR PROTEIN EXPRESSION - The present disclosure is directed to expression vectors, comprising a weakened SV40 promoter, and recombinant mammalian cells capable of producing high levels of a polypeptide of interest, methods of generating and using such recombinant mammalian cells. | 10-02-2014 |
| 20140302559 | RAPID METHOD FOR CLONING AND EXPRESSION OF COGNATE ANTIBODY VARIABLE REGION GENE SEGMENTS - In the method as reported herein the isolation of nucleic acid segments encoding antibody variable domains and the insertion of the isolated nucleic acid segments in eukaryotic expression plasmids is performed without the intermediate isolation and analysis of clonal intermediate plasmids. Thus, in the method as reported herein the intermediate cloning, isolation and analysis of intermediate plasmids is not required, e.g. by analysis of isolated transformed | 10-09-2014 |
| 20140315249 | INDUCIBLE EUKARYOTIC EXPRESSION SYSTEM - Compositions and methods for the inducible expression of genes in eukaryotic cells are provided. Expression of a nucleotide sequence of interest encoding a protein of interest is controlled by a regulatory fusion protein that consists of a transcription blocking domain and a ligand-binding domain. When a cognate ligand for the ligand-binding domain is present, transcription of the nucleotide sequence of interest is blocked. Upon removal of the cognate ligand, the nucleotide sequence of interest is transcribed. The method is useful for large scale bioreactor production of a desired protein of interest in eukaryotic cells. | 10-23-2014 |
| 20140315250 | HUMANIZED ANTIBODIES AGAINST TL1A - Disclosed are humanized antibodies that bind specifically to TNF superfamily member 15 (TNFSF15), also known as TL1A. Methods of making and using the anti-TL1A antibodies are also described. The humanized antibodies may be antagonists and may used to treat or diagnose conditions associated with TL1A function. | 10-23-2014 |
| 20140315251 | Interleukin-31 Monoclonal Antibody - An isolated antibody that specifically binds to at least one of canine Interleukin-31 (IL-31) or feline IL-31 is provided. Such antibodies can be in the form of diagnostic and/or veterinary compositions useful for treating a pruritic and/or allergic condition in dogs or cats. | 10-23-2014 |
| 20140315252 | CD40L EXPRESSING MAMMALIAN CELLS AND THEIR USE - Herein is reported a co-cultivation system for co-cultivating a pool of rabbit B-cells or single deposited rabbit B-cells wherein cells CD40L expressing CHO cells are used as feeder in the presence of IL-2 and IL-21. | 10-23-2014 |
| 20140322756 | METHOD FOR MAKING MULTISPECIFIC ANTIBODIES HAVING HETEROMULTIMERIC AND COMMON COMPONENTS - The invention relates to a method of preparing heteromultimeric polypeptides such as bispecific antibodies, bispecific immunoadhesins and antibody-immunoadhesin chimeras. The invention also relates to the heteromultimers prepared using the method. Generally, the method provides a multispecific antibody having a common light chain associated with each heteromeric polypeptide having an antibody binding domain. Additionally the method further involves introducing into the multispecific antibody a specific and complementary interaction at the interface of a first polypeptide and the interface of a second polypeptide, so as to promote heteromultimer formation and hinder homomultimer formation; and/or a free thiol-containing residue at the interface of a first polypeptide and a corresponding free thiol-containing residue in the interface of a second polypeptide, such that a non-naturally occurring disulfide bond is formed between the first and second polypeptide. The method allows for the enhanced formation of the desired heteromultimer relative to undesired heteromultimers and homomultimers. | 10-30-2014 |
| 20140322757 | ANTIBODIES THAT BIND COLONY STIMULATING FACTOR 1 RECEPTOR (CSF1R) - Antibodies that bind CSF1R are provided. Antibody heavy chains and light chains that are capable of forming antibodies that bind CSF1R are also provided. Polynucleotides encoding antibodies to CSF1R are provided. Polynucleotides encoding antibody heavy chains and lights chains are also provided. Methods of treatment using antibodies to CSF1R are provided. Such methods include, but are not limited to, methods of treating rheumatoid arthritis, bone loss, and multiple sclerosis. | 10-30-2014 |
| 20140329277 | METHOD FOR CULTURING CELLS IN ORDER TO PRODUCE SUBSTANCES - The invention concerns a method for culturing cells in order to produce substances. According to the invention a cell line producing substances is cultured while feeding a nutrient medium in such a manner that glucose limitation occurs in the culture solution. The degree of glucose limitation DGL=qGlc/qGlc | 11-06-2014 |
| 20140329278 | AMINO ACID SEQUENCES DIRECTED AGAINST IL-6R AND POLYPEPTIDES COMPRISING THE SAME FOR THE TREATMENT OF IL-6R RELATED DISEASES AND DISORDERS - The present invention relates to amino acid sequences that are directed against/and or that can specifically bind Interleukin-6 Receptor (IL-6R) with improved affinity and/or avidity, and/or that have an improved efficacy and/or potency, and which are capable of (partially, or preferably totally) blocking the IL-6/IL-6R interaction and/or inhibit signalization through IL-6, IL-6R and/or the IL-6/IL-6R complex. The invention further relates to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. | 11-06-2014 |
| 20140329279 | COMPOSITIONS FOR CELL CULTURE AND METHODS OF USING THE SAME - Supplementation of the bioflavonoids such as epigallocatechin gallate, rutin, naringin, or genistein into mammalian cell culture media are shown to be effective in reduction of acidic species variants on recombinant antibodies. The demonstrated reduction in acidic species through the use of bioflavonoids, facilitates the manufacturing of a less heterogeneous product with potential improvements in antibody structure and function. | 11-06-2014 |
| 20140335563 | STABILIZED HUMAN IGG2 AND IGG3 ANTIBODIES - It is intended to provide highly stable variants of human antibody IgG2 and IgG3 subclasses. The present invention provides an IgG heavy chain comprising the constant region of a human IgG2 heavy chain having at least a substitution of Y for F at the 300th position, L for V at the 309th position, or A for T at the 339th position designated by the EU index of Kabat et al. and an IgG heavy chain comprising the constant region of a human IgG3 heavy chain having at least a substitution of K for N at the 392nd position or V for M at the 397th position designated by the EU index of Kabat et al. The present invention also provides monoclonal antibodies comprising these heavy chains. | 11-13-2014 |
| 20140335564 | IL-17 BINDING PROTEINS - Proteins that bind IL-17 and/or IL-17F are described along with there use in composition and methods for treating, preventing, and diagnosing IL-17 related diseases and for detecting IL-17 in cells, tissues, samples, and compositions. | 11-13-2014 |
| 20140335565 | METHOD FOR PRODUCTION OF POLYPEPTIDE - The present invention provides a method capable of producing a natural or recombinant protein in high yield. The present invention relates to a method of producing a polypeptide, comprising culturing a cell which strongly expresses cysteine sulfinic acid decarboxylase and has a transferred DNA encoding a desired polypeptide and thereby allowing the cell to produce the polypeptide. Hamster cysteine sulfinic acid decarboxylase, a DNA encoding the same, a recombinant vector and a transformed cell are also provided. | 11-13-2014 |
| 20140342404 | POLYPEPTIDE VARIANTS WITH ALTERED EFFECTOR FUNCTION - The present invention concerns polypeptides comprising a variant Fc region. More particularly, the present invention concerns Fc region-containing polypeptides that have altered effector function as a consequence of one or more amino acid modifications in the Fc region thereof. | 11-20-2014 |
| 20140342405 | VASCULAR ENDOTHELIAL GROWTH FACTOR 2 - Disclosed are human VEGF-2 antibodies, antibody fragments, or variants thereof. Also provided are processes for producing such antibodies. The present invention relates to methods and compositions for preventing, treating or ameliorating a disease or disorder comprising administering to an animal, preferably a human, an effective amount of one or more VEGF-2 antibodies or fragments or variants thereof. | 11-20-2014 |
| 20140342406 | DNA ENCODING FUNCTION MODIFYING NAv1.7 ANTIBODIES | 11-20-2014 |
| 20140342407 | NEUTRALIZING GP41 ANTIBODIES AND THEIR USE - Monoclonal neutralizing antibodies are disclosed that specifically bind to the HIV-1 gp41 membrane-proximal external region (MPER). Also disclosed are compositions including the disclosed antibodies that specifically bind gp41, nucleic acids encoding these antibodies, expression vectors including the nucleic acids, and isolated host cells that express the nucleic acids. The antibodies and compositions disclosed herein can be used for detecting the presence of HIV-1 in a biological sample, or detecting an HIV-1 infection or diagnosing AIDS in a subject. In additional, the broad neutralization breadth of the disclosed antibodies makes them ideal for treating a subject with an HIV infection. Thus, disclosed are methods of treating and/or preventing HIV infection. | 11-20-2014 |
| 20140349342 | INTERLEUKIN-6 RECEPTOR BINDING POLYPEPTIDES - The invention relates to amino acid sequences that are directed against and/or that can specifically bind to IL-6 receptor, compounds or constructs that comprise said amino acid sequence, nucleic acids that encode said amino acid sequences, compounds or constructs, pharmaceutical compositions comprising said amino acid sequences, compounds or constructs as well as methods for the prevention and/or treatment of diseases and disorders associated with IL-6 receptor. | 11-27-2014 |
| 20140356907 | ANTIBODY PRODUCTION - A transgenic non-human mammal containing a heterologous lambda light chain gene locus, and/or a heterologous kappa light chain gene locus, and/or a heterologous heavy chain gene locus, each of which can re-arrange so that immunoglobulin heavy and light chain genes are formed and expressed in B-cells following antigen challenge. | 12-04-2014 |
| 20140356908 | BINDING MOLECULES - A transgenic non-human mammal containing a heterologous heavy chain gene locus that is capable of producing soluble heavy chain only antibodies and antigen-binding fragments thereof following immunization. | 12-04-2014 |
| 20140356909 | IL-17 BINDING PROTEINS - Proteins that bind IL-17 and/or IL-17F are described along with their use in composition and methods for treating, preventing, and diagnosing IL-17 related diseases and for detecting IL-17 in cells, tissues, samples, and compositions. | 12-04-2014 |
| 20140356910 | METHODS FOR INCREASING MANNOSE CONTENT OF RECOMBINANT PROTEINS - The present invention relates to methods of upregulating the high mannose glycoform content of a recombinant protein during a mammalian cell culture by manipulating the mannose to total hexose ratio in the cell culture media formulation. | 12-04-2014 |
| 20140356911 | Method for Producing Protein - The present invention relates to a recombinant host cell, wherein the cell is modified to increase the expression levels of Ero1 and XBP1 relative to the expression levels of Ero1 and XBP1 in an unmodified cell. The present invention also relates to a method of producing a recombinant protein of interest comprising expressing the recombinant protein of interest in the recombinant host cell. | 12-04-2014 |
| 20140363845 | CHOLESTEROL-BASED MEDIA SUPPLEMENTS FOR CELL CULTURE - The disclosure provides compositions and methods for high density cell culture and banking of cholesterol auxotrophic cells. | 12-11-2014 |
| 20140370547 | EXPRESSION VECTOR ORGANIZATION, NOVEL PRODUCTION CELL GENERATION METHODS AND THEIR USE FOR THE RECOMBINANT PRODUCTION OF POLYPEPTIDES - Herein is reported an expression vector comprising—an antibody light chain expression cassette,—an antibody heavy chain expression cassette, and—a selection marker expression cassette, wherein the expression cassettes are arranged unidirectional, and wherein the expression cassettes are arranged in the 5′ to 3′ sequence of antibody heavy chain expression cassette, antibody light chain expression cassette and selection marker expression cassette. Further are reported herein methods for the generation of antibody producing cells and the use of these cells for the recombinant production of antibodies. | 12-18-2014 |
| 20140370548 | ANTIBODIES IMMUNOREACTIVE WITH HEREGULIN-COUPLED HER3 - Recombinant materials and methods for producing antibodies that specifically bind heregulin-coupled HER3, at a site distinct from the heregulin binding site, are described. These antibodies are particularly useful in treating cancer that expresses HER3. | 12-18-2014 |
| 20140377803 | ENHANCEMENT OF PROTEIN PRODUCTION YIELD MEDIATED BY A FAST SHUTTLING CDC42 GTPASE - The present invention relates to a cell for producing a secreted protein comprising a polynucleotide comprising a nucleic acid sequence encoding a fast cycling cdc42 mutant and a polynucleotide comprising a nucleic acid sequence encoding a secreted protein. It also relates to a method for producing said cell and to a method for producing a secreted protein using said cell. | 12-25-2014 |
| 20140377804 | Filamentous Fungi Having Reduced UDP-Galactofuranose Content - A filamentous fungal cell having reduced UDP-galactofuranose is provided. The fungal cell may, in certain embodiments, contain a nuclear genome comprising an inactivated UDP-galactopyranose mutase (UDP-galp mutase) gene and a recombinant nucleic acid for expression of a protein. Also provided are methods of producing a protein using the subject fungal cell, as well as methods of producing the subject fungal cell. | 12-25-2014 |
| 20140377805 | Dual Variable Domain Immunoglobulin and Uses Thereof - The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention and/or treatment of acute and chronic inflammatory and other diseases. | 12-25-2014 |
| 20140377806 | ANTI-CXCR3 ANTIBODIES AND METHODS OF USE THEREOF - The present disclosure provides anti-CXCR3 antibodies and methods of using the antibodies to diagnose and/or treat CXCR3-associated disorders such as diabetes mellitus type I (T1D), particularly new-onset T1D. In certain embodiments, disclosed herein are CXCR3 neutralizing antibodies. | 12-25-2014 |
| 20150010946 | POLYNUCLEOTIDES ENCODING ZCYTOR17 LIGAND ANTIBODIES - The present invention relates to zcytor17lig polynucleotide, polypeptide and anti-zcytor17 antibody molecules. The zcytor17lig is a novel cytokine. The polypeptides may be used within methods for stimulating the immune system, and proliferation and/or development of hematopoietic cells in vitro and in vivo. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto. | 01-08-2015 |
| 20150017686 | METHODS FOR REDUCING MANNOSYLTRANSFERASE ACTIVITY IN LOWER EUKARYOTES - Disclosed are methods for reducing detectable mannosylation of N-linked and O-linked oligosaccharides in lower eukaryote host cells. In particular, recombinant lower eukaryote host cells are provided in which expression of the GDP-mannose transporter encoded by the Vanadate Resistant Glycosylation 4 (VRG4) gene has been disrupted. In general, the VRG4 gene is essential for cell viability; however, the present invention provides host cells that are viable when expression of the VRG4 gene therein has been disrupted. The host cells are capable of producing proteins or glycoproteins that have reduced or no detectable α-linked mannose, β-linked mannose or phosphomannose containing N- and/or O-glycans. | 01-15-2015 |
| 20150024432 | METHODS FOR IDENTIFYING IMMUNOBINDERS OF CELL-SURFACE ANTIGENS - The invention provides methods for identifying immunobinders, such as scFv antibodies, capable of specifically binding to cell surface antigens, and compositions identified according to said methods. | 01-22-2015 |
| 20150024433 | Humanized Antibodies That Recognize Alpha-Synuclein - The present application discloses humanized 1H7 antibodies. The antibodies bind to human alpha synuclein and can be used for treatment and diagnosis of Lewy body disease. | 01-22-2015 |
| 20150024434 | METHOD FOR OBTAINING FAB FRAGMENTS FROM SINGLE ANTIBODY PRODUCING CELLS BY MULTIPLEXED CPR IN COMBINATION WITH TaqMan PROBES - Herein is reported a method for a multiplex one tube real-time reverse-transcriptase gene-specific polymerase chain reaction for the amplification and quantification of cognate IgG heavy and light chains encoding nucleic acids (human IgG isotype) from a single cell. | 01-22-2015 |
| 20150031081 | METHODS AND MATERIALS FOR REDUCING DEGRADATION OF RECOMBINANT PROTEINS - Described herein are methods and materials for reducing degradation of recombinant proteins in fungal cells such as | 01-29-2015 |
| 20150044722 | SIGLEC-15 ANTIBODIES IN TREATING BONE LOSS-RELATED DISEASE - Novel antibodies and antigen binding fragments that specifically binds to Siglec-15 are described herein In some embodiments, the antibodies or antigen binding fragments may block the biological activity of Siglec-15 and are useful in composition for the treatment of bone loss, more particularly in bone diseases that have increased cell surface expression of Siglec-15, such as conditions where there is an increase in the bone degradative activity of osteoclasts The invention also relates to cells expressing the antibodies or antigen binding fragments such as monoclonal, humanized or chimeric antibodies Additionally, methods of detecting and treating bone loss, bone-related diseases or cancer using the antibodies and fragments are also disclosed. | 02-12-2015 |
| 20150050693 | METHODS FOR CONTROLLING THE GALACTOSYLATION PROFILE OF RECOMBINANTLY-EXPRESSED PROTEINS - The present invention relates to methods for modulating the glycosylation profile of recombinantly-expressed proteins. In particular, the present invention relates to methods of controlling the galactosylation profile of recombinantly-expressed proteins by supplementing production medium, e.g., a hydrolysate-based or a chemically defined medium, with manganese and/or D-galactose. | 02-19-2015 |
| 20150056654 | PROCESS FOR THE PURIFICATION OF RECOMBINANT ALBUMIN - A process is provided for the preparation of a highly pure albumin solution the process comprising subjecting albumin (preferably expressed and secreted by transformed yeast) to a series of chromatographic steps. Preferably, the process comprises the steps of positive mode cation exchange chromatography, positive mode anion exchange chromatography, positive mode affinity chromatography, negative mode affinity chromatography (preferably using immobilised aminophenylboronic acid), negative mode cation exchange chromatography, and negative or positive mode anion exchange chromatography. A process for reducing the level of nickel in an albumin solution is also disclosed, as is a recombinant albumin coding sequence comprising two or more in-frame translation stop codons. Also disclosed is a process for producing recombinant albumin, the process comprising culturing a fungal cell expressing a recombinant albumin coding sequence, wherein the cell has a reduced capacity of mannosylation of the recombinantly-expressed albumin. | 02-26-2015 |
| 20150056655 | EXPRESSION CONSTRUCTS AND METHODS FOR EXPRESSING POLYPEPTIDES IN EUKARYOTIC CELLS - The invention relates to an expression construct for the expression of polypeptides in host cells using alternative splicing. The expression construct can be used for the expression of polypeptides such as antibodies, antibody fragments and bispecific antibodies by expressing the gene products required for protein expression at the ratio leading to the highest titres or the best product quality profile. | 02-26-2015 |
| 20150056656 | METHOD FOR REDUCTION OF 1->2 READING FRAME SHIFTS - Herein is reported a method for the recombinant production of a polypeptide, which comprises the dipeptide AR, characterized in that the method comprises the recovering of the polypeptide from the cells or the cultivation medium of a cultivation of a cell comprising a nucleic acid encoding the polypeptide and thereby producing the polypeptide, whereby the dipeptide AR comprised in the polypeptide is encoded by the oligonucleotide gca cgt, or the oligonucleotide gcg cgt, or the oligonucleotide gcc cgt. | 02-26-2015 |
| 20150056657 | METHOD OF PRODUCING RECOMBINANT HIGH MOLECULAR WEIGHT vWF IN CELL CULTURE - Among other aspects, the present invention relates to cell culture conditions for producing high molecular weight vWF, in particular, highly multimericWF with a high specific activity and ADAMTS13 with a high specific activity. The cell culture conditions of the present invention can include, for example, a cell culture medium with an increased copper concentration and/or cell culture supernatant with a low ammonium (NH | 02-26-2015 |
| 20150064746 | METHOD FOR REDUCTION OF 1->3 READING FRAME SHIFTS - Herein is reported a method for the recombinant production of a polypeptide, which comprises the tripeptide QKK, characterized in that the method comprises the step of recovering the polypeptide from the cells or the cultivation medium of a cultivation of a cell comprising a nucleic acid encoding the polypeptide and thereby producing the polypeptide, whereby the tripeptide QKK comprised in the polypeptide is encoded by the oligonucleotide cag aaa aaa or the oligonucleotide caa aag aaa. | 03-05-2015 |
| 20150079634 | REDUCTION OF FORMATION OF AMIDATED AMINO ACIDS IN CELL LINES FOR PROTEIN EXPRESSION - The present invention is related to a method to reduce peptide amidation activity in a given cell line, cell lines with reduced peptide amidation activity, and uses thereof. | 03-19-2015 |
| 20150087024 | Cell Culture Improvements - The invention describes improved methods and compositions for producing a recombinant protein, e.g., an antibody, in mammalian cell culture. In addition, the invention provides improved cell culture media, including improved production media, feed solutions, and combination feeds, which may be used to improve protein productivity in mammalian cell culture. | 03-26-2015 |
| 20150093782 | COMPOSITIONS AND METHODS FOR REDUCING FUCOSYLATION OF GLYCOPROTEINS IN INSECT CELLS AND METHODS OF USE THEREOF FOR PRODUCTION OF RECOMBINANT GLYCOPROTEINS - Compositions for reducing fucosylation of glycoproteins in insect cells are provided. Also disclosed are methods of use of such compositions for the production of recombinant humanized proteins. | 04-02-2015 |
| 20150093783 | HUMANIZED ANTIBODIES TO CA215 - Provided herein are humanized forms of murine RP215 monoclonal antibodies and methods of using the same. These humanized RP215 monoclonal antibodies were characterized in terms of their respective affinity and specificity to the corresponding tumor-associated antigen, CA215, and shown to be comparable to those of murine RP215. | 04-02-2015 |
| 20150093784 | Cell Culture Improvements - The invention describes improved methods and compositions for producing a recombinant protein, e.g., an antibody, in mammalian cell culture. In addition, the invention provides improved cell culture media, including improved production media, feed solutions, and combination feeds, which may be used to improve protein productivity in mammalian cell culture. | 04-02-2015 |
| 20150099278 | POLYNUCLEOTIDES ENCODING ANTIBODIES - The present invention relates to antagonizing the activity of IL-17A, IL-17F and IL-23 using bispecific antibodies that comprise a binding entity that is cross-reactive for IL-17A and IL-17F and a binding entity that binds IL-23p19. The present invention relates to novel bispecific antibody formats and methods of using the same. | 04-09-2015 |
| 20150104831 | Antibodies and Uses Thereof - The present invention provides antibodies which bind to an epitope in the extracellular domain of human CC chemokine receptor 4 (CCR4) and which are capable of inhibiting the binding of macrophage-derived chemokine (MDC) and/or thymus and activation regulated chemokine (TARC) to CCR4. Also provided are inter alia immunoconjugates and compositions comprising such antibodies and methods and uses involving such antibodies, particularly in the medical and diagnostic fields. | 04-16-2015 |
| 20150111250 | METHODS AND COMPOSITIONS FOR MODULATING TUMOR CELL ACTIVITY - Antibodies which target clusterin, a protein involved in the epithelial-to-mesenchymal transition of carcinoma cells, are identified and characterized. The antibodies may be used to modulate tumour cell activity through binding to clusterin. | 04-23-2015 |
| 20150111251 | TNF-ALPHA BINDING PROTEINS - TNF-α binding proteins, including chimeric, CDR-grafted, and humanized antibodies that bind TNF-α are provided. Binding proteins have high affinity for TNF-α and neutralize TNF-α activity. A binding protein can be a full-length antibody or a TNF-α-binding portion thereof. Methods of making and methods of using the binding proteins are also described. The TNF-α binding proteins are useful for detecting TNF-α and for inhibiting TNF-α activity, including in a human subject suffering from a disease or disorder in which TNF-α activity is detrimental. | 04-23-2015 |
| 20150118711 | Humanized Anti-IL-20 Antibody And Uses Thereof - Humanized antibodies specific to human interleukin 20 (IL-20) and uses thereof in treating diseases associated with the IL-20 signaling pathway, e.g., osteoporosis, inflammatory disease (e.g., rheumatoid arthritis), cancer, stroke, and renal failure. | 04-30-2015 |
| 20150125905 | CELL CULTURE IMPROVEMENTS - The invention describes improved methods and compositions for producing a recombinant protein, e.g., an antibody, in mammalian cell culture. In addition, the invention provides improved cell culture media, including improved production media, feed solutions, and combination feeds, which may be used to improve protein productivity in mammalian cell culture. | 05-07-2015 |
| 20150132801 | LOW ACIDIC SPECIES COMPOSITIONS AND METHODS FOR PRODUCING AND USING THE SAME - The instant invention relates to low acidic species (AR) compositions comprising a protein, e.g., an antibody, or antigen-binding portion thereof, and methods, e.g., cell culture and/or protein purification methods, for producing such low AR compositions. Methods for using such compositions to treat a disorder, e.g., a disorder in which TNFα is detrimental, are also provided. | 05-14-2015 |
| 20150132802 | ALKALINE FEED - A method for cultivating a bacterial cell comprising the addition of an amino acid in an alkaline solution used for pH regulation. Also an aspect is a method for producing a polypeptide comprising the steps of a) providing a bacterial cell comprising a nucleic acid encoding the polypeptide, b) cultivating the provided cell, c) adjusting the pH value during the cultivating with a basic solution comprising an amino acid, d) recovering the polypeptide from the cell or the cultivation medium and thereby producing the polypeptide | 05-14-2015 |
| 20150140608 | METHODS RELATED TO OMALIZUMAB - The present invention relates to the characterization and production of omalizumab. | 05-21-2015 |
| 20150140609 | Anti-alpha(v)beta(6) Antibodies - Monoclonal antibodies that specifically bind to M.96. Also included are methods of using these antibodies to treat mammals having or at risk of having 006-mediated diseases, or to diagnose % Q mediated diseases. | 05-21-2015 |
| 20150291683 | MODIFIED APOL1 POLYPEPTIDES - Modified ApoL1 polypeptides are provided, in particular, the modified polypeptides are expressed without an N-terminal or f-Methionine in bacterial cells. Also provided is a method of recombinantly producing the modified polypeptide. | 10-15-2015 |
| 20150291687 | Compositions and Methods for Redox Modulated Proteins - Disclosed embodiments relate to antibodies that recognize redox modulated proteins such as glutathionylated actin. Embodiments relate to a reagent for the immunoassay of glutathionylated actin. Disclosed embodiments also relate to diagnosis of and therapies for the treatment of diseases related to impaired deglutathionylation of peptides. Additionally, disclosed embodiments relate to pharmaceutical compositions containing antibodies which recognize redox modulated proteins and kits for the detection or treatment of diseases related to redox modulated proteins which include antibodies that recognize redox modulated proteins. | 10-15-2015 |
| 20150299305 | ANTI-C5 ANTIBODIES HAVING IMPROVED PHARMACOKINETICS - The disclosure provides antibodies that are useful for among other things, inhibiting terminal complement (e.g., the assembly and/or activity of the C5b-9 TCC) and C5a anaphylatoxin-mediated inflammation and, thus, treating complement-associated disorders. The antibodies have a number of improved properties relative to eculizumab, including, e.g., increased serum half-life in a human. | 10-22-2015 |
| 20150299330 | Human Anti-CD27 Antibodies, Methods and Uses - Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions. | 10-22-2015 |
| 20150299644 | DISCONTINUOUS FED BATCH PROCESSING WITH THE USE OF ALTERNATING BIOREACTORS - The present invention relates to discontinuous fed batch cell culturing of mammalian cells (more specific CHO cells) with the use of alternating bioreactors in combination with discontinuous separation of biomass from biological substance (more specific monoclonal antibodies) and waste components. | 10-22-2015 |
| 20150299688 | CO2 PROFILE CULTIVATION - A dissolved CO | 10-22-2015 |
| 20150315278 | Anti-Glypican-3 Antibody Having Improved Kinetics in Plasma - A method of modulating the plasma half-life of anti-glypican 3 antibody, a pharmaceutical composition comprising as an active ingredient the anti-glypican 3 antibody that has a plasma half-life that has been modulated, a method of preparing the anti-glypican 3 antibody and a pharmaceutical composition comprising the anti-glypican 3 antibody as an active ingredient are provided. Disclosed is a method of modulating the plasma half-life of anti-glypican 3 antibody by modifying an amino acid residue that is exposed on the surface of the anti-glypican 3 antibody; and anti-glypican 3 antibody that has a plasma half-life that has been modulated by amino acid residue modification, a pharmaceutical composition comprising as an active ingredient the anti-glypican 3 antibody, and a method of preparing the anti-glypican 3 antibody and producing a pharmaceutical composition comprising the anti-glypican 3 antibody as an active ingredient. | 11-05-2015 |
| 20150315624 | METHOD OF PRODUCING HETEROGENEOUS PROTEIN - The present invention provides a method capable of producing a natural or recombinant protein in high yield. The present invention relates to a method of producing a polypeptide, comprising culturing a cell which strongly expresses alanine aminotransferase and has a transferred DNA encoding a desired polypeptide and thereby allowing the cell to produce the polypeptide. | 11-05-2015 |
| 20150322134 | INDUCIBLE MUTAGENESIS OF TARGET GENES - The present invention relates generally to mutagenesis of target genes that takes advantage of the natural mutagenic capabilities of B cells, and enhances those capabilities by bringing the process of diversification under control. The invention provides a method for rapidly and inducibly generating point mutations and other types of diversification in expressed genes, such as antibody genes. This method can be coupled with selection to identify B cell clones that produce, for example, antibodies of high affinity or specificity. The diversification process can be modulated, accelerated, halted, switched between methods of mutagenesis and the like. The modulation of diversification in accordance with the invention is both inducible and reversible. The invention provides a means of rapid and feasible development of a repertoire of variant immunoglobulins and other polypeptides. | 11-12-2015 |
| 20150337274 | PMT2-, OCH1-, PMT5- MUTANT CELLS - The presented invention relates to the gene knockouts of the | 11-26-2015 |
| 20150344555 | ANTIBODY FORMULATIONS AND METHODS - Antibody formulations and methods useful for prophylaxis or treatment of amyloidosis, including AA amyloidosis and AL amyloidosis. | 12-03-2015 |
| 20150344579 | PROCESS OF MODULATING MAN5 AND/OR AFUCOSYLATION CONTENT OF A GLYCOPROTEIN COMPOSITION - Provided is a method for producing glycoprotein composition with an increased percentage of Man5 and/or afucosylated glycans. Use of manganese for increasing the percentage of Man5 and afucosylated glycans in glycoprotein composition is further provided. | 12-03-2015 |
| 20150353542 | METHODS OF USING CELL-CYCLE INHIBITORS TO MODULATE ONE OR MORE PROPERTIES OF A CELL CULTURE - Methods of modulating the properties of a cell culture expressing a protein of interest are provided. In various embodiments the methods relate to the addition of cell cycle inhibitors to growing cell cultures. | 12-10-2015 |
| 20150368660 | GEMINIVIRAL VECTOR FOR EXPRESSION OF RITUXIMAB - A single vector or multiple separate vectors that contain two or more non-competing replicons for transient expression of the heavy and light chains of Rituximab in | 12-24-2015 |
| 20150376221 | Carbohydrate Phosphonate Derivatives as Modulators of Glycosylation - Compounds of Formula (I) are useful as modulators of glycosylation. Compounds of Formula (I) have the following structure: (I) and the definitions of the other variables are provided herein. | 12-31-2015 |
| 20150376291 | ANTI C-MET ANTIBODIES - The present invention relates to antibodies that specifically bind to the human c-Met receptor protein and that act as strict antagonists of hepatocyte growth factor (HGF)-mediated activation of the c-Met receptor and also inhibit HGF-independent activation of the human c-Met protein. | 12-31-2015 |
| 20150376674 | Use of an amino acid auxotrophy cured prokaryotic strain for the recombinant production of a polypeptide - Herein is reported a method for producing a polypeptide in a prokaryotic cell, comprising the step of cultivating a prokaryotic cell comprising one or more nucleic acids encoding the polypeptide in a chemically defined minimal growth medium and recovering the polypeptide from the prokaryotic cell or the periplasm of the prokaryotic cell or from the medium, wherein the prokaryotic cell is an amino acid auxotrophy cured prokaryotic cell, wherein growth of the amino acid auxotrophy cured prokaryotic cell compared to the non-cured prokaryotic cell under the same cultivation conditions and in the same growth medium requires the supplementation of fewer amino acids to the growth medium, and wherein the chemically defined minimal growth medium is free of the amino acid corresponding to the auxotrophy that has been cured in the auxotrophy cured prokaryotic cell. | 12-31-2015 |
| 20160002592 | FORMULATIONS AND METHODS FOR INCREASED RECOMBINANT PROTEIN PRODUCTION - Formulations and methods to increase the production of recombinant proteins, and other aspects, are disclosed. The formulations and methods relate to increasing mannose or calcium concentration, or both, in a cell culture medium formulation for culturing cells that express recombinant proteins. In some embodiments, a mammalian cell culture medium formulation is provided that has at least one of mannose at about 3.5 g/L or more and calcium in a range from about 1.5 mM to about 9.5 mM. Numerous other aspects and/or embodiments are provided. | 01-07-2016 |
| 20160002642 | POLYPEPTIDE EXPRESSION SYSTEMS - The present invention relates to polypeptide expression systems and methods of using the same. | 01-07-2016 |
| 20160009798 | Human Oncostatin M Antibodies and Methods of Use | 01-14-2016 |
| 20160017036 | CELL LINE 3M - The present invention provides, inter alia, an isolated cell line, 3M as well as methods for making such a cell line and methods of using such a cell line, e.g., to produce a protein such as an immunoglobulin. | 01-21-2016 |
| 20160024217 | PRODUCTION OF PROTEINS IN GLUTAMINE-FREE CELL CULTURE MEDIA - The present invention relates generally to glutamine-free cell culture media supplemented with asparagine. The invention further concerns the production of recombinant proteins, such as antibodies, in asparagine-supplemented glutamine-free mammalian cell culture. | 01-28-2016 |
| 20160024221 | HUMAN MONOCLONAL ANTIBODIES TO FUCOSYL-GM1 AND METHODS FOR USING ANTI-FUCOSYL-GM1 ANTIBODIES - The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to Fucosyl-GM1 with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting Fucosyl-GM1, as well as methods for treating various diseases, including cancer, using anti-Fucosyl-GM1 antibodies. | 01-28-2016 |
| 20160024502 | RECOMBINANT POLYPEPTIDE PRODUCTION - Disclosed herein is a method for producing a recombinant polypeptide in a mammalian cell culture in which the mammalian cells have a modified microRNA activity level. In one embodiment, a microRNA activity level is increased. In another embodiment, a microRNA activity level is decreased. In a more particular embodiment, the mammalian cells have a reduced miRNA-let-7a activity level. | 01-28-2016 |
| 20160031970 | FERMENTATION PROCESS FOR ANTIBODY PRODUCTION - A feedback control mechanism for a fermentation of yeast cells to make recombinant proteins uses a respiratory quotient measurement which adjusts the levels of oxygenation and/or fermentable sugar feed. The feedback control mechanism permits well controlled cultures that produce good amounts of product while avoiding toxic accumulation of ethanol. Additionally, recombinant proteins so produced have excellent qualitative properties, such as excellent homogeneity and proper inter-subunit assembly. | 02-04-2016 |
| 20160032343 | METHODS FOR INCREASING MANNOSE CONTENT OF RECOMBINANT PROTEINS - The present invention relates to methods of modulating the mannose content of recombinant proteins. | 02-04-2016 |
| 20160039911 | TEMPERATURE SHIFT FOR HIGH YIELD EXPRESSION OF POLYPEPTIDES IN YEAST AND OTHER TRANSFORMED CELLS - Methods for producing heterologous proteins are disclosed. In particular, the present disclosure provides improved methods of producing desired proteins, including multi-subunit proteins such as antibodies, with a higher yield and improved purity. In exemplary embodiments, the transformed cells are a yeast, e.g., methylotrophic yeast such as | 02-11-2016 |
| 20160039927 | Cell Culture Improvements - The invention describes improved methods and compositions for producing a recombinant protein, e.g., an antibody, in mammalian cell culture. In addition, the invention provides improved cell culture media, including improved production media, feed solutions, and combination feeds, which may be used to improve protein productivity in mammalian cell culture. | 02-11-2016 |
| 20160039937 | NOVEL ANTIBODY AND ANTIBODY FRAGMENT INTRODUCED NEW MODIFICATION SITES - The present invention relates to an antibody or antibody fragment comprising novel Cys residue, to which a hydrophilic macromolecular group or amphipathic macromolecular group can be bound at a high efficiency. In addition, the present invention relates to a monoclonal antibody modified product or an antibody fragment modified product in which cysteine residue is chemically modified. | 02-11-2016 |
| 20160046694 | METHODS AND CONSTRUCTS FOR EXPRESSING BIOLOGICALLY ACTIVE PROTEINS IN MAMMALIAN CELLS - Methods and constructs for expressing biologically active proteins in eukaryotic cells are disclosed. A method for producing a non-conventional expression vector for production of biologically active compounds comprising a primary transcriptional unit and one or more secondary transcriptional units, a primary transcriptional unit encoding promoter, synthetic intron, selectable marker gene and polyadenylation signal or transcriptional terminator and a second transcriptional unit encoding promoter and polypeptide of interest surrounded by insulator sequences and placed in the intron of primary transcriptional unit. The synthetic intron disclosed is positioned at the 5′ end of the coding sequence and the synthetic intron capable for accommodating secondary transcriptional unit with base pairs ranging from 500 to 6000 and more. | 02-18-2016 |
| 20160046908 | METHODS FOR IN VITRO MEMORY B CELL DIFFERENTIATION AND TRANSDUCTION WITH VSV-G PSEUDOTYPED VIRAL VECTORS - The present disclosure relates to the in vitro differentiation of memory B cells to plasmablasts or plasma cells and genetic modification of these cells to express a protein of interest, such as a specific antibody or other protein therapeutic. | 02-18-2016 |
| 20160053028 | MEDIUM ADDITIVE FOR CELL CULTURE - Provided are a composition for enhanced production of a useful substance in cells containing a polysaccharide, a medium for cell culture containing a polysaccharide, and a process for preparing a useful substance including culturing cells in a medium for cell culture containing a polysaccharide. | 02-25-2016 |
| 20160053280 | Efficient Selectivity of Recombinant Proteins - The invention provides a new expression system comprising a mammalian selectable marker that promotes desirable post-translational modifications of glycoproteins. In particular, the invention includes methods and compositions for optimal recombinant protein expression in mammalian cells by employing a selection marker system based on GPT genes of mammalian origin. The invention includes methods that facilitate selectivity and enhanced expression copies as well as protein yield of recombinant proteins in mammalian cells, and methods of using GPT expression systems. | 02-25-2016 |
| 20160060330 | POLYPEPTIDE VARIANTS WITH ALTERED EFFECTOR FUNCTION - The present invention concerns polypeptides comprising a variant Fc region. More particularly, the present invention concerns Fc region-containing polypeptides that have altered effector function as a consequence of one or more amino acid modifications in the Fc region thereof. | 03-03-2016 |
| 20160060332 | THERAPEUTIC DLL4 BINDING PROTEINS - Improved DLL4 binding proteins are described, including antibodies, CDR-grafted antibodies, human antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis, and/or other angiogenesis-dependent diseases such as ocular neovascularization, or angiogenesis-independent diseases characterized by aberrant DLL4 expression or activity such as autoimmune disorders including multiple sclerosis. | 03-03-2016 |
| 20160060359 | Human Lambda Light Chain Mice - Genetically modified mice are provided that express human λ variable (hVλ) sequences, including mice that express hVλ sequences from an endogenous mouse λ light chain locus, mice that express hVλ sequences from an endogenous mouse κ light chain locus, and mice that express hVλ sequences from a transgene or an episome wherein the hVλ sequence is linked to a mouse constant sequence. Mice are provided that are a source of somatically mutated human λ variable sequences useful for making antigen-binding proteins. Compositions and methods for making antigen-binding proteins that comprise human λ variable sequences, including human antibodies, are provided. | 03-03-2016 |
| 20160067351 | SPECIFIC SITES FOR MODIFYING ANTIBODIES TO MAKE IMMUNOCONJUGATES - The present invention provides specific sites for modifying antibodies or antibody fragments by replacing at least one native amino acid in the constant region of a parental antibody or antibody fragment with cysteine, which can be used as a site of attachment for a payload or linker-payload combination. | 03-10-2016 |
| 20160068587 | OLIGOPEPTIDE-FREE CELL CULTURE MEDIA - The present invention relates to oligopeptide-free cell culture media comprising at least 0.5 mg/L of a polyamine and to methods for cultivating cells in said oligopeptide-free cell culture media comprising at least 0.5 mg/L of a polyamine. The invention also relates to methods for expressing at least one protein in a medium comprising at least 0.5 mg/L of a polyamine and to methods for producing at least one virus in a medium comprising at least 0.5 mg/L of a polyamine. | 03-10-2016 |
| 20160068602 | SEQUENCE DEPENDENT AGGREGATION - Herein is reported a method for reducing the aggregation of an immunoglobulin in solution comprising the steps of i) comparing the amino acid sequence of the fourth framework region of the heavy chain of an antibody with a reference or germline sequence and determining whether one or more threonine residues and/or serine residues have been replaced by a different amino acid residue, and ii) modifying the amino acid sequence of the immunoglobulin by reverting the exchanged threonine residues and/or serine residues back to threonine or serine of the reference or germline sequence and thereby reducing the aggregation of an immunoglobulin in solution. | 03-10-2016 |
| 20160068604 | ANTI-OX40 ANTIBODIES AND METHODS OF USING THE SAME - Human antibodies, preferably recombinant human antibodies, both humanized and chimeric, which specifically bind to human OX40 are disclosed. Preferred antibodies have high affinity for OX40 receptor and activate the receptor in vitro and in vivo. The antibody can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, are useful for modulating receptor activity, e.g., in a human subject suffering from a disorder in which OX40 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies are provided, and methods of synthesizing the recombinant human antibodies, are also provided. | 03-10-2016 |
| 20160075747 | METHOD FOR PRODUCING PROTEIN - It has been believed that promoting the assembly of polysomes composed of many ribosomes attached to mRNA is very effective for highly efficient protein synthesis. However, the mechanism for p180 protein's capability of promoting polysome formation has been yet to be elucidated. | 03-17-2016 |
| 20160075794 | ANTIGEN BINDING MOLECULES WITH INCREASED Fc RECEPTOR BINDING AFFINITY AND EFFECTOR FUNCTION - The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human CD20. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function. | 03-17-2016 |
| 20160075795 | Antibodies to Carcinoembryonic Antigen (CEA), Methods of Making Same, and Uses Thereof - The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies or variants thereof specific for cell surface or membrane bound human CEA. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function. | 03-17-2016 |
| 20160076051 | Expression Process - A process for the production of a target polypeptide is provided. The process comprises expression of an expression vector for expressing a target polypeptide in a host cell, preferably a mammalian cell, the expression vector comprising an expression cassette comprising a polynucleotide encoding a recombinant polypeptide operably linked to a fibronectin secretion leader sequence; and recovering the target polypeptide. | 03-17-2016 |
| 20160083765 | METHOD FOR PREPARING ANTIBODIES HAVING IMPROVED PROPERTIES - The present invention is directed to methods and compositions for the production of Fc-containing polypeptides having improved properties and comprising mutations at positions 243 and 264 of the Fc region. | 03-24-2016 |
| 20160090410 | FUCOSYLATION-DEFICIENT CELLS - An isolated nucleic acid encoding an FX protein having a serine at position 79, a lysine at position 90, a leucine at position 136, an arginine at position 211, a serine at position 289, and a combination thereof is provided. Cells having a gene encoding a modified FX protein are provided, wherein the cells exhibit a reduced ability to fucosylate a glycoprotein at a first temperature, but exhibit the ability to fucosylate the glycoprotein at a second temperature. Methods and compositions for making glycoproteins with reduced fucosylation are provided. | 03-31-2016 |
| 20160096889 | B7-H1, A NOVEL IMMUNOREGULATORY MOLECULE - The invention provides novel polypeptides useful for co-stimulating T cells, isolated nucleic acid molecules encoding them, vectors containing the nucleic acid molecules, and cells containing the vectors. Also included are methods of making and using these co-stimulatory polypeptides. | 04-07-2016 |
| 20160108112 | METHODS OF REPLICATING A LARGE SCALE ECULIZUMAB PRODUCTION CELL CULTURE - Provided herein are methods of replicating a large scale eculizumab production cell culture in a small scale culture. | 04-21-2016 |
| 20160108136 | RECOMBINANT ANTIBODY COMPOSITION - The present invention relates to a recombinant antibody composition having higher complement-dependent cytotoxic activity than a human IgG1 antibody and a human IgG3 antibody, wherein a polypeptide comprising a CH2 domain in the Fc region of a human IgG1 antibody is replaced by a polypeptide comprising an amino acid sequence which corresponds to the same position of a human IgG3 antibody indicated by the EU index as in Kabat, et al.; a DNA encoding the antibody molecule or a heavy chain constant region of the antibody molecule contained in the recombinant antibody composition; a transformant obtainable by introducing the recombinant vector into a host cell; a process for producing the recombinant antibody composition using the transformant; and a medicament comprising the recombinant antibody composition as an active ingredient. | 04-21-2016 |
| 20160108357 | METHODS OF CULTURING A CELL - Provided herein are methods of culturing a mammalian cell that include culturing a mammalian cell comprising a recombinant protein-encoding nucleic acid in a liquid culture medium containing 0.1 g/L or more processed Bovine Serum Albumin (BSA) under conditions sufficient to produce the recombinant protein, where the processed BSA is present in and/or added to the liquid culture medium prior to and/or during the culturing step. | 04-21-2016 |
| 20160115225 | Methods of Reducing Methylglyoxal (MGO) Modification of Recombinant Proteins in Cell Culture - Methods are provided for controlling the levels of acidic species when a protein of interest is expressed by host cells. One particular example of an acidic species is methylglyoxal (MGO). Reduction of acidic species such as MGO may be achieved by regulating the glucose consumption of the cell culture or by modulating the cysteine/glutathione metabolic pathways. | 04-28-2016 |
| 20160115438 | Integrated Continuous Isolation of Fluid Streams From Sterile Process Vessels - Provided herein are isolation processes and the associated hardware to allow fluid streams to be isolated from a sterilized system (e.g., a sterile process vessel) that contains a sterile process. The isolation processes described herein allow for continuous removal of fluid streams (e.g., waste streams, liquid containing recombinant therapeutic proteins) from a sterilized system (e.g., a biological manufacturing system), which provides for less manual manipulation of the sterilized system and a decreased risk of contaminating the sterilized system. | 04-28-2016 |
| 20160115443 | VP16-CREB FUSION GENE - The present application describes a cell that has integrated into its genome fusion molecule V16-CREB. | 04-28-2016 |
| 20160115502 | NOVEL CHO INTEGRATION SITES AND USES THEREOF - Expression-enhancing nucleotide sequences for eukaryotic expressions systems are provided that allow for enhanced and stable expression of recombinant proteins in eukaryotic cells. Genomic integration sites providing enhanced expression and methods of use thereof are provided for expression of a gene of interest in a eukaryotic cell. Chromosomal loci, sequences, and vectors are provided for enhanced and stable expression of genes in eukaryotic cells. | 04-28-2016 |
| 20160122428 | FD CHAIN GENE OR L CHAIN GENE CAPABLE OF INCREASING SECRETION AMOUNT OF FAB-TYPE ANTIBODY - It is an object of the present invention to provide a method for producing a low-molecular-weight antibody such as a Fab-type antibody, using yeast as a host, wherein the method is able to produce the low-molecular-weight antibody with high productivity. According to the present invention, there is provided a gene comprising a nucleotide sequence encoding an amino acid or an amino acid sequence capable of increasing the secretion amount of a Fab-type antibody at the 3′-terminus of a nucleotide sequence encoding the amino acid sequence of the Fd chain or L chain of an antibody. | 05-05-2016 |
| 20160130364 | METHOD FOR PRODUCING POLYPEPTIDES USING PDK-INACTIVATED CELLS - Provided is a recombinant cell including inactivated pyruvate dehydrogenase kinase (PDK) gene, a composition for producing a polypeptide of interest including the recombinant cell, and a method of producing a polypeptide of interest using the recombinant cell. | 05-12-2016 |
| 20160130367 | GENERATION OF BINDING MOLECULES - Provided are methods for efficiently and comprehensively screening antibody repertoires from B cells to obtain and produce molecules with binding characteristics and functional activities for use in human therapy. | 05-12-2016 |
| 20160130624 | HARVEST OPERATIONS FOR RECOMBINANT PROTEINS - The present invention contemplates a method of producing a recombinant protein comprising (a) fermenting a prokaryotic host cell wherein said prokaryotic host cell has been transformed with a nucleic acid encoding said recombinant protein, and (b) harvesting said recombinant protein under conditions where dO | 05-12-2016 |
| 20160137996 | Stabilization of Alpha-Amylases Towards Calcium Depletion and Acidic pH - The present invention relates to variants of a parent alpha-amylase, the variant having improved stability or activity at low calcium conditions or at low pH. | 05-19-2016 |
| 20160138064 | METHODS TO CONTROL PROTEIN HETEROGENEITY - The instant invention relates to the field of protein production, and in particular to compositions and processes for controlling and limiting the heterogeneity of proteins expressed in host cells. | 05-19-2016 |
| 20160145349 | Humanized Anti-Factor D Antibodies And Uses Thereof - The invention relates to anti-Factor D antibodies, their nucleic acid and amino acid sequences, the cells and vectors that harbor these antibodies and their production and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation. These antibodies are useful for diagnostics, prophylaxis and treatment of disease. | 05-26-2016 |
| 20160152669 | NOVEL POLYPEPTIDE, AND USE THEREOF | 06-02-2016 |
| 20160152975 | METHOD FOR RECOMBINANT PROTEIN PRODUCTION IN MAMMALIAN CELLS | 06-02-2016 |
| 20160153019 | Production of Glycoproteins Having Increased N-Glycosylation Site Occupancy | 06-02-2016 |
| 20160159898 | METHODS OF PRODUCING TWO CHAIN PROTEINS IN BACTERIA - Provided herein are methods of producing a polypeptide containing two chains, such as an antibody including a light chain and a heavy chain. In particular, methods are provided for producing heterologous secretory proteins in bacteria through utilization of optimized expression vectors and culture processes. | 06-09-2016 |
| 20160159926 | FUSION POLYNUCLEOTIDE CONTAINING MURINE CMV PROMOTER AND METHOD OF PREPARING A POLYPEPTIDE OF INTEREST USING THE SAME - A fusion polynucleotide including a murine CMV promoter and an intron, a recombinant vector including the fusion polynucleotide and a gene encoding a polypeptide of interest, a recombinant cell including the recombinant vector, and a method of producing a polypeptide of interest using the recombinant vector and/or the recombinant cell. | 06-09-2016 |
| 20160168264 | ANTIBODIES DIRECTED TO HER-3 AND USES THEREOF | 06-16-2016 |
| 20160176952 | PHAGE DISPLAYING SYSTEM EXPRESSING SINGLE CHAIN ANTIBODY | 06-23-2016 |
| 20160176955 | Anti-Malarial Compositions | 06-23-2016 |
| 20160176958 | TNF-ALPHA BINDING PROTEINS | 06-23-2016 |
| 20160177361 | METHODS OF CULTURING A MAMMALIAN CELL | 06-23-2016 |
| 20160185850 | STABLE AND SOLUBLE ANTIBODIES INHIBITING TNF ALPHA - The present invention relates to particularly stable and soluble scFv antibodies and Fab fragments specific for TNFα, which comprise specific light chain and heavy chain sequences that are optimized for stability, solubility, in vitro and in vivo binding of TNFα, and low immunogenicity. Said antibodies are designed for the diagnosis and/or treatment of TNFα-related disorders. The nucleic acids, vectors and host cells for expression of the recombinant antibodies of the invention, methods for isolating them and the use of said antibodies in medicine are also disclosed. | 06-30-2016 |
| 20160186206 | OPTIMIZED EXPRESSION CASSETTE FOR EXPRESSING A POLYPEPTIDE WITH HIGH YIELD - The present invention is based on the finding that the combination of a specific 5′UTR polynucleotide sequence (see SEQ ID NO 1) and the hCD33 secretory leader sequence in an expression cassette for expressing a polypeptide of interest results in a surprisingly better expression level of the polypeptide of interest compared to prior art expression cassettes. Based on this finding, the present invention inter alia provides novel expression cassettes, expression vectors and methods for producing a polypeptide of interest with high yield. | 06-30-2016 |
| 20160194660 | EXPRESSION VECTORS FOR RECOMBINANT PROTEIN PRODUCTION IN MAMMALIAN CELLS | 07-07-2016 |
| 20160200810 | BACTERIAL HOST STRAIN | 07-14-2016 |
| 20160251410 | COMPOSITIONS AND METHODS FOR EXPRESSING RECOMBINANT POLYPEPTIDES | 09-01-2016 |
| 20160376358 | HUMAN ANTIBODIES TO FEL D1 AND METHODS OF USE THEREOF - The present invention provides antibodies that bind to the cat allergen, Fel d1, compositions comprising the antibodies, nucleic acids encoding the antibodies and methods of use of the antibodies. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to Fel d1. The antibodies of the invention are useful for binding to the Fel d1 allergen in vivo, thus preventing binding of the Fel d1 allergen to pre-formed IgE on the surface of mast cells or basophils. In doing so, the antibodies act to prevent the release of histamine and other inflammatory mediators from mast cells and/or basophils, thus ameliorating the untoward response to the cat allergen in sensitized individuals. The antibodies of the invention may also be useful for diagnostic purposes to determine if a patient is allergic to the Fel d1 cat allergen. | 12-29-2016 |
| 20160376361 | IL-18 binding molecules - IL-18 participates in both innate and acquired immunity. The bioactivity of IL-18 is negatively regulated by the IL-18 binding protein (IL18BP), a naturally occurring and highly specific inhibitor. This soluble protein forms a complex with free IL-18 preventing its interaction with the IL-18 receptor, thus neutralizing and inhibiting its biological activity. The present invention discloses binding molecules, in particular antibodies or fragments thereof, which bind IL-18 and do not bind IL-18 bound to IL-18BP (IL-18/IL-18BP complex). Apart from its physiological role, IL-18 has been shown to mediate a variety of autoimmune and inflammatory diseases. The binding molecules of the inventions may be used as therapeutic molecules for treating IL-18-related autoimmune and inflammatory diseases or as diagnostic tools for characterizing, detecting and/or measuring IL-18 not bound to IL-18BP as component of the total IL-18 pool. | 12-29-2016 |
| 20160376601 | Hybrid immunoglobulins with moving parts - Hybrid immunoglobulins containing moving parts are provided as well as related compositions and methods of use and methods of production. In addition, analogous genetic devices are provided as well as related compositions and methods of use and methods of production. | 12-29-2016 |
| 20160376602 | VECTORS FOR USE IN AN INDUCIBLE COEXPRESSION SYSTEM - The present invention provides expression vectors for use in an inducible coexpression system, capable of controlled induction of expression of each gene product. | 12-29-2016 |
| 20160376624 | CELL CULTURE PROCESS - Polypeptides having target levels of C-terminal variants are described. | 12-29-2016 |
| 20170233461 | COMPOSITIONS AND METHODS FOR PHAGOCYTE DELIVERY OF ANTI-STAPHYLOCOCCAL AGENTS | 08-17-2017 |
| 20170233477 | CELL LINE 3M | 08-17-2017 |
| 20170233486 | POLYNUCLEOTIDES ENCODING ANTI-NOTCH1 NRR ANTIBODY POLYPEPTIDES | 08-17-2017 |
| 20220136026 | METHODS FOR INCREASING MANNOSE CONTENT OF RECOMBINANT PROTEINS - The present invention relates to methods of modulating the mannose content of recombinant proteins. | 05-05-2022 |
